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Skin-mediated promotion of thrombosis is abrogated following IL-23/IL-17 inhibition or IL-6 
deletion in mouse models of psoriasis 
J Golden,1 Y Fritz,1 Y Wang,2 Y Li,1 D Simon,2 TS McCormick1 and NL Ward1 1 Dermatology, 
Case Western Reserve University, Cleveland, OH and 2 Cardiovascular Medicine, Case 
Western Reserve University, Cleveland, OH
Psoriasis patients are at increased risk of dying of heart attack and stroke and have elevated S100A8/9 
levels, which are predictive of poor CVD event outcomes. S100A9-deficient (-/-) mice develop less 
atherosclerosis and are protected against thrombosis. KC-Tie2 mice develop a psoriasis-like skin phe-
notype, have elevated skin and serum S100A9 and are pro-thrombotic. We hypothesized that genetic 
deletion of S100A9 in KC-Tie2 mice would improve skin disease and thrombosis. However throm-
bosis was similar between KC-Tie2 x S100A9-/- and KC-Tie2 mice (n=14-20/grp; P=0.9), perhaps 
due to persistent skin inflammation, elevated pro-inflammatory cytokines including IL-6, IL-17A, 
IL-12/23 (n=9-12; ~5-6-fold; P<0.05) and sustained circulating Ly6Chi monocytes (n=3-7; ~1.5-fold; 
P<0.05). To explore the contributions of these cytokines in promoting thrombosis, we backcrossed 
KC-Tie2 with IL-6-/- mice or treated KC-Tie2 mice with clinically validated cytokine function blocking 
antibodies targeting IL-17A, IL-17RA, IL-12p40, and IL23p19 (n=7-14/grp). Thrombosis returned to 
control mouse levels in KC-Tie2 x IL-6-/- mice (n=14-20) and was significantly improved in KC-Tie2 
mice treated with each of the cytokine function blocking antibodies vs. IgG controls (P<0.05 each). 
Improvement in skin inflammation was only observed in KC-Tie2 mice treated with antibodies, not 
KC-Tie2 x IL-6-/- animals, consistent with clinical reports of skin improvement following IL-23/IL17 
pathway inhibition, but not IL-6. Circulating monocytes decreased following functional inhibition 
of IL-23/IL-17 pathways but not IL-6 deletion, despite improving thrombosis, thus correlating better 
with skin inflammation than thrombosis. These data reveal a critical role for skin-derived IL-6 and 
the IL-23/IL-17 pathways in promoting thrombosis related to psoriasiform inflammation and also 
rule out CD11b+Ly-6Chi monocytes as necessary for thrombotic events in the KC-Tie2 mouse model.   
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Murine macrophage NADPH oxidase controls wound healing
A Kügler,1 S Schatz,1 S Vander Beken,1 D Jiang,1 T Peters,1 L Schneider,1 A Rück,2 B De 
Geest,3 K Scharffetter-Kochanek1 and A Sindrilaru1 1 Dermatology and Allergic Diseases, 
University of Ulm, Ulm, Germany, 2 Core Facility for Confocal and Multiphoton Microscopy, 
University of Ulm, Ulm, Germany and 3 Department of Pharmaceutics, University of Ghent, 
Ghent, Belgium
Reactive oxygen species (ROS) released by the phagocyte nicotinamide adenine dinucleotide phos-
phate (NADPH) oxidase (NOX2) are key players in infection and inflammation. We here provide first 
evidence for the critical role of b2 integrins-mediated activation of NOX2 in macrophages for trans-
forming growth factor-β1 (TGF-β1)-induced granulation tissue formation and proper healing of skin 
full-thickness excisional wounds. Targeting the NOX2 activator rotenone encapsulated in clodronate 
liposomes to wound macrophages fully restored reduced ROS levels, impaired TGF-β1 activation 
and granulation tissue formation and wound healing of β2-integrin–deficient CD18
-/- mice; this 
effect was completely reversed by the NOX2 inhibitor ebselen. NADPH-based fluorescence lifetime 
imaging (FLIM) revealed that NOX2 failed to assemble for its activation at the CD18-/- macrophages 
membrane upon adhesion to apoptotic neutrophils. Similar to CD18-/- mice, also mice lacking the 
p40phox domain of NADPH (p40phox-/-) with impaired oxidase function presented with significantly 
reduced ROS levels and defective wound healing. Impaired TGF-β1 activation by p40
phox-/- wound 
macrophages was causal for reduced angiogenesis, myofibroblasts differentiation and wound con-
traction of p40phox-/- mice. Injection of wildtype, but not of p40phox-/- or CD18-/- macrophages, into 
wound margins fully restored the impaired wound healing of CD18-/- mice, supporting a central role 
of the β2-integrins-NADPH oxidase pathway in macrophages for tissue repair and inflammation.   
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Newly defined ABCB5-expressing dermis mesenchymal stem cells promote healing of chronic 
wounds via secretion of interleukin-1 receptor antagonist
S Vander Beken,1 A Sindrilaru,1 JC de Vries,1 A Kluth,2 B Over,2 C Ganss,2 NY Frank,3 
MH Frank,3 M Wlaschek1 and K Scharffetter-Kochanek1 1 Dermatology and Allergic Diseases, 
Ulm University, Ulm, Germany, 2 Ticeba GmbH, Heidelberg, Germany and 3 Medicine, 
Brigham and Women’s Hospital, Boston, MA
Chronic skin wounds are difficult to treat and impose a considerable burden on both the patient 
and national health care institutions. We and others have previously shown that chronic wounds 
are marked by a persistent and exaggerated inflammatory response, mediated by an M1 activated 
macrophage population, that impedes proper healing and tissue repair. In line with most chronic 
inflammatory disorders, the IL-1 pathway that has detrimental effects on tissue repair mechanisms 
plays a central role in the physiopathology of such chronic wounds. Mesenchymal stem cells (MSC) 
feature many characteristics that are beneficial for therapeutic applications in injury and trauma. 
Interestingly, MSC are known to suppress inflammatory macrophage M1 activation and to promote 
pro-wound healing M2 type macrophages. Here we describe the isolation of an ATP-binding cassette 
sub-family B member 5 (ABCB5)-expressing plastic-adherent dermal cell subpopulation from the 
dermis and its characterization as MSC. We show that ABCB5+ MSC accelerated resolution of the 
inflammatory phase in the iron-overload mouse model for chronic venous ulcers and contributed 
to wound healing. Furthermore, we demonstrate that ABCB5+ dermal MSC secreted interleukin-1 
receptor antagonist (IL-1RA) in response to inflammatory stimulation, which dampened classical 
macrophage activation with TNF-alpha release in vitro and mediated a switch from an M1 towards 
M2 macrophage activation profile in vivo in the wound bed. The importance of the anti-inflamma-
tory effects on wound macrophages by MSC-secreted IL-1RA for chronic wound healing was sub-
stantiated by siRNA-mediated gene-silencing. In conclusion, human dermal ABCB5+ MSC represent 
an easy accessible source for cell-based therapy of chronic skin wounds that accelerate healing at 
least in part by the secretion of IL-1RA.    
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Intravenous immunoglobulin regulates anti-desmoglein 3 autoantibody production in B220- 
antibody-producing cells in mice with pemphigus vulgaris
Y Kase,1 J Yamagami,2 N Wada,2 H Takahashi,2 S Koyasu3 and M Amagai2 1 Central Research 
Laboratory, Japan Blood Products Organization, Kobe, Japan, 2 Department of Dermatology, 
Keio University School of Medicine, Tokyo, Japan and 3 Center for Integrative Medical 
Sciences, RIKEN, Yokohama, Japan
Although intravenous immunoglobulins (IVIG) is one of effective therapies in pemphigus vulgaris 
(PV), an autoimmune blistering disease caused by autoantibodies against desmoglein 3 (Dsg3), its 
functional mechanism has not been fully understood. In this study, we analyzed the effect of IVIG 
in PV model mice produced by adoptive transfer of immunized Dsg3-/- splenocytes to Rag2-/- mice 
as well as B cell knock-in (AK23 KI) mice generated from AK23 pathogenic monoclonal antibody. 
We found circulating anti-Dsg3 IgG ELISA titers were suppressed by 60% in mice on day 5 with 5 
day treatment of 800 mg/kg of IVIG compared with PBS-treated mice (p<0.01). In contrast, F(ab’)2 
fragment failed to show any suppression, suggesting that the Fc region of IVIG are necessary for 
the effect. Next, we examined anti-Dsg3 antibody-secreting cells (ASCs) in lymphoid organs using 
ELISPOT assay and found that IVIG reduced the numbers of the spots by ASCs almost by half in the 
spleen (p<0.01). To characterize the subsets of ASCs, we sorted the splenocytes with B220 mag-
netic beads. The decrease of the number of ASCs mainly attributed to B220- cells, but not B220+ 
cells (p<0.05). To further determine whether IVIG induces suppression of antibody production or 
deletion of ASCs, we utilized AK23 KI mice. IVIG decreased the circulating anti-Dsg3 IgG as well 
as the number of the spots of anti-Dsg3 ASCs in the spleen as found in PV model mice, while the 
total number of B220-CD138+ cells was not changed in the flow cytometry. These results together 
indicate that IVIG decreases circulating antibody titers, not only at protein level as shown before, 
but also regulates the autoantibody production in B220- cells containing plasma cells in PV mice.   
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Programmed cell death-ligand 1 alleviates psoriatic inflammation by suppressing IL-17A 
production from PD-1hi T cells
J Kim,1 Y Choi,1 B Lee,2 S Park,3 H Kim,4 Y Sung,5 S Kim6 and E Shin1 1 Laboratory of 
Immunology and Infectious Diseases, Graduate School of Medical Science and Engineering, 
KAIST, Daejeon, Korea (the Republic of), 2 Genexine, Inc., Seongnam, Korea (the Republic 
of), 3 Laboratory of Translational Immunology and Vaccinology, Graduate School of 
Medical Science and Engineering, KAIST, Daejeon, Korea (the Republic of), 4 Department 
of Environmental Medical Biology, Institute of Tropical Medicine, Yonsei University College 
of Medicine, Seoul, Korea (the Republic of), 5 Division of Integrative Biosciences and 
Biotechnology, Pohang University of Science and Technology, Pohang, Korea (the Republic 
of) and 6 Department of Dermatology and Cutaneous Biology Research Institute, Gangnam 
Severance Hospital, Yonsei University College of Medicine, Seoul, Korea (the Republic of)
Psoriasis is a chronic inflammatory skin disease, and IL-17-producing T cells play a critical role 
in psoriatic inflammation. Programmed cell death-1 (PD-1) is a co-inhibitory receptor, and PD-1 
overexpression on T cells is reported in various chronic inflammatory diseases. In psoriatic inflam-
mation, however, PD-1 expression on T cells and its regulatory role are not fully understood. Here, 
we demonstrate that PD-1 was overexpressed in CD27-Vγ1- γδ T cells during IMQ-induced psoriatic 
inflammation. PD-1 expression on IL-17A+ T cells was confirmed in the psoriatic skin of patients. In 
the CD27-Vγ1- γδ T cell population, Vγ4- γδ T cells with Vγ6 mRNA expression showed high level 
of PD-1 expression. PD-1hiVγ4- (Vγ6+) γδ T cells were specialized for anti-CD3-induced IL-17A 
production, which was inhibited by PD-L1-Fc protein treatment. In IMQ-treated mice, PD-L1-Fc 
protein reduced disease activity of psoriatic inflammation by alone and enhanced therapeutic effect 
of anti-p40 by combination. In conclusion, PD-1 is overexpressed in IL-17A-producing T cells in 
IMQ-treated mice and psoriasis patients, and recombinant PD-L1-Fc protein alleviates psoriatic 
inflammation in IMQ-treated mice.    
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Molecular diagnostics of psoriasis and eczema- a novel approach to establish personalised 
therapy 
NV Garzorz,3 L Krause,1 F Lauffer,3 A Atenhan,2 J Thomas,2 FJ Theis,1 T Biedermann,3 
C Schmidt-Weber,2 S Eyerich2 and K Eyerich3 1 Institute of Computational Biology, 
Helmholtz Center Munich, Neuherberg, Germany, 2 Center of Allergy and Environment, 
Technical University, Munich, Germany and 3 Department of Dermatology and Allergy, 
Technical University Munich, Munich, Germany
Over the past years, many specific therapies for eczema and especially for psoriasis have been 
developed. Thus, it becomes more and more relevant to correctly diagnose both diseases as ther-
apy is not only inefficient, but may be even harmful if for instance a TNF alpha inhibitor is chosen 
in cases when eczema is misdiagnosed as psoriasis. The other way round psoriasis patients are 
unnecessarily detained from early induction of specific systemic therapies when misdiagnosed as 
eczema. While typical psoriasis plaques can easily be distinguished from classical eczema, certain 
phenotypes of both diseases overlap and may not be diagnosed by clinical eye nor histology. Here, 
we developed a novel method to reliably diagnose histologically and clinically indistinct cases. 
Based on a broad intra-individual gene expression analysis in patients suffering from both eczema 
and psoriasis simultaneously, we identified a robust disease classifier consisting of the two markers 
NOS2 and CCL27 that correctly diagnosed eczema or psoriasis, respectively, in an independent 
cohort of 140 patients on the level of real-time PCR. Furthermore, this classifier identified initially 
misdiagnosed patients (n=10) and gave a clear prediction for therapeutic response in two patients 
that was in line with the subsequent clinical course. Thus, the molecular analysis of NOS2 and 
CCL27 expression in lesional skin is superior to current diagnostic gold standard methods to dis-
tinguish psoriasis from eczema. Next, we established fluorescent double stainings for iNOS and 
CCL27 on paraffin sections. Also here, the disease classifier showed clear-cut and robust results. 
This disease classifier may build the basis for molecular diagnosis of chronic inflammatory skin 
diseases that is required to establish personalised medicine in the field.    
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Aryl hydrocarbon receptor activation at keratinocyte leads to atopic dermatitis-like lesion 
via artemin induction
T Hidaka,1 E Ogawa,2 E Kobayashi,1 T Suzuki,1 T Fujimura,1 S Aiba,3 R Okuyama2 and 
M Yamamoto1 1 Medical Biochem, Tohoku Univ, Sendai, Japan, 2 Dermatol, Shinshu Univ, 
Matsumoto, Japan and 3 Dermatol, Tohoku Univ, Sendai, Japan
Recent epidemiologic studies revealed a correlation between rapid increase in the prevalence 
of atopic dermatitis (AD) and air pollution levels. Polycyclic aromatic hydrocarbons have been 
identified as the component responsible for the air pollutant-induced inflammation. They exert 
biological effects by binding to a transcription factor, aryl hydrocarbon receptor (AhR). To investi-
gate mechanisms underlying the air pollution-induced AD, we have established transgenic mouse 
lines that express constitutive-active form of AhR under keratin-14 promoter (AC mice), which 
mimic the chronic exposure of air pollutants to the skin. In this study, we found that the AC mice 
recapitulate nicely various characteristics of human AD. The AD phenotypes, including pruritus, 
barrier insufficiency, and allergic inflammation, were all developed in AC mice, starting from a 
tiny tactile pain-induced scratch behavior (alloknesis), increased trans-epidermal water loss, and 
infiltration of helper T cells, mast cells, eosinophils and basophils into the dermis. Trans-nasal 
administration of ovalbumin to AC mice after its topical application provoked airway hypersensi-
tivity, recapitulating the allergic march in human. We also found hyper-innervation at epidermis 
in immunohistochemistry, which may be the cause of alloknesis. We investigated AhR-regulated 
genes responsible for this human AD-like phenotype through cDNA expression array and ChIP-seq 
analyses of AhR-activated keratinocytes. We found that the expression of artemin (Artn), a nerve 
growth factor, preceded intra-epidermal nerve elongation and AhR bound to the Artn gene, sug-
gesting AhR direct regulation of the gene. Indeed, subcutaneous administration of Artn neutralizing 
antibody prevented both intra-epidermal nerve elongation and alloknesis. These results demonstrate 
that the AhR activation in keratinocytes is sufficient to induce AD phenotypes and the AhR-Artn 
axis is the one of the critical mechanisms for this induction.    
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Innate immune signal triggered co-factor dependent anaphylaxis is mediated by TLR ligation
F Wölbing,2 S Kaesler,1 W Kempf,2 A Umbach,3 Y Skabytska,1 F Lang,3 P Yu,4 D Vöhringer,5 
M Röcken1 and T Biedermann2 1 Dermatology, Eberhard Karls University Tübingen, 
Tübingen, Germany, 2 Dermatology, Technical University Munich, Munich, Germany, 
3 Physiology, Eberhard Karls University Tübingen, Tübingen, Germany, 4 Institute of 
Immunology, Philipps-University Marburg, Marburg, Germany and 5 Infection Biology, 
Friedrich-Alexander-University Erlangen, Erlangen, Germany
Classically, anaphylaxis is mediated by cross linking of IgE bound to FcεRI on mast cells (MC) and 
basophils. Interestingly, cross linking of IgG antibodies and FcgRs can also initiate anaphylaxis, 
however, the clinical significance of this alternative pathway to anaphylaxis is unknown. Generally, 
the onset of anaphylaxis can be triggered by co factors. This is best documented for wheat dependent 
exercise induced anaphylaxis, alcohol consumption or infections. To study how infections trigger 
anaphylaxis, we sensitized mice with Ovalbumine (OVA) and prior to low dose OVA-challenge, 
pretreated them with pathogen associated molecular patterns (PAMPs) mimicking infection. The 
results show that pretreatment with Peptidoglycan (PGN), Pam2cys or CpG triggers anaphylaxis 
as proven by significantly decreased core body temperature and significant reduction in systolic 
blood pressure. Further experiments with either passively or actively sensitized basophil depleted 
or mast-cell-deficient Kitw-sh/w-sh mice showed that PAMP driven anaphylaxis depends on basophils 
and IgG but is independent from MC and IgE. PAMP dependent anaphylaxis after pretreatment with 
PGN is strongly impaired, although not absent, in mice double deficient in TLR2 and NOD2. In 
contrast, PAMP triggered anaphylaxis is completely absent in TLR2-/- mice after pretreatment with 
Pam2cys or in TLR9-/- mice after pretreatment with CpG, respectively. Thus, our results for the first 
time show a relevance of IgG and basophil dependent anaphylaxis in a clinically relevant setting. 
The modulating effect of PAMPs on the onset of anaphylaxis is specifically mediated by activation 
of TLRs. Those results should help to develop new therapeutic strategies and to improve diagnosis 
and management in patients with anaphylaxis.    
009
Roles of Brn2 in Epidermal Homeostasis
J Shin, D Choi, I Chang, K Sohn, C Kim and J Lee Dermatology, Chungnam University, 
Daejeon, Korea (the Republic of)
Skin epidermal proliferation and differentiation are regulated by many regulatory and signaling 
pathways, such as Wnt and bone morphogenic protein (BMP) signaling and Notch- and p63-me-
diated transcriptional regulation. In a previous study, we identified the POU domain-contain-
ing transcription factor Brn2 as an important regulator in keratinocyte differentiation. Brn2 was 
expressed primarily in the upper granular layer and overexpression of Brn2 in keratinocytes led to 
increased expression of the differentiation-related genes including involucrin, filaggrin, and loric-
rin. Brn2 regulated differentiation-related genes by binding to their promoter regions. To further 
investigate the role of Brn2 in epidermis in vivo, we generated a transgenic mice overexpressing 
Brn2 in epidermal keratinocytes using K5 promoter (K5-Brn2 transgenic mice). K5-Brn2 transgenic 
mice showed a thickend epidermis with hyperkeratosis and parakeratosis, and exhibited abnormal 
proliferation and differentiation. Moreover, K5-Brn2 transgenic mice was more sensitive to TPA 
treatment than normal mice in terms of skin inflammation induction. Our results indicate that Brn2 
is a critical transcription factor in epidermal homeostasis by regulating epidermal proliferation, 
differentiation and inflammation.    
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Blocking neutrophil transmigration prevents cutaneous hemorrhage in the absence of platelets
C Hillgruber,1 B Pöppelmann,1 C Weishaupt,1 WE Berdel,2 D Vestweber3 and T Goerge1 
1 Dept. of Dermatology, University Hospital of Münster, Münster, Germany, 2 Dept. of 
Hematology and Oncology, University Hospital of Münster, Münster, Germany and 3 Dept. 
of Vascular Cell Biology, Max Planck Institute of Molecular Biomedicine, Münster, Germany
Platelets are important mediators not only of hemostasis but also of vascular integrity during inflam-
mation. In the absence of platelets inflammation leads to hemorrhage. Here, we observed UVB-in-
duced bleeding (Purpura solaris) in thrombocytopenic patients phototested for UVB tolerance (30200 
mJ/cm2). In analogy, thrombocytopenic mice (anti-GPIbα) subjected to UVB-radiation developed 
cutaneous bleeding that occurred time- and dose-dependent. UVB-radiation induced a significant 
influx of neutrophils as confirmed by analysis of the neutrophil-specific enzyme myeloperoxidase 
and intra-vital microscopy. Interestingly, under leukocytopenic conditions (anti-Gr-1) skin bleed-
ing was virtually absent. In two additional murine models of cutaneous inflammation, immune 
complex-mediated vasculitis and irritative contact dermatitis, thrombocytopenic mice developed 
petechial bleeding as well. By gradual interference with single steps of leukocyte extravasation we 
identified neutrophils as the key inducer of thrombocytopenic bleeding during cutaneous inflamma-
tion. In particular, inhibition of neutrophil transmigration – via either the leukocyte or the endothe-
lium – significantly protected thrombocytopenic mice from cutaneous hemorrhage. First, blocking 
neutrophil-mediated mechanisms, which act downstream of capturing, adhesion and crawling on 
the blood vessel wall and require neutrophil Gαi-signaling, diminished thrombocytopenic hem-
orrhage. Second, mutating Y731 in the cytoplasmic tail of endothelial VE-cadherin, known to 
selectively affect neutrophil diapedesis, but not the induction of vascular permeability, attenuated 
bleeding in the absence of platelets. In conclusion, neutrophil diapedesis through the endothelial 
barrier may represent a new specific target to prevent fatal bleeding in thrombocytopenic patients.   
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Keratin mutations cause TSLP upregulation: implications for itch in blistering skin disorders
TM Magin,2 V Kumar,2 M Behr,2 D Kiritsi,1 A Scheffschick,2 M Homberg,2 A Schwieger-Briel1 
and L Bruckner-Tuderman1 1 Universitätshautklinik, Uni Freiburg, Freiburg, Germany and 2 
TRM & Biological Sciences, Uni Leipzig, Leipzig, Germany
Missense mutations in KRT5 or KRT14 cause EBS (epidermolysis bullosa simplex), characterized by 
blistering and extensive itch, the cause of which remains unknown. The IL-7 like cytokine TSLP has 
been recognized as a major driver of itch in AD (atopic dermatitis) and is upregulated upon barrier 
damage through activation of protease-activated receptors. The mechanisms governing TSLP regu-
lation in EBS and AD remain incompletely understood. To seek a link between epidermal keratins 
and TSLP regulation, we analysed TSLP at the mRNA and protein level in prenatal mice lacking all 
keratins specifically in the epidermis. This revealed highly elevated TSLP levels in keratin-deficient 
keratinocytes in situ and in the serum of prenatal mice, indicating a link between TSLP and keratins. 
To investigate potential cell-intrinsic mechanisms independent of barrier defects, TSLP was analysed 
in keratin-deficent keratinocytes ex vivo. While TSLP was highly elevated in keratin-deficient cells, 
stable re-expression of KRT5/14 strongly reduced TSLP. Of note, murine keratinocytes expressing 
the frequent EBS mutant KRT14Arg125Cys displayed increased TSLP in comparison to controls. 
Preliminary data indicate that keratins regulate TSLP via MAPK downstream of elevated intracellular 
Ca2+. Thus, in addition to barrier defects, cell-intrinsic and keratin-dependent mechanisms are 
involved in TSLP regulation. Furthermore, we report elevated TSLP levels in 7 out of 17 patients 
suffering from EBS. Collectively, our data identify a novel role of cytoskeletal keratins in the reg-
ulation of itch with implications for the treatment of itch. Furthermore, our data suggest a role of 
keratins in atopic dermatitis.    
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Development and characterization of a compromised organotypic model mimicking Atopic 
Dermatitis
P Rouaud,1 D Boudier,1 L Marchand,1 V Barruche,1 S Bordes,1 H Coppin,2 M Roth2 and 
B Closs1 1 R&D, SILAB, Saint Viance, France and 2 Centre de Physiopathologie de Toulouse 
Purpan, Inserm, U1043; CNRS, U5282, Université de Toulouse, Toulouse, France
Since Atopic Dermatitis (AD) is the most common inflammatory chronic disease of the skin, the 
understanding of its pathogenesis and the screening of therapeutic molecules dedicated to atopic 
skins is a growing priority in dermatological fields. Although several 3-dimensional (3D) in vitro 
models of AD have been published, no study presents a fully characterized and controlled model 
of AD-related inflammation. In this context, the aim of this study was to set up a “compromised” 
Reconstructed Epidermis (RE) modelling the inflammatory context of AD and to perform its phe-
notypic characterization from the morphologic to the transcriptomic level. For this purpose, we 
used normal human keratinocytes to generate RE and treated them with an inflammatory cocktail 
(Poly I:C, TNFα, IL-4 and IL-13). Untreated keratinocytes served as controls. Then, influence of 
inflammation on RE was analyzed at four levels: (1) epidermal morphology by HE staining; (2) 
epidermal differentiation by IHF staining and RT-QPCR; (3) secretion of inflammatory molecules by 
ELISA and (4) transcriptomic profile by microarrays. The results show that the inflamed RE presents 
some of the modifications observed in AD patients, in comparison to normal RE: (1) it leads to 
spongiosis within the lower layers without alteration of the whole thickness of the epidermis; (2) 
it decreases the expression, the synthesis and the localization of early and terminal differentiation 
proteins such as Filaggrin, Loricrin and Involucrin; (3) it increases TSLP and IL-8 secretion and (4) 
it results in transcriptomic variations of, at least, 26 genes including key markers of AD. These 
results confirm that the inflammatory context contributes to the morphologic, functional and tran-
scriptomic changes clinically observed in AD skins. As this compromised RE model shares some of 
AD skin characteristics, it provides a very powerful tool for screening potential natural molecules 
dedicated to AD treatment.    
Auto-immunity, allergy and Inflammation  | ABSTRACTS
www.jidonline.org   S3
013
The soluble form of Fas Ligand plays a pivotal role in blister formation in pemphigus
R Lotti,1 A Strasser,2 A Marconi,1 L O’Reilly2 and C Pincelli1 1 Laboratory of Cutanous 
Biology, University of Modena and Reggio Emilia, Modena, Italy and 2 Molecular Genetics 
of Cancer Division, The Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, 
Australia
Pemphigus is a chronic autoimmune bullous disease of the skin and mucous membranes. While 
anti-desmoglein (dsg) antibodies are essential for the development of pemphigus, the molecular 
mechanisms underlying cell-to-cell detachment (acantholysis) are still to be fully clarified. We 
and others have demonstrated that PVIgG induce the up-regulation of Fas Ligand (FasL) mRNA 
in keratinocytes in vitro and the release of FasL from keratinocytes, while high levels of FasL are 
present in sera from pemphigus patients. Against this background, we aim to investigate the role of 
FasL in the induction of the acantholytic process in pemphigus. Human recombinant FasL induced 
a dose- and time-dependent degradation of both dsg1 and dsg3 in association with acantholysis 
in vitro. Keratinocytes treated with FasL siRNA were protected from dsg cleavage and acantholysis 
induced by IgG from pemphigus patients. Using the passive transfer pemphigus mouse model, we 
demonstrated that PVIgG induced the increase of the intracellular active form of FasL starting at 1hr 
with a peak at 3hrs at the skin level. To definitively dissect the role of FasL in the pathogenesis of 
pemphigus, we injected PVIgG into two different gene-targeted mutant mice that selectively lack 
either the secreted soluble FasL (sFasL), FasLΔs/Δs mice, or the membrane-bound FasL (mFasL), FasL 
Δm/Δm mice. Both strains were on a C57BL/6 background. 20 hrs after PVIgG treatment, clinical 
blisters were visible only in FasL Δm/Δm animals, lacking mFasL, but still capable of producing sFasL, 
in a way similar to WT (C57BL/6) animals. On the other hand, a statistically significant decrease 
in the relative acantholytic area was observed only in FasLΔs/Δs animals. Collectively, these results 
suggest a pivotal role for soluble FasL in the skin blister formation of pemphigus.    
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PDE4 inhibition as potential treatment of epidermolysis bullosa acquisita
H Koga,1 A Recke,2 G Vidarsson,3 H Pas,4 MF Jonkman,4 D Zillikens2 and R Ludwig2 1 
Department of Dermatology, Kurume University School of Medicine, Kurume, Japan, 
2 Institute of Experimental Dermatology, University of Lübeck, Lübeck, Germany, 3 
Department of Experimental Immunohematology, Sanquin Research and Landsteiner 
Laboratory, Academic Medical Center, Amsterdam, Netherlands and 4 Center for Blistering 
Diseases, Department of Dermatology, University Medical Center Groningen, University of 
Groningen, Groningen, Netherlands
Autoimmune bullous dermatoses (AIBD) such as epidermolysis bullosa acquisita (EBA) are difficult 
to treat. In all AIBD (muco)-cutaneous blistering is caused by autoantibodies to (hemi)-desmosomal 
antigens; in EBA the antigen is type VII collagen (COL7). Despite the growing insights into the 
pathogenesis of AIBD, use of corticosteroids is still the mainstay of treatment. In experimental 
models of EBA, neutrophil activation has been identified as a key event leading to blistering. In 
parallel, neutrophil activation has been documented to depend on phosphodiesterase (PDE) 4 
activation. Therefore we evaluated the potential of PDE4 inhibition in experimental models of EBA. 
We found PDE4 highly expressed on inflammatory cell in dermis of EBA patient skin compared to 
that of normal skin as well as in epidermis. The PDE4 inhibitors rolipram (ROL), roflumilast (ROF) 
and roflumilast-N-oxide (RNO) prevented immune-complex (IC)-induced reactive oxygen species 
(ROS) release from neutrophils, and dermal-epidermal separation of normal human skin incubated 
with antibodies to COL7 and neutrophils. The inhibitors also reduced shedding of CD62L and 
decreased CD11b expression on IC-stimulated neutrophils. To validate these in vitro findings, 
ROF was selected for further in vivo validation. For this, experimental EBA was induced in mice by 
transfer of anti-COL7 IgG or immunization with recombinant COL7 and adjuvant. 5 mg/kg of ROF 
treatment significantly reduced blistering in the antibody transfer-induced model and abolished 
disease progression in the immunization-induced model. These results support the notion that PDE4 
inhibition may be a drug candidate for treatment of EBA as well as other neutrophil-driven AIBDs.   
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Keratinocytes play an essential role on epicutaneous Staphylococcus aureus infection through 
MyD88
S Nakagawa,1 Y Nakamura,1 Y Katayama,1 G Nunez2 and H Matsue1 1 Dermatology, Chiba 
University, Chiba city, Japan and 2 Pathology and Comprehensive Cancer Center, University 
of Michigan, Ann Arbor, MI
Staphylococcus aureus is known to colonize the skin of atopic dermatitis (AD) patients, but not of 
healthy people. We discovered δ-toxin derived from S.aureus, directly stimulating mast cells and 
thus inducing Th2 type skin inflammation in AD. However, the mechanism by which S.aureus 
induces eczematous skin inflammation is yet to be clarified. MyD88 is known to act as an adaptor 
in almost all Toll-like receptor-and IL-1 receptor-mediated signaling pathways for innate immune 
responses against microorganisms including S.aureus. Myd88-/- mice reportedly exhibited more 
severe skin inflammation than WT mice due to high bacteria burden if S.aureus was subcutaneously 
injected, indicating MyD88 has a protective role against subcutaneous S. aureus infection. We first 
sought to determine whether or not MyD88 was involved in eczematous inflammation induced 
by epicutaneous S. aureus inoculation. In this model, S. aureus was applied occlusively on shaved 
dorsal skin. Contrary to the subcutaneous injection, we found that Myd88-/- mice showed no skin 
inflammation, whereas WT mice showed severe eczematous lesions with the similar colonization 
of S. aureus in either mice, indicating that MyD88 signaling promoted skin inflammation but not 
cleared S. aureus in the epicutaneous model. To explore the involvement of TLR2/4 and whether 
keratinocytes are involved in this MyD88-mediated inflammation, we inoculated S. aureus on Tlr2/4-
/- and epidermal cell specific Myd88 knock-down, K14CreMyd88-/- mice. Compared to WT mice, 
eczematous skin inflammation was significantly reduced in K14CreMyd88-/-, but not in Tlr2/4-/- 
mice. mRNA and protein levels of IL-17 were significantly reduced in K14CreMyd88-/- infected 
mice. In accordance with these, Il17a-/--Il17f-/- mice showed significantly less skin inflammation. 
In conclusion, we found that keratinocyte is an essential cell type for MyD88 signaling, leading to 
IL-17 production that was important for epicutaneous S. aureus infection-induced inflammation.   
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TSLP downregulates human β-defensin 2 through STAT3-dependent pathway in keratinocytes
S Son Dermatology, Korea University College of Medicine, Seoul, Korea (the Republic of)
Atopic dermatitis (AD) is a chronic and pruritic inflammatory skin disease associated with a defective 
skin barrier and a dysregulation of Th2 immune response. Most patients with AD show reduced 
expression of antimicrobial peptides (AMPs), which may plays an important role in host defense 
against bacteria, fungi, and viruses infection. Thymic stromal lymphopoietin (TSLP) has a patho-
genetic role in the initiation and maintenance of allergic inflammatory diseases including AD. 
The function of TSLP was revealed in previous studies. However, it remains unknown that the 
regulatory mechanism of HBD-2 expression by TSLP in primary human keratinocytes. The present 
study demonstrates dose-dependent decreases of human β-defensin-2 (HBD-2) mRNA and protein 
levels in keratinocytes following stimulation to TSLP. In addition, this study demonstrated the 
effect of TSLP on HBD-2 expression in human skin equivalent models. We further investigated 
the regulatory mechanisms of TSLP-reduced HBD-2 expression in primary human keratinocytes. 
TSLP induced STAT-3 protein expression in primary human keratinocytes. Data from immunohisto-
chemical stain for skin lesions of atopic patients demonstrated the increased expression of STAT-3 
than normal skin. HBD-2 was regulated through STAT-3-dependent pathway in keratinocytes. Our 
results from chromatin immunoprecipitation (ChIP) assay and electrophoretic mobility shift assay 
(EMSA) showed the direct regulation of TSLP on HBD-2 promoter. Taken together, this study reveals 
that TSLP stimulation may reduce HBD-2 expression through a STAT–3 dependent mechanism in 
human keratinocytes. The present study suggests a novel and key role of STAT-3 in TSLP-mediated 
immune response in keratinocytes. Moreover, it would be helpful for understanding the pathologic 
signal transduction in AD.    
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Neutralization of stratum corneum accelerates the progress from atopic dermatitis to asth-
ma-like lesion in flaky tail mice treated by house dust mite allergen
H Lee,1 N Lee,1 B Kim,1 M Jung,1 D Kim,1 C Moniaga,2 K Kabashima2 and E Choi1 1 
Department of Dermatology, Yonsei University Wonju College of Medicine, Wonju, Korea 
(the Republic of) and 2 Department of Dermatology, Kyoto University Graduate School of 
Medicine, Kyoto, Japan
A disrupted skin barrier of atopic dermatitis (AD) permits easier penetration and sensitization of 
external allergens and then induces the development of asthma and allergic rhinitis, so called the 
‘atopic march’. Maintenance of normal acidity in the stratum corneum (SC) is an important factor 
for normal skin barrier function. Elevation of SC pH accompanied by the increase of serine protease 
activity and TSLP expression provokes skin inflammation. We determined whether the neutralized 
SC environment can accelerate airway inflammation more easily in flaky tail mice, a representative 
AD murine model with congenital skin barrier abnormality, after the exposure of house dust mite 
(HDM). Dermatofagoides pteronyssinus (Dp), a HDM was applied on the dorsal skin of flaky tail 
mice twice a week, which accompanied by the application of neutral cream (pH 7.4) and acidic 
cream (pH 2.8) twice a day for 6 weeks. Intranasal inhalation of Dp was done daily during last 3 days. 
Gross findings, functional study for skin barrier, blood sampling, bronchoalveolar lavage and biop-
sies of skin and lung were done at 24 h after last treatment. Repeated topical applications followed 
by intranasal inhalations of Dp to flaky tail mice made the respiratory allergic inflammation as well 
as the AD-like skin lesion. Accompanying neutral cream treatment accelerated or aggravated the 
allergic inflammation in the respiratory system as well as the skin. Atopic march-like progress from 
AD to asthma-like lesion can be observed in flaky tail mice after topical and intranasal application 
of HDM, and the neutralization of SC can accelerate or aggravate it.    
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Effect of Ezetimibe and Simvastatin combination on Alopecia Areata in the C3H/HeH Mouse 
Model
JJ Jimenez,1 VA Petit,1 CI Perez,1 A Vila Granda,1 KG Alejo,1 GM DelCanto2 and 
LA Schachner1 1 Dermatology and Cutaneous Surgery, University of Miami, Miami, FL and 2 
Biochemistry and Molecular Biology, University of Miami, Miami, FL
Alopecia Areata (AA) is one of the most common forms of alopecia, affecting as many as 1-2% of 
the population worldwide. AA is an autoimmune disorder underscored by the presence of T-cell 
infiltrate throughout the lesions, although its exact pathogenesis remains elusive. The C3H/HeH 
mouse provides an excellent model of AA. In this model, transplantation of CD8+ T cells has been 
shown to induce localized alopecia, whereas CD4+/CD25- lymphocytes induce protracted disease. 
Conversely, CD4+/CD25+ T cell regulators block disease onset in C3H/HeH mice. The transcription 
factor FOXP3 is a powerful regulatory T cell marker and has been shown to play a critical role in 
immune tolerance. We have demonstrated previously that treatment with simvastatin, a lipid-low-
ering drug, increases naturally occurring CD4+/CD25+/FOXP3+ T regulators and induces remission 
of AA lesions in affected C3H/HeH mice. As simvastatin and ezetimibe are often used in combi-
nation to treat hypercholesterolemia, in the present study we tested the effect of this combination 
on AA in the C3H/HeH mouse model. C3H/HeH mice were randomized into three cohorts: one 
untreated, one receiving simvastatin alone, and one receiving combination simvastatin/ezetimibe. 
Treatments were carried out for three months. Of these, both simvastatin and simvastatin/ezetimibe 
resulted in remission of AA lesions in affected mice, but the combination treatment resulted in a 
marked increase in FOXP3+ T-regulators compared to simvastatin alone. These findings provide a 
compelling rationale for the use of simvastatin/ezetimibe as a novel therapeutic approach for AA.   
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Epicutaneous and oral low zone tolerance protects from colitis by activation of regulatory 
T cells
T Schmidt,1 N Lorenz,1 V Raker,1 S Reissig,2 A Waisman,2 B Weigman3 and K Steinbrink1 1 
Department of Dermatology, University Medical Center Mainz, Mainz, Germany, 2 Institute 
of Molecular Medicine, University Medical Center, Mainz, Germany and 3 Department of 
Gastroenterology, Univerisity of Erlangen, Erlangen, Germany
The model of TNBS-induced colitis in mice represents features of human Crohn’s disease involving 
key cellular and immunologic mechanisms making it a suitable model for the investigation of immu-
nologic phenomena such as tolerance. Previously, we were able to prevent the development of an 
allergic skin inflammation in mice through epicutaneous and oral applications of small amounts 
of haptens leading to induction of low zone tolerance (LZT). In the current study, we analyzed the 
impact of orally and epicutaneously-induced LZT on the outcome of the TNBS-colitis. We found 
that repeated applications of low doses of the hapten TNCB inhibited the course of colitis resulting 
in a significantly reduced inflammation of the gut, which were evaluated by use of endoscopy and 
histology. In line with these results, we observed a diminished Th1/Th17-mediated T cell response 
(hapten-specific proliferation and Th1/Th17-cytokine production). Use of a second, unrelated hap-
ten (DNFB) for LZT induction revealed an antigen-specific tolerance mechanism. Furthermore, we 
addressed the question of the role of CD4+CD25+ regulatory T cells (Tregs) in LZT regulation of 
colitis. Here, mice were either treated with anti-CD25 mAb or DEREG mice with diphtheria toxin 
for Treg depletion prior to LZT induction and subsequent colitis challenge. In the absence of Tregs, 
LZT failed to develop but a pronounced colitis response was observed. In addition, in the absence 
of IL-10, the induction of LZT by epicutaneous as well as oral hapten applications was completely 
inhibited, implying a suppressive function of IL-10 as well as of Tregs in colitis prevention by LZT. 
This study demonstrates that oral as well as epicutaneous LZT to haptens results in prevention of a 
Th1/Th17-mediated colitis through IL-10 and CD4+CD25+ Treg-mediated mechanisms, highlighting 
the skin as organ for tolerance induction in preventive and therapeutic approaches.    
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Expanded αβ T cell clones are present in the healed lesions of psoriasis and likely represent 
the autoreactive T cells of origin
TR Matos,1 JT O’Malley,1 A Gehad,1 JE Teague,1 E Lowry,1 H Robins,3 TS Kupper,1 JG Krueger2 
and R Clark1 1 Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, 2 
Rockefeller University, New York, NY and 3 Adaptive Biotechnologies,, Seattle, WA
Psoriasis is a uniquely human autoimmune disease mediated by IL-17 producing T cells. Prior 
studies have demonstrated CD4 and CD8 T cells producing IL-17 and/or IL-22 remained behind 
after clinical resolution of psoriatic lesions, suggesting they may represent autoreactive T cells of 
origin in psoriasis. We studied lesional and previously lesional skin in patients who had cleared 
on etanercept therapy using deep TCR sequencing and immunostaining. Expanded oligoclonal T 
cell populations were present in healed psoriatic lesions. We identified expanded T cell clones by 
immunostaining for the specific TCR Vβ and found that they produced IL-17 and/or IL-22 in active 
lesions from the same patients, suggesting they represent disease initiating T cells. Further α/δ TCR 
sequencing demonstrated that these putative disease initiating T cell clones were universally αβ T 
cells. In contrast to studies in mouse models, γδ T cells were rare in human psoriasis, previously 
lesional psoriatic skin and in healthy human skin, making up only 1.6%, 0.45% and 1.8% of the 
total T cell population respectively. By matching TCR α and β sequences of initiating clones based 
on T cell frequency, we have obtained for the first time the complete TCR sequence of putative 
initiating T cells in psoriasis. In short, we have identified and characterized the T cells of origin in 
psoriasis and find that they are universally αβ T cells producing IL-17 and/or IL-22. In dramatic 
contrast to experiments in mice, none of the initiating cells were γδ T cells and γδ T cells were rare 
in both active and cleared disease. These results show that human psoriasis is a disease mediated 
by αβ T cells. Lastly, we have identified for the first time the full TCR sequences of initiating T 
cells in psoriasis, the first step in future studies designed to identify the auto-antigen in psoriasis.   
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Autoantibodies to parts of type XVII collagen outside of the non-collageneous 16A domain 
lead to mild bullous pemphigoid due to the non-depletion of autoantigen
H Iwata,1 K Imafuku,1 K Izumi,1 M Wada,2 K Natsuga,1 H Ujiie,1 W Nishie1 and H Shimizu1 1 
Dermatology, Hokkaido University Graduate School of Medicine, Sapporo, Japan and 2 Oral 
Diagnosis and Medicine, Hokkaido University Graduate School of Medicine, Sapporo, Japan
Bullous pemphigoid (BP) is an autoimmune subepidermal blistering skin disease associated with 
autoantibodies to type XVII collagen (COL17) and BP230. The non-collagenous 16A (NC16A) 
domain is regarded as the major pathogenic epitope for BP. Some BP patients, however, have 
autoantibodies against parts of COL17 outside of the NC16A domain (non-NC16A-BP). In non-
NC16A-BP, patients mostly present mild clinical manifestations. We investigate the BP patho-
mechanism of non-NC16A-BP and NC16A-BP. For this study, four cases each of NC16A-BP and 
non-NC16A-BP were investigated. There were no differences in titer levels between NC16A-BP 
and non-NC16A-BP as determined by indirect immunofluorescent microscopy and by a full-length 
COL17 ELISA recently developed in our group. IgG subclasses were not significantly different 
between non-NC16A-BP and NC16A-BP. Both NC16A-IgG and non-NC16A-IgG activated neu-
trophils. It is hard to explain the clinical diversity based on IgG subclasses and reactive oxygen 
species (ROS) release. Interestingly, NC16A-IgG caused the depletion of COL17 in keratinocytes, 
but non-NC16A-IgG did not. Moreover, stimulation with NC16A-IgG reduced the adhesion strength 
to the culture dish, but stimulation with non-NC16A-IgG did not. Typical BP patients, with auto-
antibodies against the NC16A domain, may present more severe clinical blistering due to the 
prominent depletion of COL17 induced by autoantibodies than non-NC16A-BP patients, without 
autoantibodies against the NC16A domain, present. These data suggest that the NC16A domain of 
COL17 is a domain that is unique in inducing COL17 depletion and that autoantibodies against 
NC16A may be strongly involved in the BP pathogenesis.    
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Proposal of a novel concept of necroptosis-mediated skin inflammation using an imiquim-
od-induced psoriasis-like dermatitis model
T Honda,1 O Yamamoto,2 Y Miyachi1 and K Kabashima1 1 Dermatology, Kyoto University, 
Kyoto, Japan and 2 Dermatology, Tottori University, Tottori, Japan
Necroptosis is a newly identified form of programed cell death, and the activation of receptor-inter-
acting protein (RIP)1, RIP3, and the mixed-lineage kinase domain-like (MLKL) is a central pathway 
for its development. Recent reports indicate a crucial role of necroptosis-dependent inflammation 
in the pathogenesis of chronic inflammatory diseases, including Crohn’s disease. However, its 
involvement in inflammatory skin diseases remains unknown. Here, we investigated the involve-
ment of necroptosis in the pathogenesis of psoriasis. An electron microscopy analysis elucidated 
the existence of dead keratinocytes in the human psoriasis skin lesion with positive signals for RIP3, 
implicating a possible involvement of necroptosis in psoriasis. To further evaluate this, we used 
an imiquimod (IMQ)-induced murine psoriasis-like dermatitis model and found that RIP3 expres-
sion was significantly upregulated both in mRNA and protein levels in the skin. Next we applied 
RIP3-deficient mice to the model, which exhibited impaired skin swelling and neutrophil infiltration. 
Consistently, necrostatin-1, a specific inhibitor of RIP1 kinase, attenuated IMQ-induced skin inflam-
mation in wild-type mice. In addition, IMQ promoted activation of MLKL and keratinocyte death, 
which was significantly suppressed by necrostatin-1. These results suggest that necroptosis mediates 
the IMQ-induced psoriasis-like murine dermatitis, and lead to a proposal of a novel concept of 
necroptosis-dependent inflammation in the development of psoriasis.    
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Psoriasis skin inflammation modulates microRNA expression of subcutaneous adipose tissue 
- a missing link between psoriasis and co-morbidities? 
L Cheung, R Fisher, N Kuzmina, D Li, X Li, O Werngren, L Blomqvist, M Ståhle and 
NX Landén Karolinska Institute, Stockholm, Sweden
Psoriasis is an immune-mediated inflammatory disease, which is associated with a high risk of 
developing systemic co-morbidities, such as obesity, cardiovascular disease and diabetes mellitus. 
However, the mechanistic links between psoriatic skin inflammation and systemic co-morbidities 
remain largely unknown. MicroRNAs (miRNAs) are recently discovered gene regulators playing 
important roles in psoriasis skin inflammation. Here we aimed to explore whether the skin inflam-
mation in psoriasis affects miRNA expression of the underlying subcutaneous adipose tissue (scAT) 
and whether this may be a link between psoriasis and co-morbidities. To this end, we compared the 
miRNA expression profile of scAT underneath lesional (L) and non-lesional (NL) psoriatic skin. We 
further validated the differential expression of several miRNAs and characterized their expression 
patterns in different cell types present in scAT. We focused on miR-26b, which was highly up-regu-
lated in scAT underneath L psoriasis skin, and herein we show that it targets and downregulates neu-
tral cholesterol ester hydrolase 1 (NCEH1), an enzyme essential for cholesterol efflux, in monocytes/
macrophages, adipocytes, vascular endothelial cells and fibroblasts. We conclude that this miRNA 
may serve as a mechanistic link between psoriatic skin inflammation and its systemic co-morbidities.   
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Cytosolic DNA detected in the psoriatic lesion is the result of endogenous reverse tran-
scription. J-P Molès, A Griez, J-J Guilhou, N Nagot, P Vande Perre, P Dujols. Inserm U1058, 
Montpellier, France
J Molès, A Griez, J Guilhou, N Nagot, P Vande Perre and P Dujols UMR1058, Inserm, 
Montpellier, France
Psoriasis is a chronic skin disease characterized by skin inflammatory erythemato-squamous lesions 
involving dermal infiltrate, epidermal hyperplasia and abnormal differentiation of keratinocytes. 
Recent works suggest that a large amount of cytosolic DNA (cyDNA) promotes inflammation in 
the psoriatic lesion by breaking keratinocytes DNA tolerance, activating the Toll-like receptor 
pathway and promoting ton self-sustained inflammation. However, the origin of the cyDNA remains 
unknown. Since endogenous retroelements are overexpressed in lesional skin we aim at testing 
the hypothesis that part of the cyDNA originates from reverse transcriptase activity (RTA). We 
have developed an in situ approach to detect the RTA on skin section. In upper layers of lesional 
psoriatic epidermis and also in neutrophils of Munro-Saboureau’s abscesses, the RTA was detected 
with a clear cytosolic localisation. No staining was observed in the dermis. The RTA was almost 
undetectable in normal skin. The first step of the RTA produces a RNA:DNA duplex. Immuno-
fluorescence analysis using two different monoclonal anti-duplex antibodies, showed a strong, 
clearly cytoplasmic, staining in the basal and upper layers of psoriatic skin. In non lesional skin or 
in atopic dermatitis sections, the signal became barely detectable. In vitro, demethylating agents 
stimulate endogenous RT of cultured cells. We observed that azacytidine and/or desoxiuridine 
lead to RNA:DNA duplexes detection in the cytosol of cultured keratinocytes within 48 hours. 
After quantification by real time PCR, HERV-K and LINE-1 copy numbers increased by 3.9 and 3.2 
respectively and, after 72 hours of stimulation, decreased back to almost baseline level. Upon the 
same demethylating treatment, an increased cytokine secretion was observed for IP10, IL17, IL33 
and IFNγ but not for IL1RA, IL8 and TNFα. Our results provide evidence for an endogenous reverse 
transcriptase origin of the cytosolic DNA triggering the inflammation in psoriasis.    
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Proof- of -Concept study to investigate efficacy of selective type-4 phosphodiesterase (PDE4) 
inhibitor OPA-15406 for topical treatment adult subjects with mild to moderate Atopic 
Dermatitis (AD)
S Shideler,1 S Sugaya,2 A Secci,3 A Smith,3 P Bricmont3 and E KOrnyeyeva3 1 Shideler 
Dermatology, Carmel, IN, 2 OPCJ, Tokyo, Japan and 3 OPDC, Princeton, NJ
We report Proof-of-Concept (POC) study results evaluating efficacy of ascending doses of topical 
OPA-15406 in adult subjects with mild to moderate AD. AD is chronic pruritic disorder and mono-
cytes from atopic patients have an abnormally high activity of cAMP–phosphodiesterase (PDE), 
the activity of cAMP can be normalized by PDE inhibitors. OPA is novel selective PDE4 inhibitor 
developed in AKO institute Japan. A total 90 subjects with AD (18-65) were enrolled; 60 subjects 
to 0.3%, 1%, 3% OPA or vehicle, treating 5% body surface area (BSA); and 30 subjects to 1% or 
3% OPA or 0.1% tacrolimus, BID, treating 10-66% BSA. POC efficacy was evaluated by Investi-
gator Global Assessment (IGA) success rate, defined as having a 0 (clear) or 1 (almost clear) score 
at W4. 86 subjects completed the study. Two subjects discontinued treatment due to AEs: allergic 
dermatitis (tacrolimus) and moderate skin irritation (3% OPA). One non-treatment related SAE of 
cholelithiasis was reported for 1% OPA. A total 21% (8/38) AEs were considered treatment-related; 
the most frequently reported was mild application site pain (2/90, one each for 1% and 3% OPA). 
AEs reported as possibly related to OPA were: dry mouth (1), application site edema (1), pain (1), 
moderate irritation (1), sinusitis (1) and atopic dermatitis (1). All concentrations of OPA were supe-
rior to the vehicle for efficacy analysis of IGA at W4. Notably, OPA 1% demonstrated statistically 
significant success rate in IGA score of 63.6% against 26.7% for the vehicle (p-value, 0.0448). 
When compared to tacrolimus, OPA 1% also demonstrated comparable incidence of success rate 
in IGA scores at W4 63.6% vs 53.3%. Additional efficacy analysis assessing VAS for pruritus and 
Eczema Area and Severity Index (EASI) scores, further demonstrated OPA 1% activity over vehicle. 
In summary, topical treatment with 1% OPA for 28 days was safe and demonstrated POC efficacy 
in adult subject with mild to moderate AD.    
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Keratinocyte-autonomous IL-36/IL-17C loop shapes the psoriasiform phenotype
K Ohko, K Nakajima and S Sano Kochi University, Nankoku, Kochi, Japan
IL-17C contributes to the innate defense of epithelium, promotes the barrier function of mucous 
membrane, and differentiates Th17 cells, which produce IL-17A and IL-17F. Furthermore, IL-17C 
represents the most abundant isoform of the IL-17 family in psoriatic lesional skin. However, the 
detail mechanism by which IL-17C expression in keratinocytes is regulated during development of 
psoriasis remains elusive. IL-36 cytokines are also highly expressed in psoriatic lesions and suggested 
to play a role in psoriasis development as shown by studies using transgenic and knockout mice. 
The relationship between IL-17C and IL-36 signals in keratinocytes is also unknown. We found 
that, like psoriatic lesions, IL-17C mRNA was up-regulated in skin lesions in K5.Stat3C mice, which 
recapitulate the pathology and pathomechanism of psoriasis. Gene deletion of the IL-36 receptor 
(R) resulted in a great attenuation of skin lesions of K5.Stat3C mice, clearly indicated that the IL-36 
signaling was required for psoriasiform phenotype. At the same time, IL-17C gene expression was 
decreased upon IL-36R knockout. Experiments using cultured primary keratinocytes revealed that 
stimulation with heat-killed Candida resulted in increased mRNAs of IL-36 alpha, IL-17C, and 
CCL20. Interestingly, the up-regulation of all these genes was not observed in IL-36R-/- keratino-
cytes. Furthermore, IL-17C gene expression in keratinocytes was increased by stimulation with 
IL-36 family members; however, of course, not in IL-36R-/- keratinocytes. Collectively, triggering of 
pattern recognition receptors with microbial components, toll-like receptors for example, leads to 
activation in IL-36 signaling followed by IL-17C and other psoriasis signature gene expressions in a 
keratinocyte-autonomous fashion. We speculate that the axis of IL-36/IL-17C contributes to initiation 
and continuation of autocrine amplification loop in psoriasis pathomechanism.    
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A novel specific inhibitor of PI3Kδ effectively ameliorates tissue inflammation in experimental 
epidermolysis bullosa acquisita
H Koga,1 M Pont,2 R López,2 M Erra,3 E Schmidt,1 A Kasprick,1 N Godessart,2 R Ludwig1 
and C Balagué2 1 LIED, University of Lübeck, Lübeck, Germany, 2 Dermatology Research, 
Almirall, Sant Feliu de Llobregat, Spain and 3 Medicinal Chemistry, Almirall, Sant Feliu de 
Llobregat, Spain
Epidermolysis bullosa acquisita (EBA) is an organ-specific autoimmune disease caused by autoan-
tibodies directed against type VII collagen (COL7). Clinically, EBA is characterized by muco-cuta-
neous inflammation, blistering and scaring, which are difficult to treat. Autoantibody production as 
well as immune complex (IC)- and neutrophil-mediated cutaneous inflammation are key features 
of EBA pathogenesis. Here we evaluated the therapeutic potential of LAS191954, a novel selective 
PI3Kδ inhibitor in experimental models of EBA. In vitro, LAS191954 potently and dose-dependently 
inhibited activation of human B cells as well as IC-induced human neutrophil activation. The effect 
of LAS191954 on autoantibody production was evaluated in an autoimmune disease model (MRL/
lpr strain). Daily oral administration of the compound for 4 weeks dose-dependently reduced auto-
antibody titers compared to vehicle-treated mice. In addition, in a murine model of experimental 
EBA induced by transfer of anti-COL7 IgG, oral administration of LAS191954 impaired the onset of 
cutaneous inflammation and blistering with similar efficacy as a systemic corticosteroid at high doses 
(methylprednisolone (MP), 20mg/kg). Finally, the therapeutic effect of LAS191954 was evaluated and 
compared head to head with MP in an autoimmune model of EBA induced by active immunization 
with COL7, using a curative scheme. COL7-immunized mice were allocated to treatment groups 
only after they had developed EBA skin lesions, and subsequently treated daily for 6 weeks with 
weekly clinical monitoring. Compared to vehicle-treated mice, MP treatment halted the progression 
of the disease at the end of the observation period. In contrast LAS191954 reduced the initial disease 
severity by half, effectively ameliorating inflammation and blistering. Collectively, our data suggest 
that PI3Kδ is a potential target to treat EBA and related pemphigoid diseases.    
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Blockade of the Fc gamma RIV enhances neutrophil extravasation into the skin in antibody-in-
duced cutaneous inflammation
JE Klöpper,1 M Pieper,2 F Nimmerjahn,3 D Zillikens,1 P König2 and R Ludwig1 1 Luebeck 
Institute of Experimental Dermatology, University of Luebeck, Luebeck, Germany, 2 Institute 
of Anatomy, University of Luebeck, Luebeck, Germany and 3 Department of Biology, 
University of Erlangen-Nuremberg, Erlangen, Germany
Autoimmune diseases have become a major medical burden. Epidermolysis bullosa acquisita (EBA) 
is a prototypical autoimmune bullous dermatosis where autoantibodies target type VII collagen 
(COL7), an integral part of anchoring fibrils. In an EBA mouse model, we established simultaneous 
visualization of autoantibodies, target tissue and myeloid effector cells in vivo. We identified new 
checkpoints for antibody-induced tissue injury: (i) immediate antibody binding, (ii) rapid neutrophil 
recruitment and (iii) short-term neutrophil localization to the antibody deposits. Following up these 
findings, we aimed to unravel the molecular control of these checkpoints. Therefore, we evaluated 
the impact of Fc gamma RIV (FcgRIV) inhibition on neutrophil recruitment to the dermal-epidermal 
junction (DEJ). Fluorescently labeled anti-COL7 IgG was injected into LysM-eGFP mice (eGFP 
transgenic mice under the lysozyme M promotor) in the presence of either blocking anti-FcgRIV 
antibody or corresponding isotype. Using multiphoton microscopy, we studied antibody binding 
and neutrophil extravasation into the dermis and their recruitment to the DEJ in vivo following a 
defined time course (days 1, 3 and 8 after the initial anti-COL7 IgG injection). Unexpectedly, at 
all time points, we observed a rapid extravasation of LysM-eGFP+ cells into the skin with numbers 
significantly higher in mice treated with the FcgRIV-blocking antibody compared to control mice. In 
contrast, localization of LysM-eGFP+ cells to the target antigen, located along the DEJ was, except 
of day 8, significantly reduced in anti-FcgRIV antibody-treated mice. These findings are in sharp 
contrast to the previously reported role of activating FcgRs in experimental EBA and underscore 
the importance of advanced in vivo imaging techniques to fully understand the complexity of 
antibody-mediated neutrophil-dependent inflammation.    
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Identifying disease-specific molecules of dermatomyositis and lupus erythematosus skin by 
quantitative proteomics analysis
K Nakamura, M Jinnin, K Inoue, S Fukushima and H Ihn Dermatology and Plastic Surgery, 
Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan
Dermatomyositis (DM) and systemic lupus erythematosus (SLE) have several common features in 
the skin including interferon (IFN) signaling and mucin deposition, although their roles are yet to be 
investigated. The aim is to identify common molecular changes in DM and SLE skin using proteomic 
analysis. Glycosaminoglycans were also analyzed by high performance liquid chromatography 
utilizing DM, SLE and normal subject (NS) skin. Expression of 61 proteins was up- or down-regu-
lated in DM skin compared to NS skin. Among them, PSMB9, an immunoproteasome subunit, was 
up-regulated in the epidermis of DM and SLE skin. Versican V1, a core protein for glycosamino-
glycan, was up-regulated while type 1 collagen was down-regulated in the dermis of DM and SLE. 
IFN stimulated PSMB9 expression in cultured keratinocytes, and reduced collagen expression in 
dermal fibroblasts, but not effected on versican V1. PSMB9 knockdown in keratinocytes led to the 
significant suppression of TGF-b2 and TGF–b3, inducers of versican synthesis. ΔDIHS-diS1, one of 
the components of heparin sulfates, was significantly increased only in DM. TGF-β2 significantly 
increased ΔDIHS-diS1 expression in dermal fibroblasts in vitro. Our hypothetical model is that 
interferon signature in DM and SLE skin reduces collagen expression in dermal fibroblasts, whereas 
PSMB9 overexpressed by interferon induces versican inducers in epidermal keratinocytes. Consid-
ering Nakajo-Nishimura syndrome, caused by mutations in PSMB8, has similar symptoms to DM 
and SLE, PSMB9 may be a key molecule associating with interferon in DM and SLE. Furthermore, as 
the mechanism of increased cutaneous mucin in DM and SLE, versican up-regulation and collagen 
down-regulation may accelerate mucin deposition.    
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Autoantibodies with reactivity to skin antigens spontaneously develop in Scurfy mice in the 
absence of functional regulatory T cells 
S Häberle, X Wei, A Enk and E Hadaschik Department of Dermatology, University of 
Heidelberg, Heidelberg, Germany
Scurfy mice are a suitable model to study the spontaneous development of autoimmune disease: 
In Scurfy mice a missense mutation in the foxp3 gene causes loss of function of regulatory T cells, 
which leads to multiorgan autoimmune inflammation due to the expansion of autoreactive T cells. 
We and others have previously shown that scurfy mice have elevated levels of autoantibodies in 
their sera. We are interested in the specificity of these autoantibodies to autoantigens in the skin. 
This work describes the characterization of different autoantibodies from sera of scurfy mice by 
immunofluorescence staining of skin. Frozen palate slices of wildtype (WT) mice were used for 
indirect immunofluorescence staining with sera from sick scurfy mice or WT littermate controls as 
the primary antibody followed by detection by anti-mouse IgG secondary antibodies. Sera of scurfy 
mice showed positive staining in the epidermis with different staining patterns, whereas sera of WT 
mice showed no specific staining. With indirect immunofluorescence autoantibodies from scurfy 
sera showed either a linear staining indicative of recognition of proteins of the basal membrane 
or a reticular staining indicative for desmosomal autoantigens. Using direct immunofluorescence 
frozen palate slices of sick scurfy mice showed deposits of autoantibodies in the skin whereas 
WT mice did not. An enzyme linked immunosorbent assay (ELISA) revealed that the majority of 
sera of scurfy mice contained autoantibodies specific for desmoglein 3, the known antigen for 
the blistering autoimmune disease pemphigus vulgaris. In summary our data show that in scurfy 
mice autoantibodies with reactivity to skin spontaneously develop and that some scurfy mice have 
autoantibodies specific for desmoglein 3.    
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Transcriptional regulation of increased Treg/Th17 and γδT cell plasticity in human psoriasis 
and CD18hypo PL/J psoriasiform dermatitis
MV Gatzka, K Singh, A Hainzl, R Pandey, I Krikki, M Wlaschek and K Scharffetter-Kochanek 
Dept. Dermatology&Allergic Diseases, Ulm University, Ulm, Germany
The pivotal role of IL-17 in psoriasis is impressively reflected by the efficacy of modern drugs target-
ing the IL-23/IL-17 axis. However, controversial opinions exist about the predominant immune cell 
type(s) responsible for production of IL-17A in the skin and the mechanisms of differentiation towards 
an inflammatory phenotype. To investigate the origin of IL-17 producing immune cell populations at 
different disease stages in psoriasis and to uncover potential mediators of immune cell plasticity, we 
systematically analyzed skin sections and blood samples from 15 psoriasis patients by immunofluo-
rescent microscopy and in vitro functional assays, respectively, and in parallel performed in-depth 
gene expression studies in the CD18hypo PL/J mouse model of psoriasiform dermatitis. Of note, in 
all psoriasis skin samples analyzed, highly elevated numbers of CD3+IL-17+ were detectable and 
significant numbers of γδTCR+IL-17+ as well as Foxp3+IL-17+, and Foxp3+RORγt+ double-positive 
cells - indicative of potential conversion of regulatory T cells (Tregs) into Th17 cells. In affected 
CD18hypo PL/J mice (adapted PASI-score >6), we identified the Peroxisome proliferator-activated 
receptor gamma (PPAR-γ) - previously implicated in Treg maintenance and negative regulation of 
Th17 differentiation in other autoimmune models - to be significantly down-regulated in sorted 
skin T cell populations, whereas expression levels of other regulators such as Hif-1a, Nrf2 and 
Hemoxygenase were not significantly altered. The functional role of PPAR-γ in Treg/Th17 and γδT 
cell plasticity was further evaluated in lentiviral overexpression studies in T cells and confirmed 
in human skin samples at the expression level. In conclusion, this investigation for the first time 
systematically evaluated Treg/Th17 conversion in a larger cohort of psoriasis patients and identified 
PPAR-γ as potential mediator of increased skin T cell plasticity under inflammatory conditions.   
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Mass spectrometry (MS)-based proteomic analysis of the anti-desmoglein (Dsg) antibody 
(ab) repertoire in pemphigus patients indicates wide clonal diversity and VH gene usage
J Chen,1 Q zheng,1 C hammers,2 C Ellebrecht,1 C Lin,1 H tang,3 J Langenhan,4 L Komorowski4 
and JR Stanley1 1 dermatology, university of pennsylvania, Philadelphia, PA, 2 University of 
Lübeck, Lübeck, Germany, 3 Wistar Institute, Philadelphia, PA and 4 Institute of Experimental 
Immunology, EUROIMMUN AG, Lübeck, Germany
Autoabs against Dsgs are found in pemphigus foliaceus (PF) and vulgaris (PV). Anti-Dsg B cell 
repertoires have been studied by ab phage display (APD) and heterohybridoma, but these methods 
do not answer if those B cell clones actually contribute to the serological response. We charac-
terized circulating autoabs in 3 PV and 2 PF patients by MS of their Dsg-affinity purified abs, then 
identified the spectra by matching them to a database of abs in each patient determined by next 
generation sequencing of IgG coding sequences in circulating B cells. We found an average of 
45 clones per patient (pt) (range 17-69), which is much more diverse than suggested by previous 
genetic studies (6 mean per pt). In 4 of our pts, 42 anti-Dsg IgG APD clones were found (4-25 per 
pt) of which 4 contributed to the serological response (0-2 per pt), suggesting most of these B cells 
clones are memory B cells that contribute to little or no ab production. Conversely 94 ab clones 
detected in sera were not detected by APD, suggesting that circulating B cells encoding these abs 
are extremely rare or the expression of these abs is toxic in the APD procedure. Each patient had 
preferential variable heavy gene (VH) usage for antibody production, but gene usage varied among 
patients. In one PF patient studied over 2 years, we found the same clonal abs, consistent with our 
previous finding that anti-Dsg B cell clones persist over time. In summary, proteomic analysis of 
circulating abs in pemphigus indicates: wider clonal diversity than previously suggested; variable 
VH gene usage in anti-Dsg abs among patients; and memory anti-Dsg B cells do not necessarily 
result in antibody production. Thus, more complete analysis of circulating abs in pemphigus requires 
proteomic characterization.    
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An mTORC1 /AKT1 axis controls filaggrin expression and processing, a novel mechanism for 
skin barrier disruption in atopic dermatitis 
A Naeem,1 C Cole,2 Z Yanan,1 M Moffat,3 W Cookson,3 J Harper,1 D Wei-Li,1 T Reinheckel,4 
S Brown2 and R O’Shaughnessy1 1 UCL Institute of Child Health, London, United Kingdom, 
2 Centre for Dermatology and Genetic Medicine, University of Dundee, Dundee, United 
Kingdom, 3 National Heart and Lung Institute, Imperial College, London, United Kingdom 
and 4 Institute of Molecular Medicine and Cell Research, BIOSSCentre of Biological Signalling 
Studies, Albert-Ludwigs-University, Freiburg, Germany
Atopic dermatitis (AD) is a common disease in which the skin is sensitive to external allergens 
resulting in an immune response characterised by redness and scaling. Current evidence suggests 
that the primary cause for disease development in majority of AD cases is a defective skin barrier. 
There is a strong genetic component to AD associated with skin barrier function in the disease. 
Null mutations in FLG are associated with the inherited eczematous disease, ichthyosis vulgaris, 
and are a major predisposing factor for AD. However not all patients have filaggrin mutations and 
conversely, and not all individuals with filaggrin mutations have AD, suggesting to us that other 
mechanisms might contribute to filaggrin expression and processing defects and hence to the 
barrier defect observed in AD patients, which could consititure alternative therapeutic avenues 
for this disease. We describe the relationship between the mTORC1 protein RAPTOR, AKT1 and 
the aminopeptidase cathepsin H, which we show plays a novel role in filaggrin processing. Skin 
of cathepsin H-deficient mice showed reduced filaggrin processing, impaired skin barrier and 
increased proinflammatory cytokine expression. Increased RAPTOR levels in AD correlated not 
only with decreased filaggrin expression but also an increase in the expression of number of other 
immune-related genes. Our findings highlight a novel, druggable, mechanism controlling filaggrin 
expression and processing which is defective in AD. Furthermore we demonstrate that inhibition 
of mTORC1 with the immunosuppressive drug rapamycin, upregulates AKT1 phosphorlyation and 
increase filaggrin levels in cultured keratinocytes.    
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MiR-146a, a microRNA overexpressed in psoriasis, regulates IL1β–induced production of 
inflammatory mediators in keratinocytes
F Meisgen, A Srivastava, NX Landén, M Ståhle, A Pivarcsi and E Sonkoly Dermatology and 
Venereology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden
MicroRNAs are short, endogenous non-coding RNAs that regulate gene expression at the post-tran-
scriptional level. We and others have previously shown altered microRNA expression profiles in 
psoriasis skin lesions as compared to healthy skin. MicroRNA-146a (miR-146a) is a microRNA we 
previously identified as a negative regulator of Toll-like receptor signaling in keratinocytes. Here 
we investigated the expression and function of miR-146a in psoriasis. We found that miR-146a is 
up-regulated in lesional, but not in non-lesional skin of psoriasis patients. Both epidermal keratino-
cytes and dermal infiltrating cells contribute to the overexpression of miR-146a in psoriasis skin, as 
evidenced by in situ hybridization. We identified IL-1β, a cytokine overexpressed in psoriasis skin, 
as an inducer of miR-146a in keratinocytes. A single stimulation with IL-1β resulted in long-lasting 
up-regulation of miR-146a, up to 96 hours post-treatment, contrasting to the rapid and transient 
expression of inflammatory mediators (e.g. IL-8, CCL20, TNF-α) in keratinocytes. Overexpres-
sion of miR-146a suppressed both the baseline and IL-1β–induced production of IL-8, CCL20 and 
TNF-α. Moreover, overexpression of miR-146a in keratinocytes resulted in decreased chemotactic 
attraction of neutrophils. By contrast, inhibition of endogenous miR-146a enhanced the baseline 
and IL1β–induced production of inflammatory mediators. Transcriptomic profiling revealed that 
miR-146a suppressed the expression of a large number of immune-related genes in keratinocytes, 
including cytokines, chemokines, and components of immune-related signal transduction pathways. 
Altogether, our results identify miR-146a as a potent negative regulator of keratinocyte inflammatory 
responses. Its overexpression in keratinocytes of psoriasis lesions may serve as a negative feedback 
to control inflammation.    
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Impaired function of regulatory T cells in patients with psoriasis is mediated by phosphor-
ylation of STAT3
L Yang, B Li, L Jin, E Dang, H Qiao and G Wang Department of Dermatology, Xijing Hospital, 
Fourth Military Medical University, Xi’an, China
Regulatory T cells (Tregs) are characterized by their immunosuppressive functions to maintain the 
immune balance. However, responder T cells (Tresp) isolated from psoriatic patients are poorly 
restrained by Tregs in vitro. But the mechanism involved in the pathogenesis of dysfunctional Tregs 
in psoriasis is not clarified. This work is to investigate the role of STAT3 pathway in the impaired 
function of Tregs in psoriasis. In the present study, we investigated the function of Tregs and the 
expression of phosphor-STAT3 (pSTAT3) in Tregs of psoriatic patients. Further, by using inhibitors 
of STAT3 pathway, we explored the role of STAT3 signaling in the regulation of Tregs function. 
Moreover, we used several proinflammatory cytokines to stimulate Tregs in order to identify the 
upstream factors that contribute to the activation of STAT3 pathways in Tregs. We found here that 
pSTAT3 was mainly in the cytoplasm of Tregs from healthy controls, whereas in psoriatic Tregs, it 
was largely detected in the nucleus. Interestingly, in the coculture system of Tregs and Tresp isolated 
from psoriatic patients, addition of STAT3 inhibitor (Stattic V) could partly restore the inhibitory 
function of Tregs. When Tregs from healthy controls were cocultured with IL-6, IL-21 and IL-23, 
these psoriasis-related cytokines induced robust increase of pSTAT3 and nuclear translocation of 
pSTAT3. Furthermore, by flow cytometry and Real-time PCR, we confirmed that psoriatic Tregs 
could produce more IFN-γ and TNF-α, nevertheless, this effect was restrained by exogenous addition 
of Stattic V. Taken together, our findings proposed a novel model in which psoriatic Tregs experi-
ence a predominant STAT3 phosphorylation by exposure to proinflammatory cytokines, leading to 
resistance of Tresp to Tregs-mediated suppression.    
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New insights into the effects of desmoglein 3-specific IgG antibodies against carboxy-ter-
minal epitopes
R Eming,1 Y Exner,1 T Schmidt,1 F Debus,2 R Tikkanen,2 V Spindler,3 J Waschke3 and M Hertl1 
1 Dermatology and Allergology, Philipps-Universität, Marburg, Germany, 2 Biochemistry, 
Justus Liebig Universität Giessen, Giessen, Germany and 3 Institute of Anatomy and Cell 
Biology, Ludwig-Maximilians-Universität, Munich, Germany
IgG autoantibodies (autoAb) against the desmosomal cadherins desmoglein 3 (Dsg3) and Dsg1 
induce loss of keratinocyte adhesion in pemphigus vulgaris (PV) resulting in flaccid blisters and 
erosions. The autoAb response in PV is polyclonal and patients demonstrate IgG reactivities against 
multiple epitopes of the Dsg3 ectodomain. The precise molecular mechanisms finally inducing loss 
of keratinocyte adhesion upon autoAb binding are still controversially discussed. In this study we 
aimed at characterizing the pathogenic effects of a monoclonal mouse IgG antibody (2G4) against 
the membrane-proximal domain (extracellular domain 5, EC5) of human Dsg3. The epitope spec-
ificity of 2G4 was verified by using recombinant single Dsg3-EC-domain constructs. Functional 
in vitro studies such as the keratinocyte dissociation assay demonstrated that 2G4 induces loss of 
epidermal keratinocyte adhesion. Moreover, 2G4 induced split formation at the suprabasilar level 
of the epidermis in human skin biopsies. Furthermore, single molecule atomic force microscopy 
revealed that 2G4 impaired Dsg3 interaction suggesting that the antibody interferes with Dsg3-me-
diated keratinocyte adhesion. P38 MAPK (mitogen-activated protein kinase) as a representative 
signal transduction pathway was investigated upon incubation of human keratinocytes with 2G4. 
The antibody lead to phosphorylation of p38 MAPK which was comparable with the effect of the 
well characterised Dsg3-EC1-specific monoclonal antibody Ak23. In summary, our results suggest 
that an autoAb directed against the membrane-proximal EC5 domain of the Dsg3 protein clearly 
interferes with keratinocyte adhesion. These findings provide new aspects for a more comprehensive 
understanding of the mechanisms leading to blister formation in PV.    
Auto-immunity, allergy and Inflammation  | ABSTRACTS
www.jidonline.org   S7
037
Analysis of telomere length as predictive marker in psoriasis for comorbidities
E Coussens, J Bostoen, L Grine and J Lambert Dermatology, Ghent University Hospital, 
Ghent, Belgium
In addition to their skin condition, psoriasis (PsO) patients may also suffer from comorbidities such 
as metabolic syndrome (MetS), diabetes and cardiovascular diseases (CVD). In the dermatologi-
cal practice, these comorbidities are often ignored and patients are only treated for skin-related 
symptoms. Telomere length attrition has been proposed as a marker for an increased risk of MetS 
and CVD. The main purpose of this study was to examine whether telomere length in PsO patients 
could predict the presence of MetS and CVD. We analyzed the relative telomere length (RTL) in 104 
patients (PsO n = 49, PsA n = 55) and collected whole blood for DNA purification. The average RTL 
in the study population measured 1.119785 ± 1.155200. The mean RTL was longer in PsO patients 
in comparison to psoriatic arthritis patients, but not significantly different. Telomere shortening is 
subject to various factors such as smoking and obesity, but we found no significant relationship 
between RTL and central obesity, hyperlipidemia, hypertension, mental health, smoking, C-Reactive 
Protein, sedimentation rate, BMI or diastolic blood pressure in the study population. When we 
focused on patients with or without MetS, there was no significant difference in RTL. However, we 
observed a significant difference in RTL for the presence and absence of CVD. In detail, analysis 
revealed that the shortest RTLs were associated with CVD. Since age may be a confounding factor, 
we used a regression model. We found that, independent of age, the presence of CVD increased 
the risk of short RTLs, but short RTLs could not predict the presence of CVD. Although this is based 
on a small population size, this observation suggests that the predictive power of telomere attrition 
is silenced in the context of PsO. In our study, RTL did not have significant predictive power on 
comorbidities in a group of 104 patients, which questions its value as a biomarker in psoriatic 
individuals, especially in the absence of telomere length data over the entire lifetime of patients.   
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The vitamin D analogue MC903 ameliorates imiquimod-induced psoriatic skin lesion through 
directly inhibiting IL-23 production by Langerhans cells
N Kusuba, A Kitoh and K Kabashima Department of Dermatology, Graduate School of 
Medicine, Kyoto university, Kyoto, Japan
Psoriasis is a chronic inflammatory skin disease characterized by hyperproliferation and abnormal 
differentiation of keratinocytes, which is critically mediated by IL-23/IL-17 axis. Although topical 
vitamin D analogues have been considered to improve psoriasis by inhibiting proliferation and 
inducing terminal differentiation of keratinocytes, their immunological mechanism of action is still 
unclear. In this study, we investigated the immunomodulatory effect of the vitamin D analogue 
MC903 (calcipotriol) on murine psoriatic skin lesion induced by topical application of imiquimod 
(IMQ), a TLR7/8 agonist. Topical application of MC903 significantly prevented the development of 
IMQ-induced murine psoriatic lesion clinically and histologically as demonstrated in human psori-
asis. In addition, the upregulation of Il17a, Il22, Il12p40, and Il23a (p19) in IMQ-treated skin, which 
were known to be essential for the pathogenesis of IMQ-induced psoriasis,was almost completely 
suppressed by the MC903 treatment. The proportion and number of IL-17- and IL-22-producing 
dermal gdT cells in IMQ-treated skin were also markedly reduced by MC903. Given the previous 
report that IL-17 and IL-22 production is promoted by IL-23 in IMQ-induced psoriatic lesion, we 
hypothesized that the therapeutic effect of MC903 was attributed to the impaired IL-23 expression. 
IL-23 production by Langerhans cells (LCs) is reported to be critical for the development of IMQ-in-
duced psoriasis. We found that the upregulation of Il12p40 and Il23a mRNA in the epidermis of 
IMQ-applied skin was abrogated by the MC903 treatment. Finally we examined whether MC903 
directly inhibit IL-23 expression by murine LCs and human dendritic cells (DCs) in vitro. MC903 
suppressed expression of Il12p40 and Il23a mRNA by stimulated murine primary LCs and human 
monocyte-derived DCs. Collectively, our findings indicate that MC903 treatment improve psoriatic 
skin lesion by acting directly on IL-23-producing antigen presenting cells as well as keratinocytes 
both in mice and human.    
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T cells govern immune complex-induced inflammation
M Witte,1 K Bieber,1 J Klöpper,1 R Manz,2 K Kalies,3 S Dräger,1 A Kasprick,1 D Zillikens1 and 
R Ludwig1 1 Lübeck Institute of experimental Dermatology, University of Lübeck, Lübeck, 
Germany, 2 Institute of Systemic Inflammation, University of Lübeck, Lübeck, Germany and 
3 Institute of Anatomy, University of Lübeck, Lübeck, Germany
The pathogenesis of autoimmune diseases requires T cells, which contribute to the loss of tolerance. 
However, the function of T cells in the mediation of tissue damage in antibody-driven autoimmune 
diseases, such as autoimmune skin blistering diseases (AIBDs), is unclear. In vitro data showed a 
reciprocal activation of T cells and neutrophils. In contrast, absence of T cells had either no effect, 
decreased or, in most cases, enhanced the inflammation in animal models of AIBDs. In the present 
study, we investigated the role of T cells in the effector phase of epidermolysis bullosa acquisita 
(EBA), a prototypical AIBD caused by autoantibodies to type VII collagen (COL7). In antibody 
transfer-induced experimental EBA, we found skin inflammation to depend on the presence of 
Gr-1+ myeloid effector cells. However, T cell-deficient BALB/cnude mice were almost completely 
protected from skin blistering in this model. This T cell dependency was neither strain-specific, nor 
B cell-dependent. In addition, these results were independent of the number and activation state of 
the neutrophils in wild type and T cell-deficient mice. In line, adoptive T cell transfer fully restored 
EBA susceptibility in T cell-deficient mice. Analysis of T cell/neutrophil distribution by histology and 
multiphoton in vivo imaging showed that both cell types reside in different compartments of the skin. 
T cell numbers in skin did also not increase during EBA induction, indicating that resident T cells 
become activated, leading to recruitment of neutrophils. By use of knock-out mice and depletion of T 
cell subsets, we identified γδ and NKT cells to enhance antibody-induced and neutrophil-dependent 
inflammation. Collectively, we here disentangle contradicting results on the interplay of T cells and 
neutrophils to mediate inflammation in a prototypical autoimmune disease, and identify T cells as 
mediators of antibody-induced, neutrophil-dependent inflammation.    
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CARD14 frameshift mutation via CRISPR/Cas genome editing leads to IL8 inhibition
A Zolotarenko, A Prelovskaya and S Bruskin Laboratory of functional genomics, Vavilov 
Institute of General Genetics, Moscow, Russian Federation
Recent studies have shown that mutations in CARD14, gene located at PSORS2 loci, are associated 
with alternations of NFkB signaling. Analysis of patients with plaque-type psoriasis, generalized 
pustular psoriasis and pityriasis rubra pilaris have shown CARD14 mutations and variants to be 
causal or disease susceptibility factors, depending on the mutation or variant position of CARD14. 
Activating mutations in CARD14 upregulate NFkB, subsequently increasing the transcription of 
psoriasis-associated chemokines and cytokines, including IL-8, CCL20 and IL-36. CARD14 is mainly 
expressed in keratinocytes, therefore investigation of the role of different mutations in CARD14 
as well as its inhibition or overexpression is a way to understand the background of psoriatic 
inflammation. In this research in order evaluate the effect of CARD14 inhibition on the activation 
of NFkB and downstream inflammation-related genes we have employed CRISPR/Cas system. This 
system has two ways of function: either via non-homologous end joining (NHEJ) or via homologous 
recombination (HR) if there is a donor DNA sequence. At the first stage of the research we have 
employed NHEJ to create a frameshift in CARD14. Using Addgene PX458 plasmid with 2A-eGFP 
and an optimized sgRNA to target the second exon of hCARD14, we have performed a transfection 
of HEK-293 cell line and evaluated the expression level of IL-8, an NFkB target and proinflammatory 
cytokine highly expressed in course of psoriasis. qPCR have shown more than two-fold reduce of 
expression of this cytokine in mixed culture of cells (mutant and non-mutant).    
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Laser-assisted cutaneous delivery of biological agents: A novel method for the targeted local 
treatment of psoriasis.
K Sonaje and Y Kalia School of Pharmaceutical Sciences, University of Geneva & University 
of Lausanne, Geneva, Switzerland
Psoriasis, a T-cell mediated autoimmune skin disorder, affects approximately 125 million people 
worldwide. It involves hyperproliferation of keratinocytes causing raised silvery-white patches on 
the skin. The introduction of biologic therapies in the past decade, including monoclonal antibod-
ies (mAbs), has revolutionized the treatment of severe psoriasis. However, their physicochemical 
properties and stability constraints necessitate parenteral administration, which increases the risk of 
systemic side effects and can affect patient compliance. Here, we demonstrate a novel approach for 
cutaneous delivery of infliximab (INF) using fractional laser ablation that may have potential applica-
tion in the targeted topical therapy of recalcitrant plaques. In vitro transport studies were performed 
using full thickness porcine ear skin following laser microporation using a P.L.E.A.S.E.® Er:YAG 
laser (untreated skin was used as a control). Results showed that the amount of INF delivered into 
the skin increased as a function of fluence, maximum delivery (2.76 ± 0.72 μg/cm2) was observed 
at a laser fluence of 89.9 J/cm2 with 10% pore density. Increasing the INF concentration in the for-
mulation from 1 to 5 and 10 mg/mL at the afore-mentioned laser conditions, increased INF delivery 
to 5.88 ± 1.23 and 9.09 ± 1.55 μg/cm2, respectively. The amounts of INF present in the skin were 
significantly higher than the reported therapeutic plasma levels of INF, confirming the advantages of 
administering mAbs directly into the skin. Visualization of INF delivery using confocal microscopy 
showed that INF diffused from the micropores into the surrounding tissue and the dermal-epidermal 
junction, a region where inflammatory reactions leading to psoriasis are triggered. The results suggest 
that laser microporation not only provides a minimally invasive and patient-friendly alternative to 
the parenteral administration of mAbs, but can also decrease the systemic dose and overall cost of 
treatment through targeted local delivery to the root cause of psoriatic lesions.    
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Ivermectin hampers the development of atopic skin inflammation in mice through a direct 
inhibition of T cell activation
E Ventre,1 A Rozières,1 D Dombrowicz,2 F rassendren,4 V Julia Barbero,3 E Vial,3 A Jomard,3 
F Hacini-Rachinel,3 J Nicolas1 and M Vocanson1 1 U1111-CIRI, INSERM, Lyon, France, 2 
U1011, INSERM, Lille, France, 3 R&D, Galderma, Biot, France and 4 Institut de Génomique 
Fontionnelle, CNRS, UMR5203, Montpellier, France
Ivermectin (IVM) is widely used both in human and veterinary medicine to treat parasitic infections. 
IVM kills nematodes or arthropods by inhibiting their neuronal and muscular activity. Recent reports 
have suggested that IVM could also have potent anti-inflammatory properties in mammals; however, 
the mechanisms involved in such effects remain unclear. Here, we have explored the therapeutic 
activity of IVM in a murine model of allergen-induced atopic dermatitis (AD), and in standard in 
vitro settings. Topical treatment with IVM proved almost as efficient as a reference corticosteroid 
(betamethasone valerate) to hamper the development of eczema lesions (ear swelling, production of 
inflammatory cytokines into the skin). Besides, the drug prevented the priming of allergen-specific 
T effector cells responsible for the development of the skin inflammation. While we observed no 
drug impact on the functions of mouse dendritic cells in vivo or in vitro, both murine and human 
T cells revealed as direct targets of IVM treatment. In vitro, IVM impaired their differentiation into 
CD8+ or CD4+ T effector cells upon both polyclonal and antigen-specific stimulation. Altogether, 
our results reveal that IVM, via a subtle modulation of T-cell immunity, is a potent anti-inflammatory 
drug that could have important applications for the treatment of atopic dermatitis and other T-cell 
mediated skin inflammatory diseases.    
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Efficacy and Safety of Brodalumab In Patients With Moderate To Severe Plaque Psoriasis: 
Results of AMAGINE-1, a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
K Papp,1 K Reich,2 A Blauvelt,3 W Baran,4 C Bolduc,5 D Toth,6 AB Gottlieb,7 D Thaci,8 
J Li9 and A Nirula9 1 Probity Medical Research, Waterloo, ON, Canada, 2 Dermatologikum 
Hamburg, Hamburg, Germany, 3 Oregon Medical Research Center, Portland, OR, 4 
Wroclaw Medical University, Wroclaw, Poland, 5 University of Montreal and Innovaderm 
Research,, Montreal, QC, Canada, 6 XLR8 Medical Research and Probity Medical Research, 
Windsor, ON, Canada, 7 Tufts Medical Center, Boston, MA, 8 University of Lubeck, Lubeck, 
Germany and 9 Amgen Inc, Thousand Oaks, CA
AMAGINE-1 evaluated brodalumab in moderate to severe psoriasis, with a 12-week (wk) induction 
(1:1:1 randomization to brodalumab 210 or 140mg Q2W or placebo [PBO]) and 40-wk withdrawal/
retreatment phase (brodalumab subjects with static physician global assessment [sPGA] 0/1 at 
wk 12 re-randomised to induction dose or PBO; all others received 210mg). Endpoints included: 
PASI75 at wk 12 [co-primary], PASI100 at wk 12 [key secondary] and 52, Dermatology Life Quality 
Index (DLQI) 0/1; analyzed with a Cochran-Mantel-Haenszel test, non-responder imputation for 
missing data/disease relapse in withdrawal and adjustment for baseline or wk 12 covariates. Of 
661 subjects randomized, 633 completed wk 12, 283 were re-randomized and 558 completed wk 
52. Mean (SD) baseline PASI and DLQI scores were 19.7 (7.3) and 14.1 (7.2), respectively. At wk 
12, a significantly higher proportion of brodalumab subjects achieved: PASI75 [210mg, 83% (95% 
CI: 7888); 140mg, 60% (5467); PBO, 3% (16)], PASI100 [42% (3549); 23% (1830); 1% (03)] (p 
<.001), DLQI 0/1 [56% (4963); 43% (3650); 5% (39); unadjusted p<.001]. At wk 52, 67% (56/83) 
of subjects randomized to brodalumab 210mg in titration, who achieved sPGA 0/1 at wk 12 and 
were re-randomized to 210mg, maintained PASI 100 (PBO, [0/84]; unadjusted p<.001). AEs were 
consistent with prior reports. Brodalumab resulted in significant improvements in PASI, which were 
maintained with long-term treatment.    
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Beyond the Adrenal Gland: The Essential Role of Skin-Synthesised Glucocorticoids in Health 
and Disease
R Hannen,1 C Udeh-Momoh,3 J Upton,1 L Sevilla,2 S Lightman,4 P Perez2 and M Philpott1 1 
Centre for Cell Biology and Cutaneous Research, Queen Mary University of London, London, 
United Kingdom, 2 Instituto de Biomedicina de Valencia, Valencia, Spain, 3 Imperial College 
London, London, United Kingdom and 4 University of Bristol, Bristol, United Kingdom
Endogenous glucocorticoids (GC) are essential for maintaining the epidermal skin barrier and their 
powerful anti-inflammatory effects are exploited therapeutically to treat inflammatory skin condi-
tions such as psoriasis. Healthy keratinocytes can synthesise GC de novo but little is known about 
the interplay between local and systemic GC production and the impact on skin pathologies. We 
show that de novo cortisol synthesis and GC receptor expression are dysfunctional in psoriatic 
skin. Specifically, de novo cortisol synthesis was significantly reduced in both non-lesional and 
lesional psoriatic tissue compared to healthy skin controls (healthy skin 809.6±120.4ng/ml, psoriatic 
uninvolved 63.1±7.9ng/ml, psoriatic lesional 67.7±11.8ng/ml, n=8, measured by LC-MS/MS). In 
addition, radiometric assay identified dysfunctional cortisol synthesis in primary psoriatic keratino-
cytes (healthy keratinocytes, 38.8±6.1%, uninvolved keratinocytes 8.7±0.4%, lesional keratinocytes 
8.6±0.2% of cortisol formed from [3H]pregnenolone after 24 hours, n=4, P≤0.01). This suggests that 
defective GC synthesis is an inherent defect of psoriatic skin. Expression of the GC receptor was 
reduced in non-lesional psoriatic tissue and was further down-regulated in lesional psoriatic skin. 
Experiments using adrenalectomised control and GR epidermal knockout (GREKO) mice highlighted 
the significance of systemic vs local GC production in experimental model of skin inflammation 
induced by topical PMA. Remarkably, adult GREKO mice compensated for loss of GR by up-reg-
ulating localized GC production, which protected the animals from PMA induced inflammation 
even post-adrenalectomy. These studies show that skin-derived GC production protects the tissue 
from inflammation in the absence of systemic GC. Crucially this pathway is defective in psoriatic 
skin and presents a critical pathway to target in inflammatory skin conditions.    
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PM10 penetrates into skin, producing inflammatory response
S JIN, E Seo, J Chung and S Cho Institute of Human-Environment Interface Biology, Medical 
Research Center, Seoul National University, Seoul, Korea (the Republic of)
Besides the sunlight, the damaging effects of pollutants on human skin have been the subject of 
intense research recently. Previous reports demonstrate that chronic traffic-related PM (particulate 
matter) exposure is associated with premature skin aging, with 20% increase in pigment spots on the 
forehead and cheeks, and that pollutants may aggravate atopic dermatitis. However, it is unclear if 
PM10 (PMparticulate matter less than < 10 μm in diameter) directly goes into the skin tissue and what 
the molecular mechanism involves in the response to the PM10. We investigated whether PM10 
could penetrate into barrier-disrupted skin, and produce ROS, and elicit inflammatory response. 
First, we collected PM10 during a winter in Seoul, and used cultured keratinocytes for in vitro 
study and tape-stripped BALB/c mouse for in vivo study. Keratinocyte cytotoxicity increased in 
a dose-dependent manner by PM10 treatment. By qPCR, IL-1α, IL-1β, IL-8, VEGF-A and MMP-1 
mRNA expression was significantly increased compared to control, and the protein levels of IL-8, 
VEGF and MMP-1 were also increased by ELISA. Cellular ROS production was detected using the 
DCFDA kit and flow cytometry and was measured to be increased by PM10 treatment. Congruous 
to the previous results, N-acetyl cysteine pretreatment prevented induction of inflammatory cyto-
kines IL-1α, IL-1β, IL-8, and MMP-1. In PM10-treated keratinocytes, electron-dense subcellular 
particles were observed byunder the TEM image. In the barrier-disrupted mouse, PM10 was seen 
to penetrate intercellularly through the stratum spinosum. In contrast, PM10 stayed outside stratum 
corneum in barrier-intact mouse. Regardless of barrier status, PM10 was observed inside hair fol-
licles. These results indicate that PM10 penetrates into barrier-disrupted interfollicular epidermis 
and barrier-intact follicular epidermis and that PM10 ultimately localizes within the cytoplasm 
of keratinocytesgoes through intracellular location, causing ROS production and inflammatory 
response in keratinocytes, demonstrating detrimental effects on human skin.    
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Activation of aryl hydrocarbon receptor-nuclear factor erythroid 2-related factor 2 axis by 
epidermal growth factor receptor inhibitors: a possible mechanism for acneiform eruption
G Tsuji,1 T Nakahara,2 H Uchi,3 C Mitoma1 and M Furue3 1 Research and Clinical Center for 
Yusho and Dioxin, Kyushu University Hospital, Fukuoka, Japan, 2 Division of Skin Surface 
Sensing, Kyushu University, Fukuoka, Japan and 3 Department of Dermatology, Kyushu 
University, Fukuoka, Japan
Although epidermal growth factor receptor inhibitors (EGFRIs) are effective to treat advanced car-
cinomas, acneiform eruption caused by EGFRIs is frequent, which could be related to sebaceous 
gland activity, however; its mechanism(s) remain largely unknown. Based on the facts 1) that 
activation of aryl hydrocarbon receptor (AhR)-nuclear factor erythroid 2-related factor 2 (Nrf2) 
axis regulates infundibular keratinocyte differentiation and sebaceous gland activity, 2) that EGFR 
signaling coordinately targets AhR signaling by sharing p300, and 3) that Nrf2 hyperactivation leads 
to sebaceous gland enlargement, we hypothesized that activation of AhR-Nrf2 axis by EGFRIs might 
lead to the development of acneiform eruption. To demonstrate that, we administrated gefitinib 
(GEF), a clinically utilized EGFRI, to normal human epidermal keratinocytes (NHEKs) and SEB-1 
cells, a human sebocyte cell line, and examined whether GEF activated AhR-Nrf2 axis in vitro. 
GEF induced up-regulation of CYP1A1 expression in NHEKs and SEB-1 cells, which was enhanced 
by 6-formylindolo (3,2-b) carbazole (FICZ), an endogenous AhR ligand. GEF also enhanced the 
FICZ-induced Nrf2 up-regulation in NHEKs. In the SEB-1 cells, GEF or FICZ induced IL-6 secretion, 
which was abrogated by small interfering RNA transfection against AhR. Oil red o staining of SEB-1 
cells revealed that IL-6 promoted lipogenesis of SEB-1 cells, which was potentiated by GEF or FICZ. 
To extend our in vitro observation, we administrated GEF (50 mg/kg) to C57BL/6 mice orally and 
applied FICZ on their abdomen for 24 hours. GEF induced up-regulation of CYP1A1, Nrf2 and IL-6 
expression in the epidermis, which was enhanced by FICZ. Taken together, acceleration of AhR-Nrf2 
axis with subsequent IL-6 production and sebeceous lipogenesis by EGFRIs may play an important 
role in the development of acneiform eruption.    
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The function of microRNA-146 family in the regulation of proliferation of keratinocytes 
and psoriasis
H Hermann,1 T Runnel,1 A Aab,1 B Rückert,2 L Šahmatova,3 J Maslovskaja,1 M Karelson,3 
K Kingo,3 C Akdis2 and A Rebane1 1 Insitute of Biomedicine and Translational Medicine, 
University of Tartu, Tartu, Estonia, 2 Swiss Institute of Allergy and Asthma Research, Davos, 
Switzerland and 3 Department of Dermatology and Venereology, University of Tartu, Tartu, 
Estonia
MicroRNA families often consist of multiple members that function in post-transcriptional regulation 
of the same or overlapping set of genes. The role of miRNAs in skin diseases has only very recently 
begun to be uncovered. Here, we demonstrate that miR-146 family members, miR-146a and miR-
146b (miR-146a/b) are expressed in human skin with significant increase in lesional skin of psoriasis 
patients. In human primary 3D keratinocyte cultures, miR-146b was induced in response to IFN-γ 
and IL-22, while miR-146a expression increased when stimulated by IL-1β, TNF-α and IL-17A. 
Remarkable, costimulation with psoriasis-related cytokines TNF-α and IL-17A had a very strong 
synergistic effect on miR-146a expression. The expression of miR-146a direct targets involved in 
the regulation of proliferation, SERPINB2, NUMB and FERMT1, or inflammatory responses, IRAK1, 
CARD10 and CCL5, had altered expression in the skin of psoriasis patients. FERMT1 was confirmed 
to be a novel direct target of miR-146a in luciferase assays. Consistent with this, overexpression of 
miR-146a decreased and inhibition of miR-146a increased the proliferation of keratinocytes. No 
influence of miR-146a on cell-death of unstimulated keratinocytes was observed. In keratinocytes 
stimulated with TNF-α or IFN-γ, overexpression of miR-146 suppressed the activation-induced 
apoptosis. When overexpressed in keratinocytes, miR-146b suppressed the same set of direct pso-
riasis-related targets as miR-146a. Our data together demonstrate that in addition to their function 
in the suppression of numerous pro-inflammatory factors during the inflammation, miR-146a and 
miR-146b inhibit the proliferation of keratinocytes and thereby control skin homeostasis as well as 
might have auxiliary impact in psoriasis and other inflammatory skin diseases.    
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S100A8/A9 induces skin inflammation and keratinocyte proliferation via neuroplasatin-beta/
EMMPRIN heterodimer receptor in atopic dermatitis
M Miyai,1 M Sakaguchi,1 M Yamamoto-Tanaka,2 T Maeda,2 J Hiruma,2 R Tsuboi2 and 
T Hibino2 1 Cell Biology, Okayama University Graduate School of Medicine, Okayama, 
Japan and 2 Dermatology, Tokyo Medical University, Tokyo, Japan
We previously reported a positive feedback loop between S100A8/A9 and pro-inflammatory cyto-
kines mediated by extracellular matrix metalloproteinase inducer (EMMPRIN), an S100A9 receptor. 
Here, we identify neuroplastin-beta (NPTN-beta) as a novel S100A8 receptor. When keratinocytes 
were treated with siRNAs targeted to EMMPRIN and NPTN-beta, cytokine induction and cell pro-
liferation were markedly suppressed. Upon stimulation with S100A8/A9, EMMPRIN recruited only 
TRAF2, and NPTN recruited TRAF2 and Grb2. Knockdown of EMMPRIN as well as TRAF2 abolished 
induction of p38 phosphorylation by S100A8/A9. Knockdown of NPTN as well as Grb2 caused 
profound down-regulation of ERK phosphorylation, including the steady-state level. NF-kappaB 
luciferase reporter assays showed that S100A9 but not S100A8 activated this pathway and parthe-
nolide inhibited this reaction. EMMPRIN and NPTN-beta form homodimers and a heterodimer, 
and are co-localized on the surface of cultured human keratinocytes. Keratinocyte proliferation in 
response to inflammatory stimuli was accelerated in involucrin promoter-driven S100A8 transgenic 
mice. Further, S100A8/A9 and their receptors were strongly up-regulated and co-localized in the 
lesional skin of atopic dermatitis patients. Our results indicate that NPTN-beta and EMMPRIN form 
a functional heterodimeric receptor for S100A8/A9, followed by recruitment of specific adaptor 
molecules TRAF2 and Grb2, and this signaling pathway is involved in activation of both skin 
inflammation and keratinocyte proliferation in atopic skin. Suppression of this pathway might have 
potential for treatment of skin diseases associated with chronic inflammation.    
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Development of an in vitro microbiome and infection model
D van der Krieken,1 T Ederveen,3 P Scheepers,2 S van Hijum,3 J Schalkwijk1 and 
P Zeeuwen1 1 Dermatology, Radboudumc, Nijmegen, Netherlands, 2 Health Evidence, 
Radboudumc, Nijmegen, Netherlands and 3 Centre for Molecular and Biomolecular 
Informatics, Radboudumc, Nijmegen, Netherlands
Human reconstructed skin models are available to study defence mechanisms involved in host-mi-
crobial interactions between keratinocytes and resident commensals or opportunistic pathogens. 
These cellular models, however, are laborious and expensive, prone to uncontrolled bacterial over-
growth, and do not allow high-throughput screening. Therefore, we developed a completely new in 
vitro system that mimics human skin for bacterial growth, and can be used for high-throughput test-
ing of individual microorganisms, or microbial ecology by metagenomic analysis. Microorganisms 
attach and live on the stratum corneum of our skin. In our newly developed model, human callus 
serves as substrate and nutrient source for bacteria. After 7 days of culturing, bacteria are collected 
for analysis. Bacterial survival is measured by colony forming units (CFU) counting and by qPCR 
using strain-specific primers. Prior to genomic DNA (gDNA) isolation, the bacteria are treated with 
propidium monoazide (PMA) and exposed to light to eliminate gDNA originating from non-viable 
bacteria. We succeeded to mimic in vivo conditions of human skin by infection of our model with 
human skin commensals (S. epidermidis and P. acnes), which survived for more than one week in 
vitro. Known human pathogens (S. aureus, P. aeruginosa, and S. pyogenes) were tested and survived 
in this model. Furthermore, the ratios between bacterial communities and the bacterial diversity of 
a human in vivo microbiome collected from the lower back of healthy volunteers remained stable 
after one week of culturing on the model. We envision that our experimental setup can be used 
as a model for skin diseases linked to microbial colonisation. Future investigations will focus on 
modulation of ‘disease-associated microbiomes’ by stimulation of ‘desirable’ commensal bacteria 
to prevent expansion of pathogenic species.    
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Mammalian target of rapamycin is increased in hidradenitis suppurativa and acne being 
related to insulin resistance
A Balato, S Lembo, G Caiazzo, V De Vita, R Di Caprio, M Donnarumma, G Fabbrocini and 
G Monfrecola Unit of Dermatology, Department of Clinical Medicine and Surgery, University 
of Naples Federico II, Naples, Italy
The aim of this study was to investigate the possible involvement of mammalian target of rapamy-
cin (mTOR) in hidradenitis suppurativa (HS) and acne evaluating its possible relation with insulin 
resistance. The study population comprised 30 subjects equally distributed for HS, acne and healthy 
volunteers. All subjects underwent anthropometric measurements, homeostasis model assessment 
of insulin resistance (HOMA-IR) and oral glucose tolerance test (OGTT). RNA and protein analysis 
was executed on skin biopsies from non lesional and lesional skin of all HS, acne patients and on 
healthy skin. Our results showed that mTOR was enhanced in lesional as well as non lesional skin 
of HS and acne patients compared to healthy controls. Interestingly, mTOR increases correlated with 
insulin resistance in both analyzed diseases. Indeed, 60% of HS patients were insulin resistant and 
mTOR skin gene expression correlated with insulin secretion during OGTT at 30 and 60 minutes 
(r=0.8 and r=1, respectively). Moreover, mTOR skin gene expression significantly correlated with 
the severity of HS, assessed through Sartorius score (r=0.8); being the last one related to body mass 
index (BMI; r=1). Regarding acne patients, we found a significant correlation between HOMA-IR 
and mTOR skin gene expression (r=0.7). In conclusion, our findings show a possible involvement 
of mTOR in the complex inflammatory scenario of HS and acne as well as its potential association 
with insulin resistance.    
051
Investigation of skin barrier functions and allergic sensitization in patients with Hyper-IgE 
syndrome
Z Dajnoki,1 G Mócsai,1 B Tóth,2 L Maródi,2 K Gáspár,1 G Béke,1 A Kapitány1 and A Szegedi1 
1 Division of Dermatological Allergology, Department of Dermatology, Faculty of Medicine, 
University of Debrecen, Debrecen, Hungary and 2 Department of Infectious and Pediatric 
Immunology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary
Hyper-IgE syndrome (HIES) is a rare, but severe primary immunodeficiency, characterized by 
increased serum IgE levels, recurrent infections and atopic dermatitis (AD)-like skin lesions. STAT3 
mutations are detected in the most patients, which cause impaired Th17 development. AD is a 
chronic inflammatory skin disease with immunologic alterations and skin barrier dysfunctions. 
Our aim was to investigate and compare the skin barrier alterations and allergic sensitization (AS) 
in HIES and AD patients and to find similar or different pathogenetic events in the development 
of skin lesions. Analyses of STAT3 and filaggrin (FLG) mutations were performed in 6 HIES and 30 
AD patients as controls. Laboratory parameters (LDH level and eosinophil count), immunologic 
alterations (intracellular cytokine staining), AS (total and specific IgE levels, medical history), and 
skin barrier changes [transepidermal water loss (TEWL), serum thymic stromal lymphopoietin (TSLP) 
levels] were also examined. Mutation analysis of STAT3 showed 100% positivity in HIES patients, 
although all of them had FLG wild-type concerning R501X and 2282del4 mutations, which were 
found in 31% of our AD patients in heterozygous form. No differences were found between the 
two diseases regarding LDH and IgE levels or eosinophil counts. Impaired Th17 cell numbers were 
detected in T cells of HIES patients. No altered barrier functions were found in HIES patients which 
were significantly impaired in AD patients. AS was more frequent in AD. On the basis of these 
results barrier alterations probably are not the main pathogenetic events in the development of skin 
lesions in HIES. Despite of the high IgE levels, AS is not a characteristic feature in these patients, 
which can be the consequence of their normal skin barrier functions, since outside-inside barrier 
impairment seems to be necessary for the development of AS.    
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Topical TRK-820 (Nalfurafine), a kappa-opioid receptor agonist, suppresses scratching and 
inflammatory changes in oxazolone challenged mouse ears
G Elliott,1 M Soeberdt,2 R Vanwersch,1 D Metze,3 T Lotts,3 S Staender3 and C Abels2 1 
Derphartox, Delft, Netherlands, 2 Dr. August Wolff GmbH & Co. KG Arzneimittel, Bielefeld, 
Germany and 3 Dept. Dermatology, University Hospital Münster, Münster, Germany
We investigated the effect of topical TRK-820 on scratching and inflammation in the oxazolone 
mouse ear model (inducing a chronic allergic contact dermatitis). Mouse ears were treated with 
100μl of 1% oxazolone in acetone on days 0, 7, 9 and 11. On days 11 through 18 ears were treated 
with 50μl of betamethasone dipropionate (BMDP), TRK-820 in DMSO or DMSO alone (control). 
Ear thickness was measured on days 11 through 19, and scratch events (SE) and general activity 
(GA) were measured on days 11 and 18 for 22 hours. Mice were sacrificed on day 19 and ears 
processed for histological examination. Topical BMDP (0.05%) and TRK-820 (0.2% and 1.0%) 
accelerated recovery of ear thickness (reduced tissue oedema). Histologically, vehicle control ears 
were thickened and showed abundant dermal inflammation. CD4+ and CD8+ T-cells, neutrophils, 
and eosinophils had infiltrated the dermis. Mast cells were degranulated. BMDP and, to a lesser 
extent, TRK-820 1% significantly reduced ear thickness and cell infiltration. TRK-820 0.2% had 
little effect. Mouse scratching was bi-phasic, with an initial “early” SE peak within the first 2 hrs after 
exposure to oxazolone and a second “late” period lasting from around 18.00 hrs until early morning. 
Scratch frequency (Hertz) varied between 12 and 30Hz with an optimum of 16Hz. Topical BMDP 
(0.05%) and TRK-820 (0.2% and 1.0%) inhibited scratching compared to the vehicle control on days 
11 and 18. There was also a shift in scratch frequency from higher to lower frequencies (<16Hz). 
There was an initial inhibition of GA for 4 hrs after the initial treatment with TRK-820 on day 11 
which was not present on day 18. The strong early anti-pruritic effect of TRK-820 was transient and 
would appear to be related to some extent to reduced GA at day 11. Topical KOR agonists may be 
useful in the treatment of inflammatory skin diseases and associated pruritus.    
053
IL-1 and IL-36 are the dominant cytokines in Palmar Plantar Pustulosis
A Johnston,1 X Xing,1 L Wolterink,1 DH Barnes,1 JM Kahlenberg,2 PW Harms3 and 
JE Gudjonsson1 1 Dermatology, University of Michigan, Ann Arbor, MI, 2 Rheumatology, 
University of Michigan, Ann Arbor, MI and 3 Pathology, University of Michigan, Ann Arbor, 
MI
Palmar plantar pustulosis (PPP) is a chronic pustular dermatosis restricted to the palms and soles. 
Although rare, PPP is debilitating with a large impact on quality of life and ability to work. Resistance 
to treatment and disease recurrence are common thus a better understanding the pathogenesis of 
PPP is needed and may yield new therapeutic approaches. To delineate molecular targets in PPP 
and assess the pathophysiological differences between PPP and the more common chronic plaque 
psoriasis (CP) we analyzed archived FFPE skin biopsies of confirmed cases of PPP (n=9 control, 20 
lesional) and CP (n=12 control and lesional) using Affymetrix ST 2.1 microarrays. Compared with 
healthy skin, PPP and CP lesions yielded 33 and CP 444 differentially expressed genes respectively 
(>2-fold change, FDR<.05) with 22 of these transcripts differentially expressed in both diseases. 
Using qRT-PCR we detected significantly elevated expression of IL1B (16x, p=.039), IL36G (7x, 
p=.0001), and the neutrophil chemokines CXCL1 (3x, p=.039) and CXCL2 (4x, p=.009), as well as 
the NADPHoxidase component NCF2 (2x, p=.04) in PPP compared with healthy palmar/plantar 
tissue; While IL36A, IL19 and IL8 could not be detected in healthy skin, all were significantly 
expressed in PPP lesions (p<.0001 all). These data were confirmed by IHC, and indicate a level 
of sustained activation of the IL36 and IL1 systems in PPP, which drive neutrophil infiltration. 
Compared with CP, PPP lesions expressed 2-fold more IL-36G (p=.01), but significantly less of the 
T cell chemokines CXCL9 (25x, p=.035), CXCL10 (20x, p=.038) and lower IL17A (p=.02), IL22 
(37x, p=.0005) and MX1 (2x, p=.003) expression, suggesting a less prominent role for Th1/Th17 
pathophysiology in PPP compared to CP. Our data may have major therapeutic implications as 
they suggest that the IL-1 and IL-36 inflammatory axes are the main drivers of disease pathology in 
PPP, and question the contribution of IL-17 and/or IFN-γ to its pathogenesis.    
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HSV-1 infection of keratinocytes inhibits inflammasome activation
H Beer,1 G Strittmatter,1 J Sand,1 M Sauter,2 M Seyffert,3 R Steigerwald,4 C Fraefel,3 S Smola2 
and LE French1 1 Dermatology, Univerity Hospital Zürich, Zürich, Switzerland, 2 Virology, 
Saarland University, Homburg/Saar, Germany, 3 Virology, Univerity of Zürich, Zürich, 
Switzerland and 4 Infectious Disease Division, Bavarian Nordic GmbH, Martinsried, Germany
Herpes simplex virus (HSV) is a double stranded (ds) DNA virus that is extremely well adapted 
to humans. HSV targets keratinocytes usually at mucocutaneous parts of the skin. In most cases 
infections do not cause much harm but can cause morbidity and even mortality in immunocompro-
mised patients. Inflammasomes comprise a group of innate immune complexes, which induce an 
inflammatory response upon sensing of several different stress signals. This is achieved by activation 
of the protease caspase-1, which in turn activates the proinflammatory cytokines prointerleukin(IL)-β 
and -18. In human keratinocytes the NLRP3/NLRP1 inflammasome is activated by UVB irradiation 
whereas the AIM2 inflammasomes plays an important role in psoriasis. Transfection of human pri-
mary keratinocytes with dsDNA or infection with the dsDNA virus Modified Vaccinia Virus Ankara 
(MVA) induces IL-1β and -18 secretion, which is dependent on expression of proteins of the AIM2 
inflammasome. In contrast, HSV-1 infected keratinocytes do not secrete IL-1β or -18. Further exper-
iments revealed that HSV-1 infection suppresses proIL-1β expression and inflammasome activation 
and this effect is dependent on viral gene expression. With these results we identified inflammasome 
inhibition in keratinocytes as a novel immune response evade mechanism of HSV-1, which might 
underlie the virus’ ability to cause life-long infections. However, keratinocytes can be primed to 
overcome inflammasome inhibition by HSV-1 infection.    
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Effect of eupatilin on insulin growth factor (IGF)-1-induced inflammation and lipogenesis 
in SZ95 sebocyte
J Lee, Y Lee, J Lee and Y Park Dermatology, Seoul St. Mary’s hospital, College of Medicine, 
The Catholic University of Korea, Seoul, Korea (the Republic of)
Acne vulgaris is a common skin disease which is characterized by excess sebum production, prolif-
eration of Propionibacterium acnes, hyperkeratinization, and perifollicular inflammation. Eupatilin 
(5,7-dihydroxy-3’,4’,6’-trimethaoxyflavone), is the major lipophilic flavonoid from Artemisia plant. It 
has been reported to have an anti-bacterial and anti-inflammatory activity. However, it’s therapeutic 
effect and mechanism on acne is unclear. In this study, we examined the effect of eupatilin on IGF-
1-induced inflammation and lipogenesis in human sebocytes. IGF-1 induced tumor necrosis factor 
(TNF)-α, interleukin (IL)-6 and, IL-8 mRNA expression in SZ95 sebocytes, and eupatilin significantly 
reduced the expression of these proinflammatory cytokines. Eupatilin suppressed lipid accumulation 
on IGF-1-treated SZ95 sebocytes. To investigate the molecular mechanism by eupatilin suppresses 
inflammation and lipid synthesis, we examined whether eupatilin inhibits mitogen-activated pro-
tein kinase (MAPK) and AKT signaling pathway using by Western blot. Eupatilin dose-dependently 
blocked phosphorylation of p38, JNK and AKT. These results provide the first evidence that eupatilin 
can be candidate for acne treatment.    
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Adalimumab Treatment Is Associated with a Trend Toward Reduced Need for Acute Surgical 
Interventions in Patients with Moderate-to-Severe Hidradenitis Suppurativa
CC Zouboulis,1 H van der Zee,2 HD Teixeira,3 R Gammelsaeter,4 Z Geng,3 S Rhee3 and 
M Okun5 1 Departments of Dermatology, Venereology, Allergology and Immunology, Dessau 
Medical Center, Dessau, Germany, 2 Erasmus MC, University Medical Center, Rotterdam, 
Netherlands, 3 AbbVie Inc., North Chicago, IL, 4 AbbVie AS, Fornebu, Norway and 5 Fort 
HealthCare, Fort Atkinson, WI
Adalimumab (ADA) weekly therapy has been demonstrated to improve clinical signs of hidradenitis 
suppurativa (HS) based on results from 2 randomized, double-blind, placebo-controlled phase 3 
trials (PIONEER I and PIONEER II). This analysis was conducted to determine whether ADA therapy 
was associated with reduced need for acute surgical interventions in these studies, by assessing 
the proportion of patients receiving incision and drainage (I&D) procedures and the incidence 
of complete elimination of abscesses or draining fistulas (among subjects with at least 1 of these 
lesions) as indicators for the reduced need for surgery. Adults with long-term HS were randomized 
(1:1) to receive ADA (160 mg at week 0, 80 mg at week 2, and 40 mg weekly starting at week 
4) or placebo for 12 weeks. Patients were allowed ≤2 I&D interventions or intralesional steroid 
injections to treat acutely painful lesions. A total of 633 patients (ADA, n=316; placebo, n=317) 
were randomized and 596 (ADA, n=300; placebo, n=296) completed 12 weeks of treatment. ADA 
therapy was associated with a 35% reduction in the proportion of patients receiving I&D procedures 
(ADA, n=11; placebo, n=17, P=.248). A greater proportion of patients who received ADA, compared 
with placebo, experienced complete elimination of abscesses (39% vs 33%; P=.202) or draining 
fistulas (33% vs 19%; P<.001) at week 12. Based on a variety of assessments, ADA treatment was 
associated with a consistent trend toward reduction in the need for acute surgery, with a significant 
effect noted on the complete elimination of draining fistulas.    
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IL-9 in atopic dermatitis pathogenesis: are keratinocytes to blame?
J Smits, H Niehues, D Rodijk-Olthuis, I van Vlijmen-Willems, P Zeeuwen, J Schalkwijk and 
EH Van den Bogaard Department of Dermatology, Radboudumc, Nijmegen, Netherlands
Recently, a specialized subset of T-cells, called Th9 cells, dedicated to the production of interleu-
kin-9 (IL-9), has been identified. In atopic dermatitis (AD) patients, Th9 cells and IL-9 expression 
levels are elevated and correlated to disease severity. Based on the observation that, in a colitis 
model, IL-9R signaling in the gut results in epithelial barrier defects, we hypothesized that IL-9 
could contribute to AD pathophysiology by interfering with epithelial homeostasis. We first ana-
lyzed IL-9 receptor expression levels in normal human keratinocytes (NHK). The effects of IL-9 on 
NHK proliferation, differentiation, and the expression of inflammatory mediators were studied in 
NHK monolayer cultures and 3D human skin equivalents (HSEs). IL-4 and IL-13, Th2 cytokines 
known to affect skin barrier function, were used as a reference. IL-9 receptor (IL9R) mRNA expres-
sion was present in keratinocytes and strongly induced upon interferon-γ (IFN-γ) stimulation. IL-9 
itself, IL-4, IL-13 or other pro-inflammatory cytokines did not affect IL9R expression. We found a 
strong reduction of involucrin and loricrin protein expression in HSEs exposed to IL-4/IL-13, but 
this effect was much weaker for IL-9. IL-9 had no effect on proliferation or epidermal thickness, 
while IL-4/IL-13 significantly increased the number of Ki67 positive cells and induced acanthosis. 
No effect of IL-9 on AD-related cytokine and chemokine expression levels was found in our NHK 
cultures. Furthermore, host response gene and protein expression (DEFB4, SKALP) was unaffected 
by IL-9 stimulation. In addition, no additive or synergistic effects of IL-9 to the IL-4/IL-13 effects was 
observed. In conclusion, classic Th2 cytokines (IL-4/IL-13) rather than IL-9 were shown to be the 
major drivers of increased keratinocyte proliferation, disturbed differentiation and impaired host 
defence. Therefore, the contribution of IL-9 to the pathogenesis of AD, if any, is probably in the 
regulation of the immune response rather than an effect on the epidermal compartment.    
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Increased activity of eosinophils in blister fluids and peripheral blood of patients with bullous 
pemphigoid 
E Judith, U Rüdrich, M Gehring, E Papkonstantinou, A Kapp and U Raap Dept of Dermatology 
and Allergy, Hannover Medical School, Hannover, Germany
Bullous pemphigoid (BP) is an autoimmune blistering skin disease characterized by increased levels 
of autoantibodies targeting BP180 and increased numbers of peripheral blood eosinophils. Our aim 
was to study the functional activity of blood eosinophils in BP patients and to further characterize 
eosinophils in blister fluids. Freshly isolated BP eosinophils from the peripheral blood displayed 
a significantly higher expression of CD69 and CD11b in comparison to eosinophils derived from 
healthy controls. Interestingly, the expression of CD95 in BP eosinophils was higher in addition 
to an increased number of apoptotic eosinophils 24 hours in culture compared to eosinophils 
from healthy controls. In BP we found an almost pure accumulation of 1x10-6 eosinophils per ml 
of blister fluid. CCL26 levels were significantly higher in BP blister fluids as compared to serum, 
indicating a possible reason for eosinophil accumulation. Eosinophils in blister fluids displayed a 
strong expression of CD69 and CD95. Furthermore, CD95 ligand was significantly increased in BP 
blister fluid as compared to BP sera. Thus, we wanted to clarify whether sera and blister fluid of 
BP patients were able to functionally activate eosinophils from healthy donors. The expression of 
CD69 and CD11b was significantly upregulated in eosinophils of healthy donors incubated with 
BP blister fluid in comparison to BP sera, while CD95 expression remained unchanged. Further, 
BP blister fluid significantly inhibited apoptosis in eosinophils of healthy donors in comparison to 
BP upon serum stimulation. Together, our data clearly show that eosinophils in BP patients derived 
from the peripheral blood as well as from blister fluid are significantly preactivated. Furthermore, BP 
serum can significantly activate eosinophils derived from healthy controls, underlining an important 
interplay in the regulation of inflammation in this autoimmune skin disease with eosinophils as 
main target effector cells.    
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Brimonidine may display anti-inflammatory properties in the skin through its vasoconstrictive 
activity and an associated modulation of the cutaneous vascular permeability
C Nonne, A Bogouch, A Jomard and E Vial Galderma RD, Sophia Antipolis, France
Brimonidine tartrate, an α2A-adrenergic receptor agonist, is the active ingredient of Mirvaso® gel, 
approved in the US and EU for the topical treatment of facial erythema of Rosacea. We have eval-
uated the anti-inflammatory potential of brimonidine tartrate in two mouse models of skin vascular 
inflammation induced either by a neuronal activation (resiniferatoxin or RTX at 0.03%) or by an 
inflammatory inductor (12-O-tetradecanoylphorbol-13-acetate or TPA at 0.01%). In the RTX model, 
the effect of brimonidine at 0.2% in topical pre-treatment was evaluated by measuring the reduction 
of the ear vasodilation using in vivo macroscopic observation. In the acute TPA model, the effect of 
brimonidine was evaluated by measuring the reduction of leukocyte rolling in ear capillaries. RTX 
0.03% induced a significant vasodilation measured by an increase of the vessels size at the periphery 
of the ear which is enriched in capillaries as well as at the base of the ear where larger vessels are 
localized. Brimonidine pre-treatment resulted in a significant decrease of the RTX-induced vasodi-
lation by 77%. This effect is more pronounced in vessels (-107%) compared to capillaries (-26%) 
and is seen in arteries and veins. These data are in agreement with other studies that have shown 
the inhibitory activity of Brimondine on heat- and capsaicin-induced vasodilation in ex vivo human 
skin. The brimonidine activity upon vessel reactivity may impact the vascular permeability and the 
leucocyte migration across endothelial monolayers to the inflammatory site. In the TPA model, the 
number of leukocytes rolling along the endothelium and adherent in capillaries was increased by 
82% and 175% respectively. Brimonidine pre-treatment completely and significantly prevented the 
leucocyte recruitment in this model. Both in vivo ear inflammation studies suggest anti-inflammatory 
properties of Brimonidine triggered by its vasoconstrictor activity. These results demonstrate that 
Mirvaso® could have a preventive effect on the apparition of the erythema symptom in Rosacea.   
060
Functionalized gold nanoparticles for topical delivery of Methotrexate for the possible treat-
ment of psoriasis
HA Bessar,1 I Venditti,2 I Fratoddi,2 L Benassi,3 C Vaschieri,3 E Botti,4 F Mostafa,1 
M Russo,2 A Costanzo4 and G Pellacani3 1 Zagazig university, Zagazig, Egypt, 2 Chemistry, 
Sapienza university, Rome, Italy, 3 Dermatology, Modena university, Modena, Italy and 4 
Dermatology, NESMOS, Sapienza,Sant’Andrea Hospital, Rome, Italy
Gold nanoparticle (AuNP) are potential drug delivery systems thanks to their small size, general 
non-toxicity, ease of functionalization and high surface to volume ratio. AuNPs could represent an 
effective choice for topical drug delivery. Methotrexate plays an important role in psoriasis treatment 
with insufficient percutaneous penetration owing to limited passive diffusion and dissociation at 
physiological pH. We propose a new design for Methotrexate delivery nanocarrier to improve its 
solubility, stability and biodistribution. AuNPs were prepared with an hydrophilic stabilizing layer. 
The AuNPs@MTX bioconjugate was fully characterized by spectroscopic techniques (UV-vis, FTIR) 
and DLS. MTX bioconjugated on the AuNPs showed a loading of about 80%. A release of 95% 
was obtained in 24 h. The new AuNPs@MTX bioconjugate was tested on keratinocytes monolayer 
and Skin Equivalent in order to assess the toxicity and proper dose. The bioconjugate was topically 
used on C57BL/6 mouse normal skin to trace absorption and drug delivery. In vitro studies showed 
that AuNPs@MTX is much more efficient than Methotrexate alone, proved by (TEM) Transmission 
electron microscopy. Moreover, DL50 is ten folds reduced at 48 hours by the presence of nanopar-
ticles conjugation based on MTT analysis. UV-vis spectra for in vivo tracing of the conjugate after 
24 h of application on bared rat skin show successful delivery of Methotrexate in the epidermis 
and in less intensity also in the dermis, in spite of absence of the AuNPs neither in the dermis nor 
in the epidermis, suggesting that both layers of the skin does not retain the nanoparticles. Based on 
our research, we found the novel AuNPs@MTX is an effective nontoxic carrier for the satisfactory 
percutaneous absorption of Methotrexate and could help in possible topical treatment of psoriasis.   
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A Distinct Cutaneous Microbiota Profile in Bullous-Pemphigoid Patients
M Miodovnik,1 A Kunstner,2 E Langan,3 R Glaser,4 D Zillikens,5 J Baines,6 E Schmidt,5 
E Sprecher1 and S Ibrahim2 1 Department of Dermatology, Tel Aviv Sourasky Medical 
Center, Tel Aviv, Israel, 2 Lubeck Institute of Experimental Dermatology, University of 
Lubeck, Lubeck, Germany, 3 Department of Microbiology, University of Lubeck, Lubeck, 
Germany, 4 Department of Dermatology, University of Kiel, Kiel, Germany, 5 Department 
of Dermatology, University of Lubeck, Lubeck, Germany and 6 Max Planck Institute for 
Evolutionary Biology, Plon, Germany
Bullous Pemphigoid (BP) represents the most common autoimmune blistering disease in Europe. 
Whereas some progress has been achieved in defining genetic risk factors for autoimmune blister-
ing diseases, the role of environmental agents, such as the skin microbiota, is not as well defined. 
Emerging evidence suggests that host immunity influences the skin microbiota while the latter 
modulates cutaneous immunity. Thus we characterized the skin microbiome of BP patients. Twelve 
clinically and immunopathologically well- characterized patients with BP and a similar number of 
age-matched patients with non-inflammatory skin disorders were recruited for this study between 
August 2014 and January 2015. Skin samples were obtained by a non-invasive swabbing technique 
and were then processed for microbial DNA extraction and 16S rRNA gene sequencing using the 
MiSeqIllumina platform. Skin swabs were taken from several body sites with different microenvi-
ronments. The composition of the skin microbiota in BP patients as well as controls appears to be 
site specific. However, beta-diversity was found to be affected not only by sample location but also 
by disease state. Furthermore, the relative abundance at phylum level was significantly different at 
peri-lesional vs. non-lesional sites in BP patients. We observe a clear shift from the abundant Proteo-
bacteria within control samples towards the Firmicutes phyla in patients at the same anatomic loca-
tions. The existence of a distinct cutaneous microbiota profile in BP suggests that commensal-host 
interaction may contribute to pathogenesis of this disease and suggests novel therapeutic avenues.   
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Langerhans cell migration in response to TNFα and anti-TNFα in patients with psoriasis and 
in an ex vivo skin model
L Raaby,1 A Langkilde,1 K Lauridsen,2 H Vinter,1 P Ommen,1 C Rosada,1 RB Kjellerup,1 
C Johansen1 and L Iversen1 1 Department of Dermatology, Aarhus University Hospital, 
Aarhus, Denmark and 2 Department of Pathology, Aarhus University Hospital, Aarhus, 
Denmark
The purpose of this study was to investigate the effect of TNFα and anti-TNFα on Langerhans cell 
(LC) migration in psoriasis. Biopsies from 20 psoriatic patients starting adalimumab (anti-TNFα) 
or ustekinumab (anti-IL12/23) therapy were collected 0, 4 and 14 days after initiation of therapy. 
Furthermore, we investigated the effect of daily stimulation with TNFα or anti-TNFα for four days in 
an ex vivo model of full-thickness skin samples of epidermis and dermis from normal skin cultured 
in an air-liquid interface on a permeable support system. mRNA expression was investigated using 
GeneChip array and RT-qPCR, whereas cytokine levels in the skin sample culturing media were 
measured with ELISA. CD1a staining and quantitative digital software were used to analyze LC 
migration. LC genes (CD1a and CD207) were found to be the most significantly upregulated genes 
in psoriatic skin four days after the first injection with adalimumab. This upregulation was confirmed 
with RT-qPCR and histological quantification. No regulation was seen after ustekinumab therapy. 
The effect of TNFα and anti-TNFα on LC was investigated further in the ex vivo skin model. TNFα 
stimulation lead to a decrease in the mRNA expression of CD1a and staining showed migration 
of LC from epidermis. Furthermore, increased mRNA expressions of IL8 and CCL20 were seen 
after TNFα stimulation along with increased protein levels in the media. The mRNA expression of 
IL23p19 remained unaltered. Stimulation with anti-TNFα on the other hand reduced the decrease 
in the mRNA expression of CD1a. From this study we conclude that the rapid increase of LC in 
epidermis after adalimumab therapy seems to be specific for anti-TNFα as no regulation was seen 
after ustekinumab treatment. The ex vivo skin model confirmed that TNFα and anti-TNFα can 
regulate the migration of LC. These findings suggest that regulation of LC migration may play a role 
in the anti-psoriatic effect of anti-TNFα therapy.    
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Leptin’s Mode of Action in Psoriasis
S Pedersen, P Ommen, D Lybæk, L Iversen, K Stenderup and C Rosada Dermatology, Aarhus 
University Hospital, Aarhus, Denmark
Leptin is an adipokine secreted primarily by the subcutaneous adipose tissue. It appears to play a 
major role in the chronic inflammatory state present in obesity, metabolic syndrome, and atheroscle-
rosis, which are all co-morbidities of psoriasis. Interestingly, increased levels of leptin are found in 
serum of both obese individuals and patients with psoriasis and in lesional psoriatic skin compared 
with non-lesional and healthy skin. Psoriasis treatment has been described to reduce leptin serum 
levels and weight loss to improve psoriasis. Taken together, this suggests that leptin may be a 
possible link between obesity and psoriasis. Previous results, in our laboratory, have demonstrated 
that leptin knockout mice develop an ameliorated psoriatic phenotype compared with wild type 
mice when applying the imiquimod-induced psoriasis mouse model. Moreover, leptin was shown 
to induce proliferation of keratinocytes and to have a pro-inflammatory effect on both keratinocytes 
and dermal fibroblasts. The purpose of the present study is to further investigate how leptin exerts 
its effect in psoriasis. Thus, we aim to investigate the intracellular signaling pathways activated by 
leptin in keratinocytes and dermal fibroblasts. To screen for activated kinases, a human Proteome 
Profiler™ phospho-kinase antibody array was employed and to validate interesting regulated phos-
pho-kinases, western blot analysis was utilized. Through the screening process, leptin was found 
to induce phosphorylation of several kinases such as ERK1/2, c-jun, STAT3, p53, STAT5 a/b, Akt 
1/2/3 and HSP60. Interestingly, they are activated differently among keratinocytes and fibroblasts 
isolated from healthy, non-lesional and lesional psoriatic skin. The JAK-STAT pathway was further 
investigated and leptin was shown to induce phosphorylation of STAT3 (Tyr705) in a time-dependent 
manner. Maximal activation was observed after 1 hour of stimulation. The present study suggests 
that leptin may contribute to the psoriatic phenotype by activating differently certain intracellular 
signaling pathways in keratinocytes and dermal fibroblasts.    
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Leptin induces secretion of IL-6 by human keratinocytes via decreased expression of caveolin-1
Y Watanabe, Y Yamaguchi, N Komitsu, T Watanabe and M Aihara Department of 
Environmental Immuno-Dermatology, Yokohama City University Graduate School of 
Medicine, Yokohama, Japan
Psoriasis is a chronic inflammatory and immune-mediated skin disease associated with several 
comorbidities, such as obesity. Leptin, an adipocyte-derived hormone, modulates innate and 
adaptive immunity. Although recent studies indicate the association of leptin with psoriasis, the 
pathological function of leptin in psoriasis is unclear. Caveolin-1 (Cav-1) is a membrane protein, 
which serves as a platform for membrane trafficking and signal transduction. We have previously 
shown that aberrant reduction of Cav-1 in the epidermis of psoriasis patients. RNA interference of 
Cav-1 in keratinocytes enhanced phosphorylation of signal tranducer and activator of transcription 
3 (STAT3), suggesting that decreased Cav-1 is one of the feature of psoriasis which may contribute 
to psoriatic inflammation. In this study, we examined a role of leptin on keratinocytes via Cav-1 
reduction. We first examined co-localization and binding of leptin receptor and Cav-1 by immu-
noprecipitation-western blot and immunocytochemistry. Leptin-induced activation of signaling 
molecules were further evaluated in Cav-1-silenced keratinocytes by western blot. In addition, 
levels of inflammatory cytokines and chemokines induced by leptin under psoriatic inflammation 
were also determined by quantitative PCR and ELISA. Finally, Cav-1 was restored using Cav-1 
scaffolding domain (CSD) peptide in those analysis. As a result, Cav-1 was co-localized and bound 
with leptin receptor. Leptin stimulation in Cav-1-silenced keratinocytes enhanced phosphorylation 
of STAT3, extracellular signal-regulated kinase, and nuclear factor-kappa B compared to that in 
controls. Furthermore, significant augmentation of IL-6 expression induced by leptin was observed 
in Cav-1-silenced keratinocytes co-stimulated with IL-17 or IL-22. Finally, CSD peptide inhibited 
this effect. Our findings suggest that leptin enhances IL-6 production in psoriatic keratinocytes 
through Cav-1 suppression, which may be one of mechanisms in obesity-mediated pathogenic 
inflammation in psoriasis.    
065
Interleukin-13 induces epidermal spongiosis by let-7f down-regulation and cathepsin C induc-
tion in atopic dermatitis
A Ichihara, M Jinnin, A Ogata, D Niimori, T Johno, S Fukushima and H Ihn Dermatology and 
Plastic Surgery, Kumamoto University, Kumamoto, Japan
Atopic dermatitis (AD) is an inflammatory skin disease characterized by increased T-helper type 2 
(Th2) cytokine expressions, especially in the acute stage. To determine the role of interleukin-13 
(IL-13) in AD epidermis, we investigated the genes targeted by IL-13 in human cultured keratinocytes 
using cDNA microarray. Among the up- or down-regulated genes in IL-13-stimulated keratinocytes, 
we focused on the up-regulation of cathepsin C (CTSC), lysosomal cysteine peptidase of the papain 
family, which was confirmed with quantitative real-time PCR using the specific primer and immu-
noblot analysis. Immunohistochemical findings revealed CTSC protein is localized in the upper 
and middle layer of AD epidermis. We found the treatment of skin specimen with recombinant 
CTSC resulted in spongiosis formation of the epidermis. Accordingly, we hypothesized that the 
IL-13-induced CTSC may play a role in epidermal spongiosis, one of the histopathological features 
of AD in the acute stage. We demonstrated that IL-13 reduces protein expression of E-cadherin, a 
key adhesion molecule of epidermis, and this effect of IL-13 on E-cadherin was inhibited by CTSC 
siRNA in cultured keratinocytes. We also identified let-7f as the regulator of CTSC: Among microR-
NAs targeting CTSC, let-7f levels were down-regulated in IL-13-stimulated cultured keratinocytes, 
and were significantly decreased in the skin tissues of AD patients compared to normal subjects. 
Furthermore, serum let-7f levels were also decreased in AD patients, weakly correlating with periph-
eral blood eosinophils. Taken together, our results suggest the possibility that IL-13 up-regulates 
CTSC expression in AD skin via let-7f down-regulation, which induces epidermal spongiosis by the 
degradation of E-cadherin. Proteases or peptidases may be important for epidermal spongiosis as well 
as epidermal barrier function and the desquamation process. Clarification of the role of CTSC and 
let-7f in the inflammatory skin disease may lead to find new disease markers and therapeutic targets.   
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Decreased Levels of Regulatory B cells in Patients with Systemic Sclerosis: Association with 
autoantibody production
T Matsushita,1 Y Hamaguchi,1 M Hasegawa,2 K Takehara1 and M Fujimoto3 1 Dermatology, 
Kanazawa Univ., Kanazawa, Japan, 2 Dermatology, Fukui Univ., Fukui, Japan and 3 
Dermatology, Tsukuba Univ., Tsukuba, Japan
B cell abnormalities characterized by autoantibody production and polyclonal B cell activation play 
an important role in the pathogenesis of systemic sclerosis (SSc). Regulatory B cells that produce 
IL-10 play an important role in the negative immune response. Recently, we identified a human reg-
ulatory B cell subset and it was predominantly found within the CD24hiCD27+ B cell subpopulation. 
However, the role of regulatory B cells in SSc remains unknown. In this study, we investigated the 
clinical association of regulatory B cells in patients with SSc. Blood IL-10 producing regulatory B 
cell levels were determined by FACS in 35 patients with SSc and 30 healthy subjects. The frequency 
of blood IL-10 producing regulatory B cells was significantly lower in patients with SSc [5.43 (2.38-
13.10) %] than in healthy controls [11.60 (4.29-18.80) %, P<0.0001]. Similarly, the frequency of 
CD24hiCD27+ B cells was significantly lower in SSc patients with [16.2 (7.6-42.6) %] than in healthy 
controls [28.3 (17.1-62.7), P<0.0001]. SSc patients with decreased regulatory B cell levels more 
frequently had interstitial lung disease (P<0.05). Furthermore, regulatory B cell levels correlated 
negatively with the titer of anti-topoisomerase I Ab and anticentromere Ab in SSc patients. These 
results suggest that decreased regulatory B cell levels may contribute to the development of SSc.   
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Fibroblasts contribute to psoriasis pathology due to abnormal regulation of fibronectin 
production
B Gubán,1 K Vas,1 A Bebes,1 G Groma,3 M Széll,2 L Kemény1 and Z Bata-Csorgo1 1 
Department of Dermatology and Allergology, University of Szeged, Szeged, Hungary, 2 
Department of Medical Genetics, University of Szeged, Szeged, Hungary and 3 MTA-SZTE 
Dermatological Research Group, University of Szeged, Szeged, Hungary
In psoriatic lesional skin hyperproliferation of keratinocytes could be partially induced by fibro-
blast produced keratinocyte growth factor (KGF), signaling through the fibroblast growth factor 
receptor IIIb (FGFR2-IIIb) and inducing the expression of α5 integrin among others. The α5 integrin 
is a key interacting partner for the extra-domain-A containing fibronectin (EDA+FN). In previous 
work we found that in non-lesional skin the expressions of α5 integrin, EDA+FN, KGF and FGFR2 
proteins were increased compared to healthy controls. Next we tested whether KGF influenced 
EDA+FN and total fibronectin (FN1) production in three major cell types of the skin. KGF treatment 
increased the expression of EDA+FN only in fibroblasts and this observed elevation was blocked by 
MEK1 inhibition. Fibroblasts predominantly express the FGFR2-IIIc splice variant of FGFR2, while 
keratinocytes and melanocytes show FGFR2-IIIb expression at the mRNA level. We show that the 
expressions of FN1 and EDA+FN are negatively regulated by activated STAT1 in healthy fibroblast, 
but not in fibroblast derived from non-lesional psoriatic skin. As we also show, STAT1 is activated 
in healthy skin, similar to psoriatic lesional skin, but not in non-lesional skin, indicating that altered 
STAT1 regulation of FN1 and EDA+FN may be crucial in keeping the psoriatic non-lesional skin 
in a preactivated state prone to develop a chronic wound healing phenotype. Our data provide 
evidence for the existence of a novel regulatory mechanisms in the fibroblasts of healthy skin and 
and its alterations in non-lesional psoriatic fibroblasts.    
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Cholesterol-depletion followed by interleukins-4, -13 and –25 enhances alterations in a 
reconstructed human epidermis
E De Vuyst,1 S Giltaire,1 A Chrétien,2 C Lambert de Rouvroit,1 M Salmon2 and Y Poumay1 1 
URPHYM - Narilis, University of Namur, Namur, Belgium and 2 StratiCELL, Les Isnes, Belgium
Epidermal barrier alteration combined to abnormal Th2 immune response is characteristic of atopic 
dermatitis (AD). Aetiology of AD is still puzzling but involves both epidermal and immune actors, 
each of them being able to induce the other in a vicious circle likely responsible for this chronic 
inflammatory disease. Transcriptomic studies on cultured human keratinocytes after cholesterol 
depletion previously indicated AD-like deregulated gene expression. This treatment is now applied 
on reconstructed human epidermis (RHE) to more closely mimic the in vivo situation. Although RHE 
fully recover after cholesterol depletion during tissue morphogenesis, this depletion in mature RHE 
induces TSLP expression, a Th2 immune response activating cytokine. Treated RHE then received 
for 48h interleukins (IL) -4, -13, and -25 typical of AD epidermal lesions. This study intends to 
understand and analyse potential synergistic effects of epidermal activation by plasma membrane 
cholesterol depletion, followed by IL treatment, on RHE barrier characteristics. Histology reveals 
typical features of AD including spongiosis after combined treatment. Differentiation is altered as 
confirmed by the downregulation of LOR and FLG expression whereas AD-specific markers CA2 
and NELL2 were found upregulated. The combination of both treatments results in addition into sig-
nificant alterations of the barrier functions evaluated by measurements of trans-epidermal electrical 
resistance and by permeation studies using the lucifer yellow fluorescent dye. In summary, epidermal 
and immune activations alter keratinocytes within RHE, but combined activation synergetically 
affects barrier permeability reproducing AD characteristics in vitro.    
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The role of PPARγ modulation in the control of the insulin-induced sebogenesis and 
inflammation 
A Mastrofrancesco,1 M Ottaviani,1 G Cardinali,1 M Ludovici,1 S Briganti,1 CC Zouboulis,2 
V Lora,1 E Camera1 and M Picardo1 1 Laboratory of Cutaneous Physiopathology, S Gallicano 
Dermatologic Institute (IRCSS), Rome, Italy and 2 Depts of Dermatology, Venereology, 
Allergology and Immunology, Dessau Medical Center, Dessau, Germany
The nuclear receptor peroxisome proliferators-activated receptor gamma (PPARγ) is a key factor 
involved in the regulation of lipid and glucose metabolisms, cell proliferation/differentiation, and 
inflammatory pathways. Pivotal studies in sebocytes and sebaceous glands have pointed out the 
promise of targeting PPARγ in the treatment of acne. We investigated the role of PPARγ in the 
regulation of lipid synthesis and proliferation induced by insulin in the sebocyte cell line SZ95. 
Consistently with the literature data, we demonstrated that the insulin signalling pathway induced 
lipid synthesis and cell proliferation by activating the phosphatidylinositide 3-kinase-Akt (PI3K/Akt) 
and mammalian target of rapamycin (mTOR). Oil/Nile Red staining, GC-MS analysis of bound fatty 
acids (FA) and cholesterol (CH), Real time-PCR assessments of FAS, FADS-2, SCD-1 and HMG-CoA 
reductase mRNA, demonstrated that upon modulation of PPARγ, the insulin-induced sebogenesis 
was counteracted through the inhibition of gene expression of key enzymes involved in the synthesis 
of FA and CH. Analysis of FA showed that insulin initially stimulated the formation of unsatured 
lipids and then the de novo lipid synthesis; both processes were inhibited upon PPARγ activation. 
Insulin altered normal cell proliferation through the degradation of p21 and p27 proteins. Moreover, 
insulin triggered inflammatory pathways in sebocytes resulting into the induction of gene expression 
of inflammatory cytokines, such as IL-1, IL-6 and IL-8. Upon activation of the PPARγ receptor, the 
proliferative and proinflammatory stimuli of insulin were prevented at a significant extent. A spe-
cific inhibitor of PPARγ proved to abolish the above effects, confirming the key role of the nuclear 
receptor in regulating the altered sebogenesis, proliferation and inflammation induced by insulin.   
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House dust mite allergen triggers IL-31 release from epidermal keratinocytes, via activaing 
ATP sgnaling and mobilizing intracellular calcium
X Dai, M Tohyama and K Sayama Ehime University Graduate School of Medicine, Toon, 
ehime, Japan
In allergic diseases such as atopic dermatitis (AD), allergic rhinitis, and asthma, the epithelium plays 
active roles by releasing cytokines and chemokines to initiate inflammation. Since epidermal barrier 
function is disrupted, AD is induced and/or exacerbated by environmental stimuli such as house 
dust mite (HDM) allergens. Interleukin-31 (IL-31), a newly discovered cytokine associated with 
chronic skin inflammation and pruritus, is involved in the pathogenesis of AD. We have detected 
IL-31 expression in human epidermal keratinocytes, however, whether keratinocytes secrete IL-31 
remains unclear. To investigate whether HDM allergens release IL-31 from keratinocytes, we treated 
human keratinocytes with Dermatophagoides pteronyssinus (Der p) and measured the supernatant 
levels of IL-31. We detected the rapid release of IL-31 from Der p-treated cultures, together with 
elevated extracellular ATP level and increased intracellular Ca2+ level. Not only degradation of 
extracellular ATP using apyrase (a specific ATPase/ADPase) or blocking ATP signal using suramin 
(an antagonist of P2 receptors), but also chelation of intracellular Ca2+ significantly suppressed the 
release of IL-31 from Der p-treated cultures, suggesting the increase of extracellular ATP and the 
mobilization of intracellular Ca2+, in response to Der p, mediate IL-31 release from human kerati-
nocytes. Furthermore, we found that extracellular ATP caused the increase of intracellular Ca2+ in 
Der p-treated keratinocytes by activating P2Y receptors. In conclusion, HDM allergen induces the 
release of IL-31 from epidermal keratinocytes through activating ATP signaling and further increasing 
intracellular Ca2+, which may play a role in the initiation and/or exacerbation of AD.    
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IL-27 in pemphigus vulgaris: a potential role in disease pathogenesis by promoting IL-21 
producing T follicular helper cells
R Pollmann,1 T Hennerici,1 T Schmidt,1 M Seipelt,2 B Tackenberg,2 M Hertl1 and R Eming1 
1 Department of Dermatology and Allergology, Philipps-Universität Marburg, Marburg, 
Germany and 2 Department of Neurology, Philipps-Universität Marburg, Marburg, Germany
Pemphigus vulgaris (PV) is an organ-specific autoimmune disease characterized by blister formation 
at the suprabasilar layer of the skin and mucous membranes in which IgG autoantibodies (autoAb) 
mainly against desmoglein 3 (Dsg3) induce blister formation. Since autoreactive CD4+ T cells are 
involved in the production of autoAb, cytokines play a crucial role in disease pathogenesis by 
mediating T cell function. However, the role of disease supporting cytokines in PV has not been 
fully characterized yet. In this context the role of IL-27, a cytokine promoting the function of T 
follicular helper (Tfh) cells, is largely unknown in PV. In a cross-sectional study including PV patients 
(n=12) and healthy controls (n=12), peripheral blood mononuclear cells were analysed for CD4+ T 
cell subsets using flow cytometry as well as for cytokine levels by ELISA. Patients with myasthenia 
gravis (n=12), another autoAb mediated autoimmune disease, served as further control. In our study 
IL-27 levels were elevated in plasma of PV patients with active disease and IL-27 levels strongly 
correlated with Dsg3-specific autoAb titers, suggesting a potential role of IL-27 in the generation 
of autoAb. In accordance with the increased IL-27 levels the frequencies of circulating Tfh cells 
(defined as CD4+CXCR5+ T cells) were significantly elevated in PV patients. Furthermore, the 
cytokine IL-21, an important factor for the maintenance of Tfh cells, was increased in PV patients 
with an active phase of disease whereas patients in clinical remission showed only minor IL-21 in 
plasma. Taken together, for the first time our current results suggest an involvement of IL-27 in the 
pathogenesis of PV by supporting the numbers and function of IL-21 producing Tfh cells. The more 
defined understanding of the role and contribution of IL-27 and IL-21 in PV might pave the road 
for innovative targeted therapies in the future.    
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Immunohistochemical analysis of the JAK family members in inflammatory skin diseases 
reveals increased expression of JAK1 and JAK3
AK Alves de Medeiros, S De Schepper and J Lambert Dermatology, Ghent University 
Hospital, Ghent, Belgium
We aimed to explore the JAK involvement in a set of prevalent inflammatory skin diseases, namely 
psoriasis (PsO), lichen planus (LP), cutaneous lupus erythematosus (CLE), atopic dermatitis (AD), 
alopecia areata (AA) and pyoderma gangrenosum (PG), in order to preview the usefulness of JAK 
inhibitors in their treatment. We analysed JAK family members immunohistochemical expression in 
human skin material from patients with LP, CLE, AD, PG (each disease, n=10), AA (n=7) and PsO 
(n= 20). We stained the samples for JAK1, JAK2, JAK3, TYK2, pJAK1, pJAK2, pJAK3 and pTYK2. In 
the dermal inflammatory cells, we classified the staining as ‘positive’ or ‘negative’. In the epidermis, 
for cytoplasm staining, we scored the extent of epidermal area stained (0 = negative, 1 = only basal 
layer, 2 = until ½ of the epidermis thickness, 3 = more than ½ of the epidermis thickness) and 
the intensity of staining (using ImageJ). For nuclear staining, we counted the stained cells per area 
(ImageJ). Statistical analysis compared each disease with stained controls (n=18) . We applied a Chi-
Square test for the analysis of epidermal area and inflammatory cells, and Kruskal-Wallis ANOVA 
for the analysis of the staining intensity and cell count area. P≤ 0.05 was considered statistically 
significant. We observed similar JAK expression in PsO, LP, CLE, AD, AA and PG, with overexpres-
sion of JAK1 and JAK3 in the epidermis (except lupus) and dermis. In the epidermis, JAK1 and/or 
pJAK1 were significantly overexpressed in PsO, LP, AA and PG and JAK3 and/or pJAK3 in AD, AA 
and PG. In the dermis, pJAK1 was significantly overexpressed in PsO, LP, CLE, AD, PG and pJAK3 
in PsO, LP, AD, AA and PG. TYK2 was underexpressed, whereas JAK2 expression did not differ 
compared to controls, except in the inflammatory cells of AA and PG, where it was overexpressed. 
We evidenced similar JAK involvement in PsO, LP, CLE, AD, AA and PG. Hence, we consider that 
JAK inhibitors should be tested in all these dermatoses, not exclusively in PsO, with selective JAK1/
JAK3 inhibition being the target.    
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Multiple regulatory effects of fumaric esters on human 6-sulfo LacNAc expressing dendritic 
cells
A Kunze, M Maas, S Oehrl, A Enk and K Schäkel Dermatology, University Hospital 
Heidelberg, Heidelberg, Germany
The fumaric acid dimethylfumarate (DMF) has immunomodulatory functions that allow long term 
control of widespread psoriasis. Underlying regulatory mechansims have been described at the level 
of cytokine expression or transcription factor activities in monocyte derived dendritic cells (MoDCs), 
T cells, keratinocytes or endothelial cells. None of these studies addressed the immunomodulatory 
function of fumaric esters at the level of human blood precursors of inflammatory dermal DCs. We 
previously described human 6-sulfo LacNAc-dendritic cells (slanDCs) as inflammatory dermal DCs 
in psoriasis. In the skin, slanDCs showed a strong expression of the key cytokines IL-23 and TNFα 
and in vitro they very efficiently programmed Th1- and Th17-T cells. Here we studied the effects 
of DMF on the in vitro maturation and cytokine production of slanDCs. Immature slanDCs were 
purified from blood and stimulated with R848, thereby mimicking the in vivo TLR7/8-stimulation 
in the skin with RNA complexed to the anti-microbial peptide LL-37. While DMF did not alter 
the viability of slanDCs it prevented spontaneous maturation characterized by the upregulation 
of HLA-DR, the costimulatory molecules CD86, CD80 as well as CD83. Moreover, DMF-treated 
slanDCs showed an increase in cell surface expression of the inhibitory molecule PDL-1 and LILRB4. 
slanDCs are known as blood leukocytes with particularly high capacity to produce TNFα, IL-12 and 
IL-23. Notably, this high level production of pro-inflammatory cytokines was efficiently blocked 
when cells were cultured in the presence of titrated doses of DMF. In contrast to previous studies 
with MoDCs we did not observe an increased production of the type II cytokine IL-10. Studies on 
intracellular signals as studied by western blotting provide evidence for a reduced phopsphorylation 
of NFkB p65, Stat1, Stat3 and no induction of HO-1 when slanDCs are cultured in the presence of 
DMF. In conclusion, the remarkable clinical effects achieved with DMF in psoriasis may in part be 
attributed to its strong immunomodulatory effects on slan+ inflammatory dermal DCs.    
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Ustekinumab: a treatment option in severe therapy-refractory atopic dermatitis? 
D Weiss,1 M Schaschinger,1 R Gruber,2 G Stingl1 and C Bangert1 1 Department of 
Dermatology Division of Immunology, Allergy and Infectious Diseases, Medical University of 
Vienna, Vienna, Austria and 2 Department of Dermatology, Medical University of Innsbruck, 
Innsbruck, Austria
Ustekinumab, a human monoclonal antibody approved for the treatment of moderate to severe 
plaque psoriasis, targets IL-12/Th1 and IL-23/Th17 immune responses by blocking the p40 subunit 
shared by IL-12 and IL-23. To our current knowledge, these pathways might also be centrally 
involved in the perpetuation of eczematous responses predominantly in the chronic phase of atopic 
dermatitis (AD). To establish the clinical efficacy of ustekinumab in the treatment of AD, we admin-
istered ustekinumab SC (45mg at weeks 0, 4 and 12) in three patients with severe recalcitrant 
AD. Two patients displayed common filaggrin loss-of-function mutations (c.2282del4). All patients 
showed an improvement of clinical disease activity in Eczema Area and Severity Index (EASI) and 
the SCORing Atopic Dermatitis index (SCORAD) already by week 8 and their skin had cleared to 
a large extent by week 16. Pruritus had subsided after 4 to 8 weeks according to the 5-D itch and 
a visual analog scale. By comparing lesional atopic skin regarding its inflammatory infiltrate and 
cytokine profile before and 8 weeks after initiating treatment, we further sought to gain insight into 
pathogenic processes involved in disease remission. By immunohistology, skin biopsies after therapy 
exhibited a significant decrease in the degree of epidermal hyperplasia/proliferation as well as in 
the number of dermal CD4+ and CD8+ T cells and CD11c+ myeloid dendritic cells. Mast cells, by 
contrast, were reduced to a lesser extent and the amount of infiltrating IgE+ cells remained nearly 
stable after two administrations of ustekinumab. Importantly, using qRT-PCR of lesional skin, we 
found a clear reduction of Th22/Th17-associated molecules such as IL-22, IL-23 and S100A8/A9 
after therapy. We conclude that ustekinumab may be an effective treatment for at least a subgroup 
of patients with severe refractory AD, exerting its action by targeting Th22 and Th17 pathways.   
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Identification of atopic dermatitis relevant cytokine cocktails for keratinocyte cultures.
T Skak-Nielsen, NW Hansen and B Ursø Molecular Pharmacology, Leo Pharma, Ballerup, 
Denmark
Immune cells and keratinocytes are able to secrete large amounts of various cytokines and chemok-
ines which are important players in atopic dermatitis (AD). Some chemokines produced by AD-skin 
are more prominent in AD than in other types of skin diseases such as psoriasis. Some of these have 
been shown to correlate with AD disease severity, e.g. TARC and CTACK. We wanted to investigate 
whether we could mimic the AD-environment in keratinocytes in vitro using different cytokine 
mixtures as stimulation. Human epidermal keratinocytes were incubated with various cytokines 
for 3 days after which the chemokine profile in the culture supernatant was analysed. The results 
showed a varied secretion pattern. The stimulation with the AD-like cytokines IL-4, IL-13 and IL-22 
did not give a significant expression of most cytokines except for Eotaxin-3 and MCP-1. A further 
addition of IFN-γ to the stimulation mixture induced an increase in the secretion of RANTES, MDC 
and TARC. MCP-1 which is not viewed as an AD-related chemokine did unexpectedly show a large 
increase by the presence of the AD-like keratinocytes IL-4, IL-13 and IL-22 and this secretion was 
again highly synergized by the presence of IFN-γ. CTACK secretion was almost solely dependent 
on the stimulation with TNF-α, and was completely inhibited upon addition of IFN-γ. The effect 
of different anti-inflammatory drugs was tested on selected stimulation parameters. In conclusion, 
it seems possible to develop an AD-like keratinocyte based assay using a stimulation cocktail 
relevant for the cytokine milieu of AD skin and measure secretion of AD-relevant chemokines, 
e.g. RANTES and MDC.    
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The production of specific mediators in human macrophages is differentially regulated via 
the histamine H4 receptor
S Mommert,1 D Aslan,1 K Gregor,1 K Schaper,1 H Stark,2 R Gutzmer1 and T Werfel1 
1 Hannover Medical School, Department of Dermatology and Allergy, Division of 
Immunodermatology and Allergy Research, Hannover, Germany and 2 Heinrich Heine 
University, Duesseldorf, Germany, Institute of Pharmaceutical and Medicinal Chemistry, 
Duesseldorf, Germany
The histamine H4 receptor (H4R) is a possible therapeutical target structure for the treatment of 
atopic dermatitis. In this study, we investigated the role of the H4R on human monocyte derived 
macrophages differentiated in the presence of GM-CSF and M-CSF and on IFNy+LPS or IL-4 acti-
vated human M1 or M2 macrophages. H1R- and H4R mRNA expressions were measured on fully 
differentiated compared to IFNy+LPS or IL-4 activated monocyte derived M1 or M2 macrophages 
respectively. We observed that both the H1R- and the H4R mRNA expression were not consistently 
influenced by IFNy+LPS in M1 macrophages whereas the activation with IL-4 led to an up-regulation 
of the H1R and H4R at mRNA level in M2 macrophages. When stimulated with IFNy+LPS in the 
presence of histamine or the H4R agonist ST1006, M1 macrophages produced substantially lower 
amounts of the Th1 cell attracting chemokine CXCL10 and of CCL4 which is chemoattractant mainly 
for NK cells and monocytes. The activation of M2 macrophages with IL-4 resulted in higher levels 
of the Th2 cell attracting chemokines CCL22 and CCL17 at mRNA- and protein level. Interest-
ingly, the stimulation with histamine showed a trend to further up-regulate the CCL22 and CCL17 
expression. In summary we show that dependent on the status of activation, histamine or the H4R 
agonist ST1006 influences the production of specific mediators in M1 and M2 macrophages. The 
down-regulation of Th1 related chemokines in M1 macrophages by histamine or the H4R agonist 
ST1006 and the trend to up-regulate Th2 related chemokines in M2 macrophages by histamine 
provide further evidence for a role of histamine to contribute to a shift from a Th1 into a more Th2 
dominated milieu. This might have an impact on the course of atopic dermatitis and for the treatment 
of the disease with H4R antagonists.    
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Inflammatory Mediator Profiling in Sweat: a potential non-invasive diagnostic for atopic 
dermatitis
K Agrawal,1 N Foolad,2 RK Sivamani2 and JW Newman3 1 Department of Nutrition, 
University of California, Davis, CA, 2 Department of Dermatology, University of California, 
Davis, CA and 3 US Department of Agriculture, Agricultural Research Service, Western 
Human Nutrition Research Center, Davis, CA
Sweat is a complex biological fluid with potential diagnostic value for the investigation of skin dis-
orders. Previous efforts in sweat testing focused on analysis of small molecules and ions for forensic 
and diagnostic testing, but with advances in analytical and sweat collection techniques, there has 
been recent interest in conducting metabolomic analyses of sweat to establish biomarkers for and 
understand mechanisms of skin inflammation and repair. Our study aims to characterize the lipid 
mediator profile in sweat and identify differences in these profiles between subjects with and without 
atopic dermatitis. Using the Macroduct® collection device, originally developed for cystic fibrosis 
diagnostic testing of sweat chloride in neonates, we collected sweat (35-80μL) from two patients 
with atopic dermatitis and two healthy controls, and profiled oxylipins and endocannabinoids 
using liquid chromatography-tandem mass spectrometry. These initial results suggest a range of 
lipid mediators present in sweat including prostaglandins, leukotrienes, lipid diols, triols and epox-
ides, monoacylglycerides and acylethanolamides. In patients with atopic dermatitis, we observed 
>2-fold increases in concentrations of linoleate-derived 9- and 13-hydroxyoctadecadienoates and 
trihydroxyoctadecenoate isomers, and a 5-fold decrease in concentration of α-linoleate-derived 
15,16dihydroxyoctadecadienoate. Some of these compounds have pro-inflammatory properties 
in skin conditions such as psoriasis and atopic dermatitis. Our current findings demonstrate the 
presence of lipid mediators in sweat, and suggest differences in the lipid mediator profile between 
subjects with and without atopic dermatitis. Sweat mediator profiling therefore may provide a 
non-invasive assessment of atopic dermatitis pathogenesis and mechanistic progression, and aid in 
novel target elucidation and assessment of therapeutic efficacy.    
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Preclinical evaluation of anti-psoriasis activity using the imiquimod-induced inflammation 
test in the mouse
P Guillaume, M Lepage, S Goineau and V Castagné Porsolt, F53940 Le Genest Saint Isle, 
France
Psoriasis is a common inflammatory disease of human skin characterized by cutaneous plaques 
with consistent scaling and erythema. Repeated topical application of imiquimod (IMQ) to mouse 
skin induces lesions that closely resemble human psoriasis. The purpose of the present study was to 
evaluate the effects of topical applications of clobetasol and tacrolimus in a model of psoriasis-like 
dermatitis, triggered by topical application of IMQ in the mouse. IMQ (20 mg/cm2 of 5% ALDARA®), 
or Vaseline, was topically applied on both the shaved back and the right ear of C57bl6/6J mice, 
once daily for 6 consecutive days. Vaseline, clobetasol propionate (0.05% DERMOVAL® cream: 
80 mg on the back and 20 mg on the ear, or 120 mg on the back and 60 mg on the ear), tacrolimus 
(0.03 or 0.1% PROTOPIC® ointment: 160 mg on the back and 40 mg on the ear) were also applied 
topically on the same days. The severity of psoriasis was evaluated on the back using the PASI score 
(Psoriasis Area Severity Index: sum of erythema, scaling and thickening, scored independently from 
0 to 4; max PASI score = 12) from day 1 to day 7. The ear thickening was also measured. Data were 
analyzed using Student’s t-test. Clobetasol significantly reduced scaling and almost totally prevented 
the erythema and thickening. The PASI score for clobetasol treated animals (0.05%, 80 and 120 
mg) reached 1.3 ± 0.3 and 2.0 ± 0.4 on Day 7 versus 8.6 ± 0.7 in controls, p 0.01 for each. The 
psoriasis severity was also decreased with tacrolimus (0.03 and 0.1%), the PASI score reaching 3.5 
± 0.5 and 3.8 ± 0.5 versus 8.6 ± 0.7 in controls, p 0.05 and p 0.01, respectively. The effects of tac-
rolimus were less pronounced than those observed with clobetasol. Clobetasol totally antagonized 
the IMQ-induced thickening of the ear while tacrolimus only slightly reduced it (0.03%: -11 % NS; 
0.1%: -18% p 0.05). These findings demonstrate that IMQ-induced psoriasis-like inflammation in 
the mouse is a suitable model for screening and evaluating the potential activity of new compounds 
for the treatment of psoriasis.    
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Demodex mites: Their role in modulation of cellular inflammatory responses
E Moran, N Lacey, F Carter and FC Powell Charles Institute of Dermatology University 
College Dublin, Belfied, Dublin 4, Ireland
Demodex mites colonize the pilosebaceous units of persons with normal skin without inducing 
inflammation. Increased Demodex mite density is seen in patients with rosacea and their potential 
to trigger inflammation has been suggested. Topical Ivermectin is effective in clearing inflammatory 
lesions of rosacea, possibly by anti Demodex activity. We postulated that in certain biological 
circumstances (normal skin) mites downregulate the inflammatory response, while in disordered 
circumstances (rosacea) they upregulated it. We studied the effects of Demodex mites (live and 
ruptured) on the production of inflammatory mediators by two primary cell types. Demodex mites 
were extracted from control subjects. Mites were ruptured to release internal contents or were 
maintained viable intact in culture medium. Rat preputial sebocytes (RPS) and human peripheral 
blood mononuclear cells (PBMCs) were challenged with live and ruptured mites. The secretion of 
inflammatory cytokines and chemokines was assessed using multiplex MSD assays and/or proteome 
profiler array analysis. In RPS cell cultures IL-6 secretion was down regulated by both intact live and 
ruptured control mites while GRO production was upregulated threefold in the presence of ruptured 
mites. Array analysis identified downregulation of MIP-3 α, CINC-4, IL-1ra, LIX, Thymus Chemo-
kine and VEGF in response to ruptured mites. PBMC cultures exposed to both live and ruptured 
control mites showed significantly increased TNF-α production. These results indicate a potential 
for Demodex mites to influence the cellular inflammatory response in vitro. The predominant effect 
in sebocytes is downregulation (as expected from the presence of mites in normal subjects without 
inflammation). However, ruptured mites (as may be increased in rosacea) have the capacity to 
stimulate GRO production and attract neutrophils. In normal circumstances mites are not exposed 
to PBMCs. Compromised or ruptured follicles may expose mites that then have the capacity to 
induce TNF-α production by these cells leading to significant inflammation.    
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Characterisation of dandruff scalp transcriptome uncovers shared features with psoriasis 
and eczema
RS Ginger, K Darling, T Dadd, F Lim, J Pople and J Jones Unilever R&D, Bedford, United 
Kingdom
To understand the biological mechanisms of host-microbe interactions we have characterised the 
scalp host transcriptome and generated a ‘dandruff signature’ by comparing gene expression profiles 
of biopsies from healthy and dandruff subjects. Congruence analysis of this signature with public 
disease data sets has revealed significant similarity between dandruff and specific inflammatory skin 
conditions. Dandruff is a flaking, pruritic skin condition localised to the scalp affecting over 40% of 
the global population post puberty. The precise aetiology is much debated and to date research has 
largely focussed on the contribution of scalp specific commensal microbes, including the Malassezia 
yeasts. New ‘big data’ tools are enabling biologists to study human biology at a broader systems 
level. Recent studies of dandruff microbiomes discovered specific microbial species (M. restricta and 
S. capitis) are enriched in dandruff scalp, but the cause and consequences of microbial population 
differences in relation to host scalp health have yet to be determined. We have used whole tran-
scriptome microarray profiling to characterise the biology of dandruff scalp at the molecular level. 
Gene Ontology analysis of the differentially expressed genes revealed significant up-regulation of 
defence and immune response genes in dandruff scalp. From this data we have defined a dandruff 
gene expression signature. Using a range of data integration tools and approaches we have identified 
dermatological conditions sharing common gene expression patterns with dandruff and uncovered 
commonly perturbed biological pathways. The insights gained from these ‘data-driven’ analyses are 
helping us to better describe and define the dandruff condition in the context of other dermatological 
conditions such as atopic eczema and psoriasis. This work provides new mechanistic insights into 
the biology of dandruff to enable the development of novel therapeutic approaches to achieve and 
maintain optimal scalp health.    
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Ex vivo demonstration of co-activity of adapalene and benzoyl peroxide on inflammatory 
acne lesions
B Dreno,1 A Khammari1 and T Zuliani2 1 Laboratory of Immuno-Dermatology and Unit of 
Dermato-Cancerology, University Hospital Nantes, Nantes, France and 2 UTCG, University 
Hospital Nantes, Nantes, France
Combination of the retinoid adapalene 0.1% with benzoyl peroxide (BPO) is recommended as first-
line treatment for acne. The mechanisms of action of these compounds may complement each other, 
making treatment more effective when used concurrently. However, the exact mechanisms of action 
have not yet been identified. This study investigated the potential molecular mechanisms of action 
of this combination in acne-inflamed skin. In this ex-vivo study, 5 punch biopsies were performed 
from the skin on the back of 8 subjects: 4 from acne-inflamed skin and 1 from uninvolved skin. 
Samples including test compounds were incubated for 24 hours, under the following conditions: 
noninflammatory skin with culture medium alone; inflammatory skin with culture medium alone; 
inflammatory skin with adapalene; inflammatory skin with BPO; and inflammatory skin with combi-
nation of adapalene and BPO. Immunohistochemical (IHC) assessment of proliferation, maturation, 
and terminal biomarkers was performed, as well as ranking of the intensity of labeling for each 
biomarker on a scale of 0 (no expression) to 5 (very strong expression). Eight male subjects (mean 
age of 22.5 years) with acne were evaluated. IHC results revealed the proliferation, maturation, and 
terminal molecular biomarkers that may be involved with adapalene and BPO treatments. Ki-67, 
α2, α3, α6 integrins, TLR-2, hBD4, and IL-8 were overexpressed in acne-inflamed skin compared 
to the uninvolved skin. The expression of Ki-67, TLR-2, and IL-8 was downregulated in the presence 
of adapalene with BPO. Expression of TLR-2 in inflammatory skin was downregulated by adapalene 
0.1%. BPO alone downregulated Ki-67 expression. IHC staining corroborated these results. A 
co-activity effect of adapalene combined with BPO was shown in keratinocyte maturation markers 
and inflammatory biomarkers. Overexpression of Ki-67, α2, α3, α6 integrins, TLR-2, hBD4 and IL-8 
biomarkers was observed in inflammatory acne skin compared to uninvolved skin.    
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Decreased abundance of Faecalibacterium prausnitzii in the gut of patients with psoriasis 
H Eppinga,1 RC Setyo,1 T Nijsten,1 MP Peppelenbosch,2 HB Thio1 and SR Konstantinov2 
1 Dermatology, University Medical Center Rotterdam, Rotterdam, Netherlands and 2 
Gastroenterology and Hepatology, University Medical Center Rotterdam, Rotterdam, 
Netherlands
Psoriasis and Inflammatory Bowel Disease (IBD) share various pathogenic and genetic similarities. 
A well-known finding in IBD is a decreased abundance of the beneficial bacterium F. prausnitzii in 
the gut microbiota. At present, it is unclear if the intestinal microbiota is involved in the pathogenesis 
of the related inflammatory disease psoriasis. In this study we investigated if a similar decrease of F. 
prausnitzii was also present in psoriasis patients. For this purpose, fecal samples from 21 patients 
with IBD, 19 patients with psoriasis, 7 patients with both IBD and psoriasis and 22 healthy con-
trols were collected and analysed using a set of (q)PCR primers. The amount of F. prausnitzii was 
compared between the four groups. The abundance of F. prausnitzii was significant decreased in 
psoriasis patients compared to healthy controls (p=0.01). In patients with both IBD and psoriasis 
the abundance was further decreased compared to healthy controls (p=0.004). Remarkable, this 
study showed no significant decrease of F. prausnitzii in patients with only IBD compared to healthy 
controls (p=0.06). A new result of this study is that the bacterium F. prausnitzii is less abundant in 
the gut microbiota of psoriasis patients. Depletion of the beneficial bacterium F. prausnitzii is not 
specific for IBD and might resemble the dysbiosis of immune-mediated inflammatory diseases in 
general. Further research is needed to establish the presumed protective role of F. prausnitzii and 
if a depletion is cause or effect of these inflammatory diseases.    
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The substance P antagonist apripetant shows no additive effect compared to standardized 
topical treatment alone, in atopic dermatitis patients
L Lönndahl,1 M Holst,2 M Bradley,1 H Killasli,3 J Heilborn,4 M Hall,4 L Zou5 and K Nordlind1 
1 Dermatology and venereology Unit, Department of Medicine, Solna, Karolinska Institutet, 
Stockholm, Sweden, 2 Pediatric Endocrinology Unit, Departmetn of Woman and Child 
Health, Karolinska Institutet, Stockholm, Sweden, 3 Dermatology and Venereology Unit, 
Department of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden, 4 Karolinska 
Institutet, Stockholm, Sweden and 5 Department of Dermatology, Södersjukhuset, Karolinska 
Institutet, Stockholm, Sweden
Atopic dermatitis (AD) is an often severely itching skin disorder which may worsen due to stress and 
anxiety. Tachykinins have been suggested to influence the level of inflammation as well as being 
involved in pruritus, stress and anxiety. Aprepitant is an NK1- receptor antagonist. In adult patients 
with moderate-severe AD, in an open randomized trial, the effect of aprepitant was compared to 
a standard topical treatment. Totally 41 patients with AD were recruited. Patients in the treatment 
group (n=21) received 80 mg aprepitant (Emend) daily for 7 days as supplement to a standard topical 
treatment with a moderately strong steroid twice a day and a moisturizer. The control group of adult 
patients with AD (n=20) received only the topical treatment. The patients have been monitored 
regarding extent of the disease (SCORAD), degree of pruritus (VAS) and scratching movements, 
as well as mood (Montgomery Åsberg Depression Rating Scale, MADRS-S). In the group treated 
by aprepitant SCORAD decreased from 42.0±12.5 (mean±SD) to 33.1±11.2, VAS decreased from 
5.7±1.8 to 3.8±2.4 and scratching movements from 73.8±93.5 to 46.3±60.0. In the control group 
SCORAD decreased from 37.0±11.3 to 26.7±14.7, pruritus (VAS) from 6.7± 2.2 to 4.3±2.9 and 
scratching movements from 65.0±100.9 to 34.7±45.0. In both the treatment group and the control 
group there was a decrease in MADRS-S score (from 6.2±4.5 to 4.5±6.2 and 9.3±8.9 to 6.5± 5.9, 
respectively). The treatment with aprepitant was well tolerated. In conclusion, aprepitant gave no 
additive effect in the treatment of atopic dermatitis compared to a standardized topical treatment.   
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Modulation of Rhealba Oat Plantlet Extract on Thymic Stromal Lymphopoietin Production 
in a Reconstructed Human Epidermis Atopic Dermatitis Model 
M Galliano, C Carrasco, B Guiraud, S Bessou-Touya and H Duplan Pharmacologie, Pierre 
Fabre Dermo-Cosmétique, Toulouse, France
 Atopic dermatitis (AD) is a common skin inflammatory disease characterized by the production 
of thymic stromal lymphopoietin (TSLP), a marked TH2 polarization and a profound alteration in 
epidermal barrier function. Recent studies have emphasized the central role of TSLP in triggering 
inflammation and pruritus. We have recently developed a model of reconstructed human epidermis 
(RHE) that displays features of an atopic dermatitis-like phenotype upon exposure to a mixture of 
inflammatory stimuli (Il-1b and TLR2/TLR3 ligands). We showed that RHE exposed to the stimula-
tion responded by (i) a robust secretion of TSLP in a NFkB-dependant manner, and (ii) a significant 
decrease in epidermal barrier function, as illustrated by reduced filaggrin and claudin-1 expression 
and increased dye penetration through the epidermis. In this study we investigated the protective 
effect of Rhealba® oat plantlets extract on this atopic dermatitis-like model. Rhealba® oat plantlets 
extract was added to the medium culture of the RHE or a balm containing Rhealba® oat plantlets was 
applied to the surface of RHE before exposure to Il-1b and TLR2/TLR3 ligands for a 24h-incubation. 
Production of TSLP was then analysed by Elisa. Both Rhealba® oat plantlets extract and the Rhealba® 
oat plantlets-containing balm significantly reduced TSLP release from keratinocytes, whereas a 
formula without Rhealba® oat plantlets did not. Using Q-PCR analysis, we found that chemokines 
markers of AD, CCL2, CCL5 and CCL7 that were strongly up-regulated upon stimulation were 
notably down-modulated by Rhealba® oat plantlets, and barrier function improved. Collectively, 
our data support that Rhealba® oat plantlets extract, by limiting TSLP production and inflamma-
tion, and improving barrier function in skin, could be beneficial for AD prevention and treatment.   
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Effect of tacrolimus ointment on House Dust Mite induced eczema phenotype in flaky tail 
mice
S Knoth Clausen,1 B Cathrina Martel,2 K Moller,1 H Norsgaard,1 P Lovato1 and L Veng1 1 Skin 
Research, LEO Pharma, Ballerup, Denmark and 2 North Carolina State University, College of 
Veterinary Medicine, Raleigh, NC
The flaky tail mice exhibit spontaneous dermatitis resembling human atopic dermatitis (AD). The 
induction of AD-like skin lesion by topically applied allergens (e.g.house dust mites, HDM) in this 
strain of mice has been proposed as one of the most representative and physiologically relevant 
mouse models of human AD. To understand the model and its translational aspects, the effect of 
tacrolimus, a calcineurin inhibitor used clinically for the treatment of AD, was investigated. To 
the best of our knowledge this has not been reported previously. HDM ointment was applied onto 
shaved backs of 7-8 week old flaky tail mice twice weekly for 8 consecutive weeks. Tacrolimus 
ointment was applied once daily to the affected area the last two weeks of the experiment. The skin 
was scored once weekly for AD-like phenotypical parameters, i.e. erythema, scaling, scratching and 
thickening of the skin. After termination skin biopsies were subjected to histopathological evaluation, 
cytokine (protein level) or flow cytometry analysis to elucidate T-cell populations (CD4+ and CD8+, 
αβ, γδ). After 4 to 5 weeks of HDM application, the mice developed, and maintained an eczematous 
phenotype evidenced by skin thickening and scaling, and some erythema. HDM application resulted 
in a histopathological AD like phenotype (increased epidermal thickness, influx of CD4+ and CD8+ 
T-cells, and patchy loricrin staining). The parameters were partially reversed upon treatment with 
tacrolimus. The HDM induced eczema lesions were dominated by Th1, Th17 and Th22 associated 
cytokines with an unexpected absence of Th2 cytokines. While tacrolimus treatment reversed the 
HDM-induced cytokines in the skin, it surprisingly also induced/increased IL-13, TARC and total 
IgE. In summary, application of HDM ointment induced an AD like clinical and histopathological 
phenotype, but unlike AD, the cytokine profile was skewed towards a Th1/Th17/Th22 phenotype. 
Tacrolimus treatment reverted many features of the eczema phenotype as seen in the clinic.    
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Is atopic dermatitis more persistent than previously estimated?
V Kiiski, P Susitaival, A Remitz and S Reitamo Department of Dermatology and Venereology, 
Helsinki Skin and Allergy Hospital, Helsinki, Finland
Atopic dermatitis (AD) is a common pruritic skin disease. The onset of AD is usually in childhood. 
It is estimated that only 20-25% of patients with AD in childhood continue to have symptoms in 
adulthood. Prevalence of AD varies across the world. Recent studies on adult populations have 
shown prevalence up to 11% but studies in adult populations are sparse. In Finland there are no 
previous nationwide population-based studies on the prevalence of AD in adults. Smaller studies 
have shown 12-months prevalence up to 14.7%. The objective was to evaluate 12-month preva-
lence, total adulthood prevalence, and lifetime prevalence of AD in adults. This cross-sectional study 
used population-based data from nationwide health examination survey ‘Health 2000’, carried out 
in 2000-2001, providing a representative sample of the general Finnish adult population. The initial 
sample consisted of 8,028 subjects, aged ≥ 30 years. Medical history and demographic data were 
collected in extensive interviews and a comprehensive clinical examinations was carried out. The 
12-month prevalence of AD was 10.0%. The prevalence was higher in women (10.2%) than in men 
(9.7%). The 12-month prevalence decreased with age, from 15.3% (subjects of 30-40 years) down 
to 5.6% (≥ 70 years). The prevalence of adulthood AD was 13.9%. It also decreased with age from 
18.7% to 9.5%. In our study population of all the subjects with a history of AD, 46% continued to 
be symptomatic. Number decreased with age from 54% (30-39 years) to 38% (≥70 years). These 
prevalence numbers are in concordance with earlier Northern European studies. AD is the most 
common inflammatory skin disease in Finnish adults. These results indicate that the estimates of only 
20-25% of childhood AD continuing into adulthood are likely underestimations and the proportion 
is presumably larger: atopic dermatitis is not only a childhood disease.    
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Possible role of insulin signalling in the sebum production. Relevance in the pathogenesis 
of acne vulgaris
M Ottaviani,1 V Lora,1 M Ludovici,1 S Briganti,1 J Sinagra,1 B Capitanio,1 A Mammone,2 
M Picardo1 and E Camera1 1 San Gallicano Dermatologic Institute (IRCCS), Rome, Italy and 
2 Lazzaro Spallanzani National Institute for Infectious Diseases (INMI), Rome, Italy
The insulinotropic effect of westernized diets is accounted among pathogenic cofactors of acne 
vulgaris (AV). We investigated the association between index of insulin resistance (IR), circulating 
lipids, and biomarkers of sebaceous gland activity in 76 patients (44F, 32M, age 19.1±7.1) with AV, 
and 44 unaffected subjects (30F, 12M, age 21.4±5.4). Fasting blood glucose, insulin, triglycerides, 
LDL, HDL, total cholesterol (CH), and BMI were measured. The homeostasis model assessment of 
IR (HOMA-IR) was used to calculate insulin resistance. Sebum was sampled from the foreheads to 
determine sebum excretion rates (SER), concentration of squalene (SQ), CH, and free fatty acids 
(FFA), along with degree of SQ oxidation. Results were reported as fold change (FC) of AV versus 
controls. BMI was slightly lower in AV (FC 0.94, p<0.05). Consistently, lower levels of CH (FC 
0.89, p<0.05), and LDL (FC 0.88, p<0.05) were observed. The average values of HOMA-IR were 
comparable between AV and controls. In contrast, the percentage of subjects with HOMA-IR≥2.5 
was significantly higher in the AV group (p<0.05). SER was higher in AV (FC 1.24, p<0.05). SQ and 
oxidized SQ tended to increase consistently with the AV severity. Extent of sebum oxidation was 
directly associated with fasting insulin levels (R=0.35, p<0.05) and HOMA-IR (R=0.36, p<0.05) in 
controls. Moreover, levels of the sebum specific sapienic acid (FA 16:1n-10) were positively and 
negatively associated with SER (R=0.31, p<0.05) and HOMA-IR (R=-0.36, p<0.05), respectively, 
in controls only. In contrast, AV lacked of association between IR and sebum parameters. Our 
data indicate that peripheral responsiveness to insulin might be implicated in sebum output and 
SQ oxidation. However, factors other than IR concur to the sebum alterations associated with AV.   
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Complement fixation test: an update of an old method for the diagnosis of bullous pemphigoid
J Jankásková,1 O Horváth N.,2 R Varga,2 T Ruzicka2 and M Sárdy2 1 Department of Dermato-
Venereology, Teaching Hospital Královské Vinohrady, Third Faculty of Medicine, Charles 
University in Prague, Prague, Czech Republic and 2 Department of Dermatology and 
Allergology, Ludwig Maximilian University, Munich, Germany
Serological tests for bullous pemphigoid (BP) have a relatively low sensitivity, thus new methods 
are needed. The complement fixation test (CFT) is an old method traditionally used for detection 
of low titer autoantibodies in gestational pemphigoid (herpes gestationis). Previous studies have 
already documented its potential usefulness for the diagnosis of BP, but its performance has not been 
investigated yet in a large patient cohort. In this single-center, retrospective, serological case-con-
trol study on 300 BP and 136 control patients, analysis of diagnostic performance of CFT in BP 
is demonstrated. CFT showed a sensitivity of 71.7% and a specificity of 100%. Furthermore, CFT 
diagnosed 20 of 46 BP patients (43.5%) who were negative for both BP180 and BP230 ELISAs, 31 
of 66 patients (47.0%) who were negative for IIF on esophagus, 5 of 14 patients (35.7%) who were 
serologically negative for all investigated serological assays, and 7 of 18 patients (38.9%) in whom 
direct immunofluorescence was negative. Combination of CFT with all other serological assays 
resulted in a sensitivity of 95.3%. CFT is sensitive enough to be used as a standard method for the 
diagnosis of BP, and it can help to diagnose serologically challenging cases.    
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Comparative diagnostic performance of commercial as well as modified mosaic indirect 
immunofluorescence assay and ELISAs for the serological evaluation of pemphigus and bul-
lous pemphigoid activity
J Gornowicz-Porowska,1 M Bowszyc-Dmochowska,1 P Pietkiewicz,1 A Seraszek-Jaros,2 
E Kaczmarek,2 P Bartkiewicz1 and M Dmochowski1 1 Department of Dermatology, 
Autoimmune Blistering Dermatoses Section, Poznan University of Medical Sciences, Poznan, 
Poland and 2 Department of Bioinformatics and Computational Biology, Poznan University 
of Medical Sciences, Poznan, Poland
Pemphigus and bullous pemphigoid (BP) are identified by autoantibodies (abs) against desmoglein 
1, 3 (DSG1/3) and BP180/BP230, respectively. These patients have Th1-regulated IgG1 and Th2-reg-
ulated IgG4 abs. A novel mosaic IIF microscopy approach using purified BP180 recombinant 
proteins spotted on slide and transfected cells expressing BP230, DSG1, DSG3 is available. The 
aims were to compare diagnostic performance of commercial mosaic IIF - cIIF (IgG detection) and 
modified mosaic - mIIF (IgG4 detection) assay and to examine the diagnostic value of ELISAs in 
relation to mosaic IIF in routine laboratory diagnostics of pemphigus and BP. The accuracy of mIIF 
and ELISA was evaluated for 37 BP and 19 pemphigus samples by calculating diagnostic sensitivity 
and diagnostic specificity in relation to the cIIF. Associations in results between tests were assessed 
using Fisher’s exact test. There is an association between the values of positive/negative samples 
detected by cIIF with DSG1/DSG3/BP230 transfected cells and ELISAs (p<0.05). There is a lack of 
association between anty-BP180 IgG detection in BP patients by IIF and ELISA (p=0.1081). The 
diagnostic sensitivity and specificity of modified (IgG4) in comparison with standard (IgG) IIF was: 
(i) DSG1 - 100% in both cases,(ii) DSG3 - 100% and 78%, respectively,(iii) BP180 - 100% and 
13%, respectively,(iv) BP230 - 55% and 87%, respectively. It seems that IIF with DSG1/DSG3/
BP230 transfected cells is an alternative way to ELISA in management of pemphigus/BP. However, 
for anty-BP180 IgG detection in BP patients the ELISA remains definitive serological test. It appears 
that BP180 spotted on slide compared to transfected cells expressing BP230/DSG1/DSG3 are less 
useful for IgG4 abs detection with mIIF.    
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Development and analysis of an in vitro model of epidermal infection by anthropophilic 
dermatophytes
E Faway,1 L Cambier,2 C Lambert de Rouvroit,1 B Mignon2 and Y Poumay1 1 URPhyM-
NARILIS, University of Namur, Namur, Belgium and 2 Faculty of veterinary medicine, 
University of Liège, Sart-Tilman, Belgium
Dermatophytosis, also called tinea, is a superficial lesion of the keratinized structures of the host 
(epidermis, nails and hairs), caused by the keratinolytic fungi named dermatophytes. Its incidence 
is about 10% in general population and has been increasing for the last decade, especially among 
some populations at risk: more than 30% of sportsmen or diabetic patients are affected. Tricho-
phyton rubrum is an anthropophilic species responsible for 70% of human dermatophytosis, but 
other zoophilic species can also cause human infections, i.e. Microsporum canis and Arthroderma 
benhamiae. In spite of their threatening incidence, there is a lack of knowledge about the biology 
of dermatophytes and possibilities to counteract the mechanisms they use to develop infection. In 
order to study this pathology on human materials, we developed a model of infection by T. rubrum 
dermatophytes on reconstructed human epidermis (RHE) produced by cell culture. The infection 
is monitored by periodic acid-Schiff (PAS) staining method of dermatophytes and by quantitative 
PCR. This model allows us to study the kinetics of infection by dermatophytes and to assess the 
expression of pro-inflammatory cytokines by keratinocytes. The efficiency of an antifungal agent has 
been successfully demonstrated in this model which could thus be used to develop new curative 
or preventive treatments against dermatophytosis.    
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Mucosal type mast cells degranulation and proliferation are stimulated by CRH in situ
Y Mizukami,1 K Sugawara,1 R Paus2 and D Tsuruta1 1 Dermatology, Osaka City University 
Graduate School of Medicine, Osaka, Japan and 2 Centre for Dermatology, Institute of 
Inflammation and Repair, University of Manchester, Manchester, United Kingdom
Corticotropin releasing hormone (CRH) has multiple biological functions in addition to its classi-
cal role as a potent, central stress mediator. Interestingly, CRH and CRH receptors (CRHRs) have 
recently been identified in peripheral tissues, which include the adrenal glands, gonads, placenta, 
gastrointestinal system, pancreas and the skin including hair follicle (HF) and sebaceous gland, 
and reported as important regulators in the peripheral tissue response to perceived stress. Mast 
cells (MCs) are crucial cells in the development of various types of diseases, including allergy, 
atopic dermatitis, acute/chronic wounds and hair disorders. They have been shown to play central 
roles in CRH-mediated stress responses. We have previously shown that CRH induces connective 
tissue type (CT)-MC degranulation and promote maturation, and thereby inhibits human HF growth 
by inducing catagen (a regression phase of hair cycle). Now we investigated whether CRH can 
also affect mucosal type (M)-MC biology by using human nasal polyp organ culture. Here, we 
found that Kit or tryptase positive human M-MCs of isolated nasal polyps express CRHR by double 
immunofluorescence. CRH treatment in the organ culture (10-7 M, 24hrs) significantly increased 
tryptase+ M-MC number and induced degranulation in situ. This was partially abrogated by the 
co-administration of stem cell factor (SCF) neutralizing antibody. Just as human HF organ culture, 
CRH also increased SCF expression within the epithelium of organ cultured human nasal polyp 
samples. In contrast to CT-MC, CRH treatment significantly increased tryptase+ M-MC proliferation 
in situ. Furthermore, the effects of CRH on M-MCs degranulation and their number were abrogated 
by CRHR gene knockdown in situ. These results indicate that CRH induces both cutaneous and 
mucosal type neuroinflammation by promoting MC activity and increasing the number and that 
blockade of SCF and CRHR might be a novel future target for treating stress-induced disorders.   
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STAT3 as a therapeutic target for the treatment of atopic dermatitis and pyoderma 
gangrenosum
AK Alves de Medeiros, S De Schepper and J Lambert Dermatology, Ghent University 
Hospital, Ghent, Belgium
This study seeks to examine if STAT3 is activated and, therefore, could be a therapeutic target for 
a set of inflammatory skin diseases (ISDs), namely lichen planus, cutaneous lupus erythematosus, 
atopic dermatitis, alopecia areata and pyoderma gangrenosum, as has already been proven to be 
the case for psoriasis. We analysed the pSTAT3 expression by means of immunohistochemistry in 
human skin biopsies collected from patients with psoriasis (n=16), lichen planus (n=20), cutane-
ous lupus erythematosus (n=20), atopic dermatitis (n=19), alopecia areata (n=7), and pyoderma 
gangrenosum (n=10). We analysed pSTAT3 staining in the epidermis (number of stained cells/area) 
and in the dermis (positivity or negativity in the inflammatory cells). Statistical analysis compared 
each disease with normal controls (n=16) using SPSS version 22. We applied a Chi-Square test for 
the analysis of inflammatory cells and Kruskal-Wallis ANOVA for the analysis of the cell count in 
the epidermis. P≤ 0.05 was considered statistically significant. We observed pSTAT3 overexpres-
sion in the epidermis of most of the studied ISDs, with statistical significance in psoriasis, atopic 
dermatitis and pyoderma gangrenosum. In the dermis, pSTAT3 was significantly overexpressed in 
atopic dermatitis. STAT3 downregulation is attributed to be one of the reasons for the efficacy of 
the recently discovered JAK inhibitors (in topical and systemic formulations) in the treatment of 
psoriasis. Similar to psoriasis, we observed that STAT3 may play an important role in other ISDs, 
such as atopic dermatitis and pyoderma gangrenosum. Therefore, patients suffering from these 
diseases might benefit from the STAT3 downregulation effect of the JAK inhibitors. Additionally, 
the development of STAT3-targeting therapies is desirable.    
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Resolution of inflammation in the skin : development of a screening tool using human pri-
mary cells and mass spectrometry for the quantification of inflammatory lipids and bioactive 
mediators
G Chêne, V Baillif, E Wanecq, C Guigné, E Van Goethem and M Dubourdeau Ambiotis sas, 
Toulouse, France
It is now well described that ending inflammation is not a passive phenomenon only due to catabasis 
of pro-inflammatory mediators. Stopping circuits are controlled by the synthesis of new mediators, 
called lipoxins, resolvins, protectin and maresins. Those mediators are issued from polyunsaturated 
fatty acids and are actively involved in resolution of inflammation and return to homeostasis. If 
specialized pro-resolving mediators are not produced, the good ending of the inflammatory process 
won’t occur and adverse chronic effects of inflammation will appear. Resolution molecules have 
numerous beneficial properties in the skin: they induce the healing and avoid fibrosis, they also 
play a positive role in tissue regeneration or in soothing in patients with eczema. Finally, they 
protect before inflammation as they are naturally present in tissues to maintain the homeostasis 
state. We describe here the development of a methodology using liquid chromatography-tandem 
mass spectrometry (LC/MS-MS). This technic allows concomitant quantification of low-level of 
inflammatory and resolutive lipid bioactive mediators (e.g. PGE2, LxA4, RvD1), inactive products 
(e.g. TxB2) and pathway biomarkers (e.g. 5-HETE). We have applied this methodology to follow the 
resolution in human primary cells (coculture of monocytes with lymphocytes or keratinocytes with 
dendritic cells). In both models and in presence of an inflammatory stimulus, molecules of resolution 
such as lipoxins and resolvins are produced allowing screening of drugs that induce resolution. To 
conclude, the measurement of lipid metabolite by LC/MS-MS associated to physiological cellular 
models relevant for skin diseases is a very valuable tool to evaluate cutaneous inflammation. These 
models are necessary for screening of molecules acting on inflammation and resolution pathways in 
the skin context (eczema, atopy…) before their enrolment in more complex assays on reconstructed 
skin, human skin samples or clinical assays.    
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Isotretinoin treatment reduces acne lesions but not directly lesional acne inflammation
AI Lauerma,1 H Kelhälä,2 N Fyhrquist,3 R Palatsi,2 H Alenius3 and K Tasanen2 1 Dermatology, 
Allergology and Venereology, University Hospital, Inflammation Centre, Helsinki, Finland, 2 
Dermatology, Oulu University, Oulu, Finland and 3 Systems Toxicology, Finnish Institute of 
Occupational Health, Helsinki, Finland
Evidence is accumulating that inflammation is a central element in the development of acne lesions. 
The anti-inflammatory drug isotretinoin has proven highly efficient in the treatment of acne, but 
the mechanisms of its actions are not yet fully understood. In this study we analyzed the effect of 
oral isotretinoin (0.5 mg/kg/d) on innate immune responses and T cell trafficking in lesional and 
nonlesional skin areas in acne patients before and during treatment. We found that the expression 
of IL-1beta and TLR2 mRNA in nonlesional skin in acne patients was significantly reduced after 
six weeks of isotretinoin treatment. Further, the initially low levels of S100A7 and LCN2 mRNA 
in nonlesional skin in acne patients were restored to normal levels by the treatment. Yet, although 
acne lesions were present at lower frequencies during treatment, the level of inflammation in the 
newly formed acne lesions was unaffected, with the exception of increased macrophage count. 
Our results suggest that isotretinoin may not reduce directly ongoing inflammation in acne lesions 
themselves, but modifies mechanisms that control immune homeostasis, as seen in unaffected skin.   
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Decreased basophil-derived IL-4 is associated to metal imbalance in patients with prurigo
T Ugajin,1 S Shibama,1 T Yamaguchi2 and H Yokozeki1 1 Department of Dermatology, Tokyo 
Medical and Dental University, Tokyo, Japan and 2 Department of Biochemical Genetics, 
Medical Research Institute, Tokyo Medical and Dental University, Tokyo, Japan
Basophils are a major source of interleukin (IL)-4. Recent studies using mice have revealed various 
roles for basophil-derived IL-4 play both inflammatory and regulatory role in skin inflammation. 
However, it remains unclear how basophil-derived IL-4 is involved in the pathogenesis of human 
skin diseases. Metallothioneins (MTs) are low-molecular-weight cysteine-rich proteins that exhibit 
high affinity for divalent heavy metal ions. In the present study, we showed that basophil-de-
rived IL4 was low in the patients with prurigo compared with healthy control donors. In addition, 
the expression levels of IL4 were highly correlated with those of MTs in basophils isolated from 
patients with prurigo, indicating that MTs are essential for IL-4 production by basophils in prurigo. 
Furthermore, the imbalance of serum zinc and copper was observed in patients with prurigo, and 
zinc-copper ratio correlated strongly with  IL4 levels in basophils. Thus decreased basophil-derived 
IL-4, which is associated to metal imbalance in patients with prurigo, might be involved in the 
pathogenesis of prurigo.    
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PsoPlus, a comprehensive consultation programme for psoriasis
E De Keyser, E De Coster, AK Alves de Medeiros, E Deprez, H Lapeere, N van Geel and 
J Lambert Dermatology, Ghent University Hospital, Ghent, Belgium
With a rising awareness of the comorbidities associated with psoriasis (PsO) and the availability of 
a broad therapeutic armamentarium, it is expedient to optimise PsO management. We developed 
an itemised consultation, PsoPlus, with a checklist of questions and areas that cover aspects of 
decision making. The patient is first seen by a nurse who takes up disease history, past and current 
treatment and certain parameters such as BMI. Next, the dermatologist finalises the consultation 
focusing on current history, clinical examination, further investigations and treatment plan. PsoPlus 
aims to consider the patient in a holistic manner, aid treatment choice, stimulate follow-up and 
refer timely (e.g. rheumatology and cardiology). Belgium has no echeloning system so any patient 
can attend this type of expert consultation. We report on 129 patients enrolled in 2013 and 2014 
in our 3rd line reference center. Average disease duration was 16±11,8 years. More than 90% 
presented with PsO vulgaris, inversa and/or guttate; 0,8% CPPP; 3,1% CPPP and PsO vulgaris; 
2,3% PsO capitis; and 1,6% isolated nail PsO. More than 60% had PASI<10, 18,9% 10≤PASI≤20, 
and 13,7% PASI>20 at first presentation. Assessing cardiovascular (CV) risks, we found that 29,7% 
was smoking, 17,5% obese, and 34,4% actively treated for CV risks. After the first consultation 
54,3% was prescribed a different treatment. In short, the use of topical monotherapies reduced 
during PsoPlus, whereas use of biologics rised from 14,7 to 69,2%. Use of conventional systemic 
treatments remained almost constant, suggesting a degree of undertreatment at intake. At least 20% 
was referred to other disciplines such as rheumatology. Mean PASI (from 9,3 to 4,2) and DLQI (from 
7 to 4) scores were reduced throughout PsoPlus, although 16,7% still showed moderate-to-severe 
PsO after 18 months. It remains interesting to discuss whether only severe PsO patients should be 
seen in this more complex 3rd line consultation setting. A study setup aiming at monitoring the long 
term health outcomes and related cost-benefit will be initiated.    
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Proteomic evaluation of the keratinocyte secretome upon stimulation with pruritic substances
AG Szöllösi,1 I McDonald,1 A Corcoran,1 L Casals,1 CD Ribeiro,1 J Meng,1 A Von Kriegsheim,2 
W Kolch2 and M Steinhoff1 1 Charles Institute of Dermatology, University College Dublin, 
Dublin, Ireland and 2 Systems Biology Ireland, University College Dublin, Dublin, Ireland
Itch (pruritus) is the most common symptom in dermatological practice, affecting 22% of the pop-
ulation over the course of their lives. Recent research has highlighted numerous new mechanisms 
behind non-histaminergic itch; a characteristic of numerous dermatological and systemic conditions 
(e.g. atopic dermatitis, psoriasis, kidney and liver diseases). The exact mediators responsible for this 
type of pruritus have not been identified, although various substances (e. g. proteinase-activated 
receptor agonists, endothelin-1) have been implicated. Interestingly, a key component of these 
novel pathways is the interaction between various non-neuronal and neuronal cells, partly in the 
epidermis. As such, our research focuses on keratinocyte-neuron communication, where we are 
intent on finding novel mediators released by keratonicytes capable of activating pruritergic nerves 
upon stimulation with pruritogens. Using a proteomic approach we investigated the secretome of 
primary human keratonicytes treated with pruritogens. Our results show that the secretome of kera-
tinocytes contains upwards of 2000 proteins, and between 160 to 1000 change significantly upon 
pruritogenic treatment. Although many of these proteins are not considered to be extracellularly 
localized, and indeed some of them may be derived from cellular detritus, their careful evaluation 
may lead to the discovery of novel pruritogenic markers.    
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Von Willebrand factor-cleaving protease serum level in systemic sclerosis microangiopathy
Z Gerlicz-Kowalczuk,2 AE Platkowska,2 A Zalewska-Janowska2 and B Dziankowska-
Bartkowiak1 1 Department of Dermatology and Venereology, Medical University of Lodz, 
Lodz, Poland and 2 Department of Psychodermatology,, Medical University of Lodz, Lodz, 
Poland
Systemic sclerosis (SSc) is an autoimmune connective tissue disease of unknown aetiology and is 
characterized by deviations in immunological investigations, generalized microcirculation disorders 
and progressive tissue fibrosis. So far, etiopathogenesis of systemic sclerosis has not been fully 
understood. At present there are complementary hypotheses of the disease development. The aim 
of the study was to determine serum level the von Willebrand factor cleaving protease (ADAMTS13) 
in patients with systemic sclerosis. Serum level of ADAMST13 was measured in 39 SSc patients and 
healthy controls by a specific enzyme-linked immunosorbent assay. The correlation between serum 
level of ADAMST13 and internal organs changes were assessed. There was statistical difference 
in serum level of ADAMST 13 in SSc patients compared with healthy controls (455,47 ± 128 vs. 
702,01 ± 142 ng/ml, p < 0.00001). Serum level of ADAMST 13 were not different between lSSc 
and dSSc. Significant correlations among serum ADAMST 13 levels and organ changes were not 
found in SSc patients. The decrease ADAMST13 concentration in the serum in patients with SSc, 
may contribute to progression of microangiopathy.    
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Gastrointestinal Comorbidities in Patients with Psoriasis in the Czech Republic
K Juzlova,1 J Votrubova,1 M Dzambova,1 Z Smerhovsky,2 D Gopfertova2 and J Hercogova1 
1 Dermatovenereology, Second Medical Faculty Charles University, Prague, Czech Republic 
and 2 Epidemiology, Second Medical Faculty Charles University, Prague, Czech Republic
Psoriasis, celiac disease and inflammatory bowel disease (IBD) are among autoimmune diseases 
whose aetiopathogenesis involves genetic predisposition of the individual as well as environmental 
factors. The present study is aiming at gastrointestinal comorbidities and identification of risk factors 
and early stages of autoimmune gastrointestinal diseases such as Crohn disease, ulcerative colitis and 
celiac disease in patients with psoriasis. The study was designed as a hospital-based case-control 
study. Patients with chronic plaque psoriasis were enrolled as cases. The control group consists of 
patients with other skin diseases who complied with the same selection criteria applied in cases. 
Two controls were selected per one case. Analyses are based on the comparison of the prevalence 
of specific antibodies (ASCA, AEP, p-ANCA, AGC, EMA, ARA, tTG, AGA) and non-specific signs of 
gastrointestinal diseases was carried out in cases and controls. The results of the study reveal signifi-
cant differences between the cases and controls in several studied parameters: in case of leucocytes 
count, CRP, total protein, transglutaminase IgA antibodies and p-ANCA these differences reached 
the level of statistical significance (p<0.05). In the binary logistic model the following parameters 
are associated with psoriasis: leucocytes count and p-ANCA (for all the parameters included in 
the logistic model p= < 0.001). The results of the study show that patients with psoriasis should 
be regularly screened for celiac disease and inflammatory bowel diseases. An early diagnostics of 
gastrointestinal diseases and risk factors may prevent potential complications and greatly improve 
the future quality of life of the patient.    
   
      
